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A B S T R A C T
Background
The World Health Organization (WHO) recommends Artemisinin-based Combination Therapy (ACT) for treating uncomplicated
Plasmodium falciparummalaria. This review aims to assist the decision-making of malaria control programmes by providing an overview
of the relative effects of dihydroartemisinin-piperaquine (DHA-P) versus other recommended ACTs.
Objectives
To evaluate the effectiveness and safety of DHA-P compared to other ACTs for treating uncomplicated P. falciparum malaria in adults
and children.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL) published in The Cochrane Library; MEDLINE; EMBASE; LILACS, and the metaRegister of Controlled Trials (mRCT) up
to July 2013.
Selection criteria
Randomized controlled trials comparing a three-day course of DHA-P to a three-day course of an alternative WHO recommended
ACT in uncomplicated P. falciparum malaria.
Data collection and analysis
Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in line
with the WHO ’Protocol for assessing and monitoring antimalarial drug efficacy’ and compared drugs using risk ratios (RR) and 95%
confidence intervals (CI). Secondary outcomes were effects on gametocytes, haemoglobin, and adverse events. We assessed the quality
of evidence using the GRADE approach.
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Main results
We included 27 trials, enrolling 16,382 adults and children, and conducted between 2002 and 2010. Most trials excluded infants aged
less than six months and pregnant women.
DHA-P versus artemether-lumefantrine
In Africa, over 28 days follow-up, DHA-P is superior to artemether-lumefantrine at preventing further parasitaemia (PCR-unadjusted
treatment failure: RR 0.34, 95% CI 0.30 to 0.39, nine trials, 6200 participants, high quality evidence), and although PCR-adjusted
treatment failure was below 5% for both ACTs, it was consistently lower with DHA-P (PCR-adjusted treatment failure: RR 0.42, 95%
CI 0.29 to 0.62, nine trials, 5417 participants, high quality evidence). DHA-P has a longer prophylactic effect on new infections which
may last for up to 63 days (PCR-unadjusted treatment failure: RR 0.71, 95% CI 0.65 to 0.78, two trials, 3200 participants, high quality
evidence).
In Asia and Oceania, no differences have been shown at day 28 (four trials, 1143 participants, moderate quality evidence), or day 63
(one trial, 323 participants, low quality evidence).
Compared to artemether-lumefantrine, no difference was seen in prolonged QTc (low quality evidence), and no cardiac arrhythmias
were reported. The frequency of other adverse events is probably similar with both combinations (moderate quality evidence).
DHA-P versus artesunate plus mefloquine
In Asia, over 28 days follow-up, DHA-P is as effective as artesunate plusmefloquine at preventing further parasitaemia (PCR-unadjusted
treatment failure: eight trials, 3487 participants, high quality evidence). Once adjusted by PCR to exclude new infections, treatment
failure at day 28 was below 5% for both ACTs in all eight trials, but lower with DHA-P in two trials (PCR-adjusted treatment failure:
RR 0.41 95% CI 0.21 to 0.80, eight trials, 3482 participants, high quality evidence). Both combinations contain partner drugs with
very long half-lives and no consistent benefit in preventing new infections has been seen over 63 days follow-up (PCR-unadjusted
treatment failure: five trials, 2715 participants, moderate quality evidence).
In the only trial from South America, there were fewer recurrent parastaemias over 63 days with artesunate plus mefloquine (PCR-
unadjusted treatment failure: RR 6.19, 95% CI 1.40 to 27.35, one trial, 445 participants, low quality evidence), but no differences were
seen once adjusted for new infections (PCR-adjusted treatment failure: one trial, 435 participants, low quality evidence).
DHA-P is associated with less nausea, vomiting, dizziness, sleeplessness, and palpitations compared to artesunate plus mefloquine
(moderate quality evidence). DHA-P was associated with more frequent prolongation of the QTc interval (low quality evidence), but no
cardiac arrhythmias were reported.
Authors’ conclusions
In Africa, dihydroartemisinin-piperaquine reduces overall treatment failure compared to artemether-lumefantrine, although both drugs
have PCR-adjusted failure rates of less than 5%. In Asia, dihydroartemisinin-piperaquine is as effective as artesunate plus mefloquine,
and is better tolerated.
P L A I N L A N G U A G E S U M M A R Y
Dihydroartemisinin-piperaquine for treating uncomplicated malaria
This review summarises trials evaluating the effects of dihydroartemisinin-piperaquine (DHA-P) compared to other artemisinin-based
combination therapies recommended by theWorldHealthOrganization. After searching for relevant trials up to July 2013, we included
27 randomized controlled trials, enrolling 16,382 adults and children and conducted between 2002 and 2010.
What is uncomplicated malaria and how might dihydroartemisinin-piperaquine work
Uncomplicated malaria is the mild form of malaria which usually causes a fever, with or without headache, tiredness, muscle pains,
abdominal pains, nausea, and vomiting. If left untreated, uncomplicated malaria can develop into severe malaria with kidney failure,
breathing difficulties, fitting, unconsciousness, and eventually death.
DHA-P is one of five artemisinin-based combination therapies theWorld Health Organization currently recommends to treat malaria.
These combinations contain an artemisinin component (such as dihydroartemisinin) which works very quickly to clear the malaria
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parasite from the person’s blood, and a longer acting drug (such as piperaquine) which clears the remaining parasites from the blood
and may prevent new infections with malaria for several weeks.
What the research says
DHA-P versus artemether lumefantrine
In studies of people living in Africa, both DHA-P and artemether-lumefantrine are very effective at treating malaria (high quality
evidence). However, DHA-P cures slightly more patients than artemether-lumefantrine, and it also prevents further malaria infections
for longer after treatment (high quality evidence). DHA-P and artemether-lumefantrine probably have similar side effects (moderate
quality evidence).
DHA-P versus artesunate plus mefloquine
In studies of people living in Asia, DHA-P is as effective as artesunate plus mefloquine at treating malaria (moderate quality evidence).
Artesunate plus mefloquine probably causes more nausea, vomiting, dizziness, sleeplessness, and palpitations than DHA-P (moderate
quality evidence).
Overall, in some people, DHA-P has been seen to cause short term changes in electrocardiographs tracing the conduction of the heart
rhythm (low quality evidence), but these small changes on the electrocardiograph resolved within one week without serious consequences.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Dihydroartemisinin-piperaquine versus Artemether-lumefantrine for uncomplicated P. falciparum malaria in Africa
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Malaria endemic settings in Africa
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artemether-lumefantrine (AL6)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
AL6 DHA-P
Treatment failure
Day 28
PCR-unadjusted RR 0.34
(0.30 to 0.39)
6200
(9 trials)
⊕⊕⊕⊕
high1,2,3,4
23 per 100 8 per 100
(7 to 9)
PCR-adjusted RR 0.42
(0.29 to 0.62)
5417
(9 trials)
⊕⊕⊕⊕
high1,2,3,5
3 per 100 1 per 100
(1 to 2)
Treatment failure
Day 63
PCR-unadjusted RR 0.71
(0.65 to 0.78)
3200
(2 trials)
⊕⊕⊕⊕
high1,3,4,6,7
45 per 100 32 per 100
(29 to 35)
PCR-adjusted RR 0.72
(0.50 to 1.04)
2097
(2 trials)
⊕⊕⊕⊕
high1,3,7,8,9
6 per 100 4 per 100
(3 to 6)
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*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.,
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Trials are generally at low risk of bias. Exclusion of studies at high or unclear risk of selection bias or detection
bias did not change the result.
2 No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.
3 No serious indirectness: The trials were conducted in different transmission settings in East, West and Southern Africa. Most studies
were limited to children.
4 No serious imprecision: Both limits of the 95% CI imply appreciable benefit, and the overall meta-analysis is adequately powered to
detect this result.
5 No serious imprecision: Although there is a benefit in favour of DHA-P, PCR-adjusted treatment failure was below 5% with both drugs.
6 No serious inconsistency: At this timepoint there is more inconsistency between trials. Both show a benefit with DHA-P but there is
variation in the size of this benefit.
7 Seven studies from East, West and Southern Africa reported outcomes at day 42. At this timepoint DHA-P still had an advantage over
AL6 on PCR-unadjusted treatment failure (RR 0.60, 95% CI 0.53 to 0.67, seven studies, 3301, high quality evidence), and PCR-adjusted
treatment failure (RR 0.58, 95% CI 0.41 to 0.81, seven studies, 2559 participants, moderate quality evidence).
8 No serious inconsistency: Statistical heterogeneity was low.
9 No serious imprecision: Both ACTs performed well in these two trials with low levels of treatment failure.
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B A C K G R O U N D
Description of the condition
Malaria is a febrile illness caused by infection with the protozoan
parasite Plasmodium, which is transmitted from person to person
by the bite of infected female Anophelesmosquitoes. Five Plasmod-
ium species are capable of causing malaria in humans, of which P.
falciparum is responsible for over 90% of malaria cases and almost
all of the malaria deaths worldwide (WHO 2012).
Uncomplicated malaria is the mild form of the disease which typ-
ically presents as a fever, with or without associated headache,
tiredness, muscle pains, abdominal pains, rigors (severe shivering),
nausea, and vomiting. If left untreated P. falciparum malaria can
rapidly develop into severe malaria with consequent renal failure
(kidney failure), pulmonary oedema (fluid in the lungs), convul-
sions (fitting), coma, and eventually death (WHO 2010; Sinclair
2012). A clinical diagnosis of malaria can be confirmed by detec-
tion of the malaria parasite in the patient’s blood. This has tra-
ditionally been done by light microscopy but increasingly rapid
diagnostic tests are being used (Abba 2011).
Resistance of P. falciparum to the traditional antimalarial drugs
(such as chloroquine, sulfadoxine-pyrimethamine, amodiaquine,
and mefloquine) is a growing problem and is thought to have
contributed to increased malaria mortality in recent years (WHO
2010). Chloroquine resistance has now been documented in all
regions except Central America and the Caribbean. There is high-
level resistance to sulfadoxine-pyrimethamine throughout South
East Asia and increasingly in Africa, and mefloquine resistance is
common in the border areas of Cambodia, Myanmar, and Thai-
land (WHO 2010; WWARN 2013).
To combat the spread of resistance, the World Health Organiza-
tion (WHO) now recommends that P. falciparum malaria is al-
ways treated using a combination of two drugs that act at different
biochemical sites within the parasite (WHO 2010). If a parasite
mutation producing drug resistance arises spontaneously during
treatment, the parasite should then be killed by the partner drug,
thus reducing or delaying the development of resistance and in-
creasing the useful lifetime of the individual drugs (White 1996;
White 1999). The current drug combinations all include a short-
acting artemisinin derivative (such as artesunate, artemether, or
dihydroartemisinin), partnered with a longer-acting drug in com-
binations known as ’Artemisinin-based Combination Therapies’
(ACTs).
Description of the intervention
The WHO recommends five ACTs for treating uncomplicated
P. falciparummalaria: dihydroartemisinin-piperaquine (DHA-P);
artesunate plus mefloquine (AS+MQ); artemether-lumefantrine -
six doses regimen (AL6); artesunate plus amodiaquine (AS+AQ);
and artesunate plus sulfadoxine-pyrimethamine (AS+SP) (WHO
2010).
Dihydroartemisinin is the active metabolite of the artemisinin
derivatives, and produces faster relief of clinical symptoms and
faster clearance of parasites from the blood than other antimalarial
drugs (McIntosh 2000; Adjuik 2004; WHO 2010). When used
as a monotherapy, the short half-life of the artemisinin derivatives
(and rapid elimination from the blood) means that patients must
take the drug for at least sevendays (Meshnick 1996; Adjuik 2004).
Failure to complete the course, due to the rapid improvement in
clinical symptoms, can lead to high levels of treatment failure even
in the absence of drug resistance. The long-acting partner drug in
ACTs therefore allows the artemisinin component to be taken for a
shorter duration (White 1999), and the current recommendation
is for three days of the artemisinin-derivative to cover two asexual
parasite life-cycles (Adjuik 2004; WHO 2010).
The artemisinin derivatives also reduce the development of game-
tocytes (the sexual form of the P. falciparum parasite that is ca-
pable of infecting mosquitoes) and consequently the carriage of
gametocytes in the peripheral blood (Price 1996; Targett 2001).
This reduction in infectivity has the potential to reduce the post-
treatment transmission of malaria (particularly in areas of low or
seasonal transmission), which may have important public health
benefits (WHO 2010).
Artemisinin and its derivatives are generally reported as being safe
and well-tolerated, and the safety profile of ACTs may be largely
determined by the partner drug (Nosten 2007; WHO 2010). An-
imal studies of artemisinin derivatives have reported neurotoxi-
city (brain damage), but this has not been seen in human stud-
ies (Price 1999). Animal studies have also shown adverse effects
on the early development of the fetus, and consequently the use
of artemisinin derivatives in pregnant women has so far been re-
stricted to the second and third trimesters and continues to be
evaluated (Nosten 2007). Other reported adverse events include
gastrointestinal (GI) disturbance (stomach upset), dizziness, tin-
nitus (ringing in the ears), neutropenia (low levels of white blood
cells), elevated liver enzymes (a marker for liver damage), and elec-
trocardiographic (ECG) abnormalities (changes in cardiac con-
duction) (Nosten 2007). The incidence of type 1 hypersensitivity
(allergic) reactions is reported to be approximately 1 in 3000 pa-
tients (Nosten 2007).
Piperaquine is a bisquinoline antimalarial whose mode of action is
thought to be similar to that of chloroquine (a 4-aminoquinolone)
(Keating 2012). In vitro studies have shown it is effective against
chloroquine-resistant P. falciparum, although there are reports of
some cross-resistance (Keating 2012). Piperaquine has a very long
elimination half-life of between two to three weeks, similar to
mefloquine but longer than lumefantrine or amodiaquine, and
consequently could be expected to provide a long period of post-
treatment prophylaxis (Davis 2005; Keating 2012).
In a previous review of DHA-P, Myint 2007 noted an association
betweenDHA-P and prolongation of theQT interval in two small
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observational trials (Karunajeewa 2004:N = 62, and Ashley 2004a
THA; N = 32). Prolonged QT interval is a cardiac conduction
defect which can sometimes lead to fatal arrhythmias.
Assessment of antimalarial drug efficacy
TheWHO recommends that first-line antimalarials should have a
treatment failure rate of less than 10%, and that failure rates higher
than 10% should trigger a change in treatment policy (WHO
2010). Treatment failure can be classified as:
Early treatment failure:
• the development of danger signs or severe malaria on days
1, 2, or 3 in the presence of parasitaemia;
• parasitaemia on day 2 higher than on day 0;
• parasitaemia and axillary temperature > 37.5 °C on day
three;
• parasitaemia on day 3 > 20% of count on day 0.
or late treatment failure:
• development of danger signs, or severe malaria, after day
three with parasitaemia;
• presence of P. falciparum parasitaemia and axillary
temperature > 37.5 °C on or after day 4;
• presence of P. falciparum parasitaemia after day 7.
The late reappearance of P. falciparum parasites in the blood can be
due to failure of the drug to completely clear the original parasite
(a recrudescence) or due to a new infection, which is especially
common in areas of high transmission. A molecular genotyping
technique called polymerase chain reaction (PCR) can be used
in clinical trials to distinguish between recrudescence and new
infection, giving a clearer picture of the efficacy of the drug and
its post-treatment prophylactic effect (White 2002; Cattamanchi
2003).
The WHO recommends a minimum follow-up period of 28 days
for antimalarial efficacy trials, but longer follow-up may be re-
quired for antimalarials with long elimination half-lives (White
2002; Bloland 2003). This is because treatment failure due to true
recrudescence of malaria parasites may be delayed until the drug
concentration falls below the minimum concentration required
to inhibit parasite multiplication, which may be beyond 28 days.
The WHO recommends 42 days follow-up for trials involving
lumefantrine and piperaquine and 63 days for mefloquine trials
(WHO 2010).
Why it is important to do this review
This review aims to assist national decision-making by providing a
concise summary of the benefits and harms of DHA-P in compar-
ison to the other recommended ACTs. Other information that is
also important when selecting national first or second-line ACTs
includes:
• the appropriateness of the partner drug within a locality,
based on regional and national overviews of drug resistance and
the intensity of malaria transmission;
• the simplicity of the treatment regimen (co-formulated
products are generally preferred as they reduce the availability
and use of monotherapy, which may in turn reduce the
development of resistance); and
• the cost (since the ACT is likely to represent a large
percentage of the annual health expenditure in highly endemic
countries).
O B J E C T I V E S
To evaluate the effectiveness and safety of DHA-P compared to
other ACTs for the treatment of uncomplicated P. falciparum
malaria in adults and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children (including pregnant women and infants) with
symptomatic, microscopically confirmed, uncomplicated P. falci-
parum malaria.
We also included trials that recruited participants with P. vivax co-
infection.
Types of interventions
Intervention
A three-day course of DHA-P.
Control
A three-day course of an alternative WHO recommended ACT.
Types of outcome measures
Primary outcomes
Total failure at days 28, 42, and 63; PCR-adjusted and PCR-
unadjusted.
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Secondary outcomes
• Gametocyte carriage at day 7 or 14 (preference for day 14
in data analyses);
• Gametocyte development (negative at baseline and positive
at follow-up);
• Change in haemoglobin from baseline (minimum 28 day
follow-up).
Adverse events
• Deaths occurring during follow-up;
• Serious adverse events (life threatening, causing admission
to hospital, or discontinuation of treatment);
• Haematological and biochemical adverse effects (for
example, neutropenia, liver toxicity);
• Early vomiting;
• Other adverse events.
Search methods for identification of studies
Electronic searches
We searched the following databases up to 29 July 2013 using
the search terms detailed in Table 1: Cochrane Infectious Dis-
eases Group Specialized Register; Cochrane Central Register of
Controlled Trials (CENTRAL) published in The Cochrane Li-
brary; MEDLINE; EMBASE; LILACS. We also examined the
metaRegister of Controlled Trials (mRCT) using the search terms
’malaria’ and ’arte* OR dihydroarte*’.
Searching other resources
We contacted individual researchers working in the field, organi-
zations including the WHO, and pharmaceutical companies in-
volved in themanufacture ofDHA-P (Atlantic, Guilin,Holleykin,
HolleyPharm) for information on unpublished trials. In addition,
reference lists of all trials identified by themethods described above
were checked.
Data collection and analysis
Selection of studies
Babalwa Zani (BZ) and Michael Gathu (MG) independently re-
viewed the results of the literature search, obtained full-text copies
of all potentially relevant trials and checked each trial report for
evidence of multiple publications from the same data set.
BZ andMGalso independently assessed each trial for inclusion us-
ing an eligibility form based on the inclusion criteria and resolved
any disagreements through discussion or, where necessary, by con-
sultation with David Sinclair (DS). We contacted trial authors
when further information was necessary. We listed the ineligible
trials and the reasons for their exclusion in the ’Characteristics of
excluded studies’ table.
Data extraction and management
BZ and MG independently extracted data on trial characteristics
including methods, participants, interventions, outcomes, dose,
and drug ratios of the combinations using a pre-tested data extrac-
tion form. We also recorded the number of participants random-
ized and analysed in each treatment group for each outcome and
reported the loss to follow-up in each group.
For dichotomous outcomes, we recorded the number of partici-
pants experiencing the event and the total number of participants
in each treatment group. For continuous outcomes, the arithmetic
means and standard deviations for each treatment group together
with the numbers of participants in each group were extracted.
Where trials reported the data using geometricmeans, we recorded
this information and extracted standard deviations on the log scale.
Where trials gavemedian values, we extracted medians and ranges.
Primary outcome
Our primary analyses drew on the WHO’s protocol for assessing
and monitoring antimalarial drug efficacy (Bloland 2003). This
protocol has been used to guide most efficacy trials since its pub-
lication in 2003, even though it was designed to assess the level
of antimalarial resistance in the study area rather than for com-
parative trials. As a consequence, a high number of randomized
participants are excluded from the final efficacy outcome as losses
to follow-up or voluntary or involuntary withdrawals. For this rea-
son we conducted a series of sensitivity analyses to restore the in-
tegrity of the randomization process and test the robustness of the
results to this methodology (For a summary of the methodology
and sensitivity analysis see Table 2).
PCR-unadjusted total failure
We calculated PCR-unadjusted total failure (P. falciparum) as the
sum of early treatment failures and late treatment failures (with-
out PCR adjustment). The denominator excluded participants for
whom an outcome was not available (for example, those who were
lost to follow-up, withdrew consent, took other antimalarials, or
failed to complete treatment) and those participants who were
found not to fulfil the inclusion criteria after randomization.
PCR-adjusted total failure
We defined PCR-adjusted total failure (P. falciparum) as the sum
of early treatment failures, and late treatment failures due to PCR-
confirmed recrudescence. Participants with indeterminate PCR
results, missing PCR results, or PCR-confirmed new infections
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were treated as involuntary withdrawals and excluded from the
calculation. The denominator excluded participants for whom an
outcome was not available (for example, those who were lost to
follow-up, withdrew consent, took other antimalarials, or failed
to complete treatment) and those participants who did not fulfil
the inclusion criteria after randomization.
These primary outcomes relate solely to failure due to P. falci-
parum. For both PCR-unadjusted and PCR-adjusted total failure,
we retained participants who developed confirmed P. vivax infec-
tion during follow-up in the calculation if they were treated with
chloroquine and continued in follow-up. They were classified as
treatment successes if they did not subsequently develop P. falci-
parum parasitaemia. We excluded from the calculation those par-
ticipants who developed P. vivax parasitaemia and were removed
from the trial’s follow-up.
Assessment of risk of bias in included studies
BZ and MG independently assessed the risk of bias for each trial
using ’The Cochrane Collaboration’s tool for assessing the risk of
bias’ (Higgins 2008) and resolved differences of opinion through
discussion with DS. We followed the guidance to assess whether
adequate steps were taken to reduce the risk of bias across six
domains: sequence generation; allocation concealment; blinding
(of participants, personnel, and outcome assessors); incomplete
outcome data; selective outcome reporting; and other sources of
bias.
For sequence generation and allocation concealment, we reported
themethods used. For blinding,we describedwhowas blinded and
the blinding method. For incomplete outcome data, we reported
the percentage and proportion of participants lost to follow-up.
For selective outcome reporting, any discrepancies between the
methods used and the results were stated in terms of the outcomes
measured or the outcomes reported. For other biases, we described
any other trial features that could have affected the trial result (for
example, if the trial was stopped early).
We categorized our risk of bias judgements as ’low’, ’high’, or
’unclear’. Where risk of bias was unclear, we attempted to contact
the trial authors for clarification and resolved any differences of
opinion through discussion.
Measures of treatment effect
We analysed the data using Review Manager (RevMan) and pre-
sented and combined dichotomous data using risk ratios (RR). For
continuous data summarized by arithmetic means and standard
deviations, we combined data using mean differences. RRs and
mean differences were accompanied by 95% confidence intervals
(CI). We reported medians and ranges in tables.
Unit of analysis issues
We split trials including more than two comparison groups and
analysed as individual pair-wise comparisons. When conducting
meta-analysis, we ensured that participants and cases in the placebo
group were counted only once, by dividing the placebo cases and
participants evenly between the intervention groups.
Dealing with missing data
If data from the trial reports were insufficient, unclear, or missing,
we attempted to contact the trial authors for additional informa-
tion. If the missing data rendered the result uninterpretable, we
excluded the data from the meta-analysis and clearly stated the
reason for exclusion. We explored the potential effects of missing
data through a series of sensitivity analyses (Table 2).
Assessment of heterogeneity
We assessed heterogeneity between trials by inspecting the forest
plots, applying the Chi² test with a 10% level of statistical signif-
icance, and using the I² statistic with a value of 50% to denote
moderate levels of heterogeneity.
Assessment of reporting biases
The possibility of publication bias was assessed by examining fun-
nel plots for asymmetry. We noted that funnel plot asymmetry
could also be caused by differences in methodological quality or
heterogeneity.
Data synthesis
To aid interpretation, we gave the included trials identity codes
including the first author, the year of publication, and the three-
letter international country code or two-letter continent code (for
trials conducted in more than one country). We listed trials in for-
est plots in chronological order of the year the trial was completed.
Using pair-wise comparisons we directly compared treatments.
For outcomes that were measured at different time points, we
stratified the analysis by the time point. The primary outcome
analysis was also stratified by geographical region as a crudemarker
for differences in transmission and resistance patterns.
We performed meta-analysis within geographic regions where ap-
propriate after assessment and investigation of heterogeneity. In
the first instance, we used a fixed-effects model and applied a ran-
dom-effects model when the Chi² test P value was less than 0.1 or
the I² statistic greater than 50%.
Quality of evidence
We assessed the quality of evidence across each outcome measure
using the GRADE approach. The quality rating across studies has
four levels: high, moderate, low, or very low. RCTs are initially
categorized as high quality but can be downgraded after assessment
of five criteria: risk of bias, consistency, directness, imprecision,
and publication bias. Similarly, observational studies are initially
categorized as low quality and can be downgraded by the same
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criteria, but in exceptional circumstances may be upgraded by
three further criteria; large effect size, all plausible confounders
would act to reduce the effect size, and evidence of a dose-response
effect (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
We investigated potential sources of heterogeneity through a series
of analyses, sub-grouping the trials by: geographical region, inten-
sity of malaria transmission (low to moderate versus high malaria
transmission), known parasite resistance, allocation concealment,
participant age, and drug dose (comparing regimens where there
are significant variations in drug dose).
Sensitivity analysis
We conducted a series of sensitivity analyses to investigate the
robustness of the methodology used in the primary analysis. The
aim was to restore the integrity of the randomization process by
adding excluded groups back into the analysis in a stepwise fashion
(see Table 2 for details).
R E S U L T S
Description of studies
See the Characteristics of included studies and Characteristics of
excluded studies section.
Results of the search
We conducted the searches up to 29 July 2013 and identified 90
trials in total. After screening titles and abstracts, we obtained full
text copies of 49 trials. Of these, 34 trials met the inclusion cri-
teria and we excluded 15 trials (Figure 1). We included 27 trials
as primary references and retained seven trials as secondary ref-
erences for additional data on secondary outcomes and adverse
events. One of the 26 trials had two different recruitment settings
which we split and considered as two separate trials (Ashley 2004a
THA; Ashley 2004b THA). One trial (Borrmann 2011 KEN (a))
is pending as we await data for a separate recruitment period from
the trial authors.
Figure 1. Study flow diagram.
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Included studies
We included 27 trials, enrolling 16,382 participants and con-
ducted between 2002 and 2010.
Twelve trials were conducted in Africa; Uganda (three trials),
Kenya (three trials), Sudan (one trial), Rwanda (one trial), Burk-
ina Faso (one trial), and three multi-centre trials with sites in
Kenya, Uganda, Rwanda, Mozambique, Zambia, Gabon, Burk-
ina Faso, Nigeria, Senegal, Côte d’Ivoire, and Cameroon (Bassat
2009 AF; The 4ABC Study 2011 AF; Yavo 2011 AF). Fourteen
trials were conducted in Asia and Oceania; Thailand (five trials),
Myanmar (two trials), Laos (one trial), Vietnam (one trial), Cam-
bodia (one trial), Indonesia (two trials), Papua New Guinea (one
trial); and one multi-centre trial had sites in Thailand, Laos, and
India (Valecha 2010 AS). Only one trial was from South America
(Peru).
The African trials focused on children, while Asian trials included
older populations and excluded children below one year of age.
All trials excluded pregnant and lactating women.
Eleven trials compared DHA-P with AS+MQ, 16 trials compared
DHA-P with AL, four trials compared DHA-P with ASAQ, and
one trial compared DHA-P with AS+SP. Some trials had more
than two arms and compared multiple ACTs.
Three trials (Hasugian 2007 IDN; Ratcliff 2007 IDN;
Karunajeewa 2008 PNG) conducted inAsia andOceania included
participants with P. vivaxmono-infection at baseline. For our pri-
mary analysis we obtained data from the trial authors for only
those participants who had P. falciparum or mixed infection (P.
falciparum and P. vivax) at baseline. Arinaitwe 2009 UGA had
an unusual trial design where participants were followed up for
more than one episode of malaria. We used data from all malaria
episodes in our primary analysis.
We listed the trial details of the included studies in the ’
Characteristics of included studies’ table.
Excluded studies
The reasons for exclusion are in the ’Characteristics of excluded
studies’ table.
Risk of bias in included studies
For a summary of the ’Risk of bias’ assessments, see Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Nine trialswere at low risk of selectionbias, with adequatemethods
for both generation of the randomization sequence and allocation
concealment. A further 18 studies were at unclear risk of selection
bias due to inadequate descriptions of their methods. For primary
outcomes we conducted a sensitivity analysis including only the
trials with adequate allocation concealment.
Blinding
Eighteen trials blinded the microscopists to treatment allocation
and so were at low risk of performance and detection bias for the
primary outcomes. Only four of the included trials blinded the
outcome assessors for adverse events.
Incomplete outcome data
We reported the proportion of participants in each treatment arm
for whom an outcome was not available and conducted sensitivity
analyses to test the possible effect of these losses. Four trials were
at high risk of bias due to high dropout rates (> 15%).
Selective reporting
Due to the varying half-lives of drugs, the choice of which day
to measure outcomes can influence the comparative effects of the
ACTs. If an ACT with a long half-life (DHA-P or AS+MQ) is
compared to a drug with a short half-life (AS+AQ or AS+SP), day
28 outcomes may underestimate PCR-adjusted failure with the
long half-life drug. At later time points (day 42 and 63), drugs
with long half-lives are likely to appear superior in preventing new
infections (PCR-unadjusted failure) which represents a prophy-
lactic effect. We noted this while interpreting the data but did not
consider this a source of trial bias.
Other potential sources of bias
Pharmaceutical companies provided financial support or study
drugs in 13 trials. In the two large trials of the new Eurartesim®
formulation (Bassat 2009 AF & Valecha 2010 AS), the pharma-
ceutical company was fully involved in the design, conduct and
analysis of the trials, In one of these (Bassat 2009 AF), it is stated
that an independent author had access to the primary dataset and
took responsibility for the analyses. We judged this trial to be at
unclear risk of bias. In the second trial, this additional safety mea-
sure was not described and we judged the trial to be at high risk
of bias.
Effects of interventions
See: Summary of findings for the main comparison
Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
for uncomplicated P. falciparum malaria in Africa
Comparison 1. DHA-P versus artesunate plus mefloquine
We found 11 trials, 10 in Asia and one in South America, that
assessed this comparison; conducted between 2002 and 2009.
Allocation concealment was at ’low risk of bias’ in only two trials
(Mayxay 2006 LAO; Grande 2007 PER). Five trials blinded lab-
oratory staff (outcome assessors) to treatment allocation (Ashley
2004a THA; Ashley 2004b THA; Ashley 2005 THA; Smithuis
2010 MMR; Valecha 2010 AS). Patients were unblinded in all tri-
als, and only one trial blinded outcome assessors for adverse effects
(The 4ABC Study 2011 AF).
Total failure
In Asia over 63 days follow-up, recurrent parasitaemias (includ-
ing both recrudescences and new infections) occurred in less than
15% of all participants, with no differences in PCR-unadjusted
treatment failure between groups (day 28: eight trials, 3487 par-
ticipants, Analysis 1.1; day 42: seven trials, 3421 participants,
Analysis 1.3; Day 63: five trials, 2715 participants, Analysis 1.5).
Once adjusted by PCR to exclude new infections, treatment fail-
ure at day 28 was below 5% for both ACTs in all eight trials for
which data was available (eight trials, 3482 participants, Analysis
1.2). Two of the eight trials, conducted in Thailand at trial sites
with multi-drug resistant P. falciparum, found slightly higher lev-
els of recrudescence following AS+MQ and statistically significant
benefits with DHA-P (Ashley 2005 THA; Valecha 2010 AS). Re-
crudescences remained low in both groups over 63 days of follow-
up (day 42: six trials, 2901 participants, Analysis 1.4; day 63: five
trials, 2500 participants, Analysis 1.6).
In the one trial fromSouth America, only day 63 data was available
(Analysis 1.5; Analysis 1.6). Recrudescences and new infections
were very rare with both treatments, but new infections were lower
with AS+MQ (RR 6.19, 95% CI 1.40 to 27.35, one trial, 445
participants, Analysis 1.5).
Gametocytes
AS+MQ appears to clear gametocytes from the peripheral blood
quicker than DHA-P (Gametocyte carriage on Day 7: RR 1.99,
95% CI 1.57 to 2.51, three trials, 2270 participants, Analysis 1.7;
Day 14: RR 5.11, 95% CI 3.26 to 7.99, three trials, 2249 partici-
pants, Analysis 1.7). In addition, the number of participants who
developed detectable gametocytes (after being negative at baseline)
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was low in both groups, but lowest with AS+MQ (RR 3.06, 95%
CI 1.13 to 8.33, three trials, 1234 participants, Analysis 1.8). Five
trials reported additional data on gametocyte carriage which could
not be pooled and are presented in Table 3.
Anaemia
Seven trials reported a variety of measures of haematological
changes between baseline and the last day of follow-up which we
could not pool. None of the individual trials reported differences
between groups (see Table 3).
Adverse events
There was no difference in the frequency of serious adverse events
(eight trials, 3522 participants, Analysis 1.9; see Appendix 2 for
details of serious adverse events).
Nine trials reported some measure of early vomiting (vomiting re-
lated to drug administration) and therewas no difference shown in
any trial (nine trials, 4114 participants, Analysis 1.10). However,
subsequent nausea and vomiting were consistently more common
with AS+MQ (Nausea: RR 0.68, 95% CI 0.60 to 0.78, nine tri-
als, 4531 participants; vomiting: RR 0.59, 95% CI 0.47 to 0.75,
five trials, 2744 participants, Analysis 1.10). Diarrhoea was more
common with DHA-P (RR 1.46, 95% CI 1.05 to 2.04, five trials,
2217 participants, Analysis 1.10).
AS+MQ was consistently associated with increased dizziness (RR
0.72, 95% CI 0.66 to 0.78, nine trials, 4531 participants), and
sleeplessness (RR 0.49, 95% CI 0.40 to 0.60, six trials, 2551 par-
ticipants, Analysis 1.11), and increases in headache (four trials),
fatigue (two trials), nightmares (one trial), and anxiety (one trial)
are reported in the few trials that recorded them (Analysis 1.11).
Palpitationswere alsomore commonwithAS+MQ(RR0.61, 95%
CI 0.45 to 0.82, three trials, 1175 participants, Analysis 1.12),
but only one trial performed routine ECGs in both treatment
groups (Valecha 2010 AS). In this trial there was a baseline imbal-
ance in the prevalence of borderline prolonged QTc (431 to 450
ms in children and adult men/451 to 470 ms in adult women),
using Bazett’s correction method (16.6% DHA-P versus 12.2%
AS+MQ, P = 0.066; authors’ own figures), but not Fridericia’s
method (2.9% DHA-P versus 1.6% AS+MQ, P > 0.05; authors’
own figures).
On day 2, a higher proportion of participants treated with DHA-
P had borderline prolonged QTc by both correction methods
(Bazett’s: 21.4% DHA-P versus 16.3% AS+MQ, P = 0.043; Frid-
ericia’s: 13.0% DHA-P versus 5.3% AS+MQ, P < 0.001; authors’
own figures). There was also a statistically significant increase in
the prevalence of prolonged QTc with DHA-P (> 450 ms in chil-
dren and adult men, and > 470 ms in adult women), using Bazett’s
method but not Fridericia’s method (one trial, 1148 participants,
Analysis 1.12). No consequent arrhythmias were noted, and these
differences were no longer present at day seven (for additional data
see Table 4).
Four trials conducted biochemical monitoring for either renal or
hepatic adverse events. Monitoring was adequate in three trials
(Ashley 2004a THA; Tran 2004 VNM; Grande 2007 PER), and
inadequate in one (Valecha 2010 AS), but incompletely reported
in all four trials. No clinically important toxicities were reported
(see Table 5).
Sensitivity analysis
As described in the methods section, we undertook a series of
sensitivity analyses to test the robustness of our results to different
analysis plans. An example of these is given in Analysis 1.14 &
Analysis 1.15. In general, the method of analysis did not change
the significance of results and so the remaining sensitivity analyses
were deleted.
Comparisons 2 and 3: DHA-P dosing concerns
Two dosing regimens were commonly used in clinical trials of
DHA-P versus AS+MQ, which give the same total dose, but di-
vided into three or four doses, given over three days (see Table 6).
One trial (Ashley 2005 THA) directly compared the three-dose
regimen with the four-dose regimen and found no difference at
any time point (one trial, 318 participants, Analysis 2.1; Analysis
2.2).
In comparisons comparing DHA-P to AS+MQ, six trials used the
three-dose regimen, four trials used the four-dose regimen, and
one trial used both. Stratifying the analysis by dosing regimen did
not reveal any important differences in efficacy between the two
regimens (Analysis 3.1 to Analysis 3.6).
Comparison 4. DHA-P versus artemether-lumefantrine (six
doses)
We found fifteen trials which assessed this comparison; eleven in
Africa, three in Asia and one inOceania; conducted between 2005
and 2011. Eleven of the fifteen trials included children only.
Allocation concealment was at low risk of bias in eight trials (
Kamya 2007 UGA; Ratcliff 2007 IDN; Zongo 2007 BFA; Yeka
2008 UGA; Arinaitwe 2009 UGA; Bassat 2009 AF; The 4ABC
Study 2011 AF; Yavo 2011 AF). Ten out of 14 trials blinded
laboratory staff to treatment allocation.
Total failure
In Africa, PCR-unadjusted treatment failure at day 28 was consis-
tently lower with DHA-P (RR 0.34, 95% CI 0.30 to 0.39, nine
trials, 6200 participants, Analysis 4.1). After PCR adjustment to
exclude new infections, treatment failure at Day 28 was below 5%
with both ACTs in all nine trials, but was consistently lowest with
DHA-P (RR 0.42, 95% CI 0.29 to 0.62, nine trials, 5417 par-
ticipants, Analysis 4.2). Six trials continued follow-up until day
42, and two until day 63. DHA-P appears to have a longer post-
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treatment prophylactic effect than AL6 in keeping with its longer
elimination half-life (Day 42 PCR-unadjusted treatment failure:
RR 0.60, 95% CI 0.53 to 0.67, seven trials, 3301 participants,
Analysis 4.3; Day 63 PCR-unadjusted treatment failure: RR 0.71,
95% CI 0.65 to 0.78, two trials, 3200 participants, Analysis 4.5).
In Asia and Oceania, PCR-unadjusted treatment failure at day
28 was similar between treatments (four trials, 1143 participants,
Analysis 4.1), and with no statistically significant differences after
PCR adjustment (three trials, 925 participants, Analysis 4.2). Of
note, PCR-adjusted treatment failure at day 28 was above 10%
in those treated with DHA-P in the one trial from Papua New
Guinea (Karunajeewa 2008 PNG), but this has not been seen
elsewhere. No differences were seen in PCR-unadjusted or PCR-
adjusted treatment failure at day 42 (two trials, 572 participants,
Analysis 4.3; Analysis 4.4), or day 63 (one trial, 323 participants,
Analysis 4.5; Analysis 4.6).
Gametocytes
SIx trials, all fromAfrica, reported the development of gametocytes
in those negative at baseline. The results were highly heterogenous
and we could not pool them (six trials, 1968 participants) hetero-
geneity: Chi² test, P = 0.001, I² = 78%, Analysis 4.7). Carriage
of gametocytes during the first two weeks was higher with DHA-
P (RR 4.32, 95% 1.48 to 12.63, four trials, 1537 participants,
Analysis 4.8), but lower with DHA-P during weeks three to six;
a finding which may reflect the lower treatment failure rates with
DHA-P at later time points (Analysis 4.8). Bassat 2009 AF reports
that person-gametocyte weeks was higher in those treated with
DHA-P (see Table 7).
In Asia, Karunajeewa 2008 PNG and Ratcliff 2007 IDN report
no differences in gametocyte carriage between groups but did not
give figures, while Smithuis 2010MMRreports higher gametocyte
carriage with DHA-P (see Table 7).
Anaemia
Six trials reported changes in haemoglobin frombaseline to the last
day of follow-up (day 28 or 42). There is a trend towards a small
benefit with DHA-P which may not be of clinical significance (six
trials, 3529 participants, Analysis 4.9).
Adverse events
No difference has been shown in the frequency of serious adverse
events, although the trend is towards a small increase in serious ad-
verse events with DHA-P (nine trials, 7246 participants, Analysis
4.10, see Appendix 2 for details of serious adverse events).
DHA-P is associated with a higher frequency of early vomiting
(drug-related vomiting), which just reached statistical significance
(RR 1.69, 95% CI 1.00 to 2.83, four trials, 2969 participants,
Analysis 4.11), but there was no difference in vomiting overall
(nine trials, 6761 participants, Analysis 4.11).
Compared to AL6, DHA-P was also associated with a slightly
higher frequency of pruritis (RR 1.74, 95% CI 1.03 to 2.92, five
trials, 2033 participants, Analysis 4.14), but there were no differ-
ences in any other clinical side effects (Analysis 4.11 to Analysis
4.14).
Only one trial conducted ECGmonitoring on participants in both
treatment groups (Bassat 2009 AF). Onday 2, a higher proportion
of participants treated with DHA-P had borderline raised QTc in-
tervals (431 to 450ms) when corrected by Bazett’s method (29.1%
DHA-P versus 19.8% AL6, P < 0.001; authors’ own figures), but
not Fridericia’s method (1.0%DHA-P versus 1.2%AL6, P = 0.76;
authors’ own figures). There were no differences in the propor-
tion of patients with prolonged QTc interval (> 450 ms), using
either Bazett’s or Fridericia’s method (one trial, 1548 participants,
Analysis 4.13) or reported at day 7 (see Table 4 for additional
data).
Three trials conducted biochemical monitoring for either renal or
hepatic adverse events (Bassat 2009 AF; The 4ABC Study 2011
AF; Yavo 2011 AF). Monitoring was adequate in all three trials
but incompletely reported in one trial. No clinically important
toxicities were reported (see Table 8).
Comparison 5. DHA-P versus artesunate plus amodiaquine
We found four trials which assessed this comparison; two in Africa
and two in Asia; conducted between 2004 and 2009.
Allocation concealment was assessed as low risk of bias in two trials
(Hasugian 2007 IDN; The 4ABC Study 2011 AF) and unclear
in the other two. In all four trials laboratory staff were blinded to
treatment allocation.
Total failure
In Africa, PCR-unadjusted treatment failure at day 28 was lower
following treatment with DHA-P in both trials (RR 0.49, 95%
CI 0.41 to 0.59, two trials, 2800 participants, Analysis 5.1). After
PCR-adjustment to exclude new infections, the difference between
treatments was no longer statistically significant, but treatment
failure was below 5% following treatment with DHA-P in both
trials, and above 5% followingAS+AQ inRwanda (two trials, 2486
participants, Analysis 5.2). One trial followed participants up to
day 63 (The 4ABC Study 2011 AF), and found no differences in
PCR-unadjusted or PCR-adjusted treatment failure at this time
point (one trial, 2292 participants, Analysis 5.5; Analysis 5.6).
In Asia, PCR-unadjusted treatment failure at day 28 was lower
following treatment with DHA-P (RR 0.38 95% CI 0.18 to 0.77,
two trials, 482participants, Analysis 5.1), and remained lower after
PCR-adjustment although the number of events was very low (RR
0.08, 95% CI 0.01 to 0.40, two trials, 466 participants, Analysis
5.2). One trial followed participants up to day 42 (Hasugian
2007 IDN), and one to day 63 (Smithuis 2010 MMR), when the
differences remained statistically significant in favour of DHA-P
(Analysis 5.3 to Analysis 5.6).
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Gametocytes
Two trials reported no statistically significant differences in game-
tocyte carriage during follow-up but did not report the data (see
Table 9).
Anaemia
Two trials reported no difference between PCV and haemoglobin
levels respectively between the treatment groups (Karema 2006
RWA; Smithuis 2010 MMR; see Table 9). Hasugian 2007 IDN
found that the prevalence of anaemia at day 7 (P = 0.02) and 28
(P = 0.006) was higher with AS+AQ (authors’ own figures); this
may be attributed to the recurrence of parasitaemia with both P.
falciparum and P. vivax being higher in the AS+AQ group.
Adverse events
The frequency of serious adverse events was lower with DHA-P,
and despite few events, this reached statistical significance (RR
0.40 95% CI 0.19 to 0.87, two trials, 2805 participants, Analysis
5.7, see Appendix 2 for details of serious adverse events). The
4ABC Study 2011 AF reported 15 serious adverse events in 1003
participants treated with AS+AQ versus 10/1468 with DHA-P.
The exact nature of these serious adverse eventswas unclear, but the
authors reported no differences in serious adverse events classified
as possibly, probably, or definitely related to the trial drug (4/1003
versus 4/1468).
Hasugian 2007 IDN and Smithuis 2010 MMR found no differ-
ence in the number of participants with early vomiting (two trials,
650 participants, Analysis 5.8).
Pyrexia was the only adverse event that was statistically more com-
mon with DHA-P (RR 1.18 95% CI 1.02 to 1.37, one trial, 2471
participants, Analysis 5.9).
Two trials conducted biochemical monitoring for renal or hep-
atic adverse events (Karema 2006 RWA; Smithuis 2010 MMR).
Monitoring was adequate in both trials but incompletely reported
in one trial. No clinically important toxicities were reported (see
Table 10).
Comparison 6. DHA-P versus artesunate plus sulfadoxine-
pyrimethamine
One trial conducted in Oceania in 2007 assessed this comparison
(Karunajeewa 2008 PNG). The trial authors did not describe any
attempt to conceal allocation. Laboratory staff were blinded to
treatment allocation.
Total failure
At day 28 PCR-adjusted treatment failure was > 10% in both
groups (Analysis 6.2).
There were no statistically significant differences in treatment fail-
ure between the two arms (one trial, 223 participants, Analysis 6.1
to Analysis 6.4)
Gametocytes
No significant differences in gametocyte carriage during follow-
up were reported (figures not reported).
Anaemia
Trial authors reported haemoglobin levels remained similar in both
groups throughout follow-up (figures not reported).
Adverse events
Monitoring for adverse events was undertaken but no differences
between the groups were reported.
D I S C U S S I O N
For summaries of the main results for efficacy see; Summary of
findings for the main comparison; Table 11; Table 12; Table 13;
Table 14; Table 15), and for adverse effects see Appendix 3.
Summary of main results
DHA-P versus artemether lumefantrine
In Africa, during 28 days follow-up, DHA-P is superior to AL6
at preventing further parasitaemia (high quality evidence), and al-
though PCR-adjusted treatment failure was below 5% for both
ACTs it was consistently lower with DHA-P (high quality evi-
dence). DHA-P has a longer prophylactic effect on new infections
which may last for up to 63 days (high quality evidence).
In Asia and Oceania, no differences in treatment failure have been
shown at day 28 (moderate quality evidence), or day 63 (low quality
evidence).
DHA-P and AL6 appear to have similar adverse effect profiles
(moderate quality evidence). DHA-P was associated with border-
line prolongation of QTc interval but no difference was seen in
prolonged QTc (low quality evidence) and no cardiac arrhythmias
were reported.
DHA-P versus artesunate plus mefloquine
In Asia, during 28 days follow-up, DHA-P is as effective as
AS+MQ at preventing further parasitaemia (high quality evidence).
Once adjusted by PCR to exclude new infections, treatment fail-
ure at day 28 was below 5% for both ACTs in all eight trials, but
lower with DHA-P in two trials from sites with multi-drug resis-
tant P. falciparum (high quality evidence). Both combinations con-
tain partner drugs with very long half-lives and no consistent dif-
ference in preventing new infections has been seen between drugs
over 63 days follow-up (moderate quality evidence).
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In the only trial from South America, there were fewer recurrent
parasitaemias over 63 days with AS+MQ (low quality evidence),
but there was no difference between treatments once adjusted by
PCR for new infections (low quality evidence).
Compared to AS+MQ, DHA-P is associated with reduced nau-
sea, vomiting, dizziness, sleeplessness, and palpitations (moderate
quality evidence). The only notable adverse event associated with
DHA-Pwas an increased frequency of prolongation of theQTc in-
terval (low quality evidence), however no cardiac arrhythmias were
reported in these trials.
Overall completeness and applicability of
evidence
DHA-P is one of the most studied ACTs, and we included 27
trials in this review, which enrolled 16,382 adults and children
with uncomplicated malaria. Notably, these trials excluded infants
aged less than six months and pregnant women, and further safety
data is required for these groups.
The efficacy of DHA-P against uncomplicated P. falciparum
malaria in adults and children however is now well established,
and although there is only limited data from South America, it is
likely that the findings of this review can be applied worldwide.
Despite the high efficacy against asexual parasitaemia, DHA-P ap-
pears to have a reduced efficacy against gametocytes. Compared
to DHA-P, both AS+MQ and AL6 reduce the carriage of gameto-
cytes during the first 14 days post-treatment. This deficiency has
been discussed in the literature, and it is likely due to a relative
underdosing of the artemisinin derivative in the combination. The
clinical significance of this effect remains unclear as gametocyte
carriage is only an indirect measure of transmission potential. Fur-
thermore, any increased risk of transmission in the early period
after treatment may be offset by the later improved prophylactic
effect of DHA-P.
DHA-P has been available and in use for several years despite the
lack of a WHO prequalified formulation manufactured according
toGoodManufacturing Practices Standards (GMP), and concerns
about the stability and shelf-life of the dihydroartemisinin combi-
nation (Jansen 2010; Schmatz 2010). However, the Eurartesim®
formulation evaluated by Bassat 2009 AF and Valecha 2010 AS
has now been registered and approved for use by the European
Medicines Agency (EMA) (European Medicines Agency 2011).
The potential for prolongation of the QTc interval is the most
notable adverse effect. This was noted in the EMA’s report where
they advised that DHA-P should not be used in people who have,
or are at risk of, QTc interval prolongation or cardiac arrhythmias,
and should not be taken with other drugs which prolong the QTc
interval (EuropeanMedicines Agency 2011).Noparticipants were
reported to have experienced confirmed cardiac arrhythmias in
these studies.
Systematic reviews in infectious diseases also need to consider the
possibility of changing drug effects over time as drug resistance
patterns change and develop. In this review, we partially explored
this possibility by presenting all forest plots with trials arranged
in chronological order, but we found no evidence of a decline in
efficacy over time. However, a systematic review may not be the
most appropriate way to examine these effects, as RCTs tend to
be conducted for new drugs with little research interest once they
are well established. Selection of first and second line antimalar-
ials should therefore take into account other knowledge on anti-
malarial resistance, such as that produced by the WorldWide An-
timalaria Resistance Network (WWARN 2013).
Quality of the evidence
We assessed the quality of the evidence in this review using the
GRADE approach and presented the evidence in six summary
of findings tables for efficacy (Summary of findings for the main
comparison; Table 12; Table 13; Table 11; Table 14; Table 15),
and in three summary of findings tables for adverse events (in
Appendix 3).
The evidence that DHA-P is at least as effective as AS+MQ in
Asia was of high quality. There was some statistical heterogeneity,
with two trials (predominantly from trial sites inThailand) finding
slightly higher levels of treatment failure with AS+MQ. This may
be a consequence of resistance to mefloquine in the area and was
not considered sufficient to downgrade the evidence.
The evidence for superiority of DHA-P over AL6 in Africa was
of high quality, with no reason to downgrade for risk of bias,
inconsistency, indirectness, or imprecision. It should be noted that
both DHA-P and AL6 performed better than theWHO standard
of 5% PCR-adjusted treatment failure at day 28 in all trials. The
choice between DHA-P and AL6 may therefore be based more on
considerations of adherence and cost, rather than efficacy.
We also assessed the quality of evidence on comparative adverse
effects and presented these in Appendix 3. In general, the evidence
was of moderate to low quality, meaning we can have reasonable
confidence in some of these effects.
Agreements and disagreements with other
studies or reviews
We found three recent systematic reviews of DHA-P (Keating
2012; Naing 2013 & WWARN 2013b), and reviewed the pub-
lic assessment report of Eurartesim® by the EMA (European
Medicines Agency 2011).
The most recent systematic review (Naing 2013) includes 26 of
the 27 trials we included in this review and reaches very similar
conclusions: “DHA-P is non-inferior to other currently usedACTs
such as AS+MQ and AL6” and “the better safety profile of DHA-
P and once-daily dosage improves adherence. For these reasons,
DHA-P has the potential to become a first-line antimalarial drug”.
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The second review (Keating 2012) is more narrative and focuses
on the Eurartesim® formulation registered with the EMA. The
review contains an extensive discussion of the effects of the formu-
lation on the QTc interval, and the author concludes that “there
are currently no data signalling that DHA-P is associated with
clinically significant arrhythmias”. Similarly, the EMA public re-
port concludes that “Treatment emergent QTc prolongation was
asymptomatic in all cases”, and “The magnitude of QTc prolon-
gation is reduced if dosing occurs between meals”. Conditional
for registration, the pharmaceutical company agreed to under-
take further post-marketing evaluation of the effects of DHA-P
on the QTc interval and the potential for arrhythmias (European
Medicines Agency 2011).
The third review (WWARN 2013b) was based on individual pa-
tient data from 24 published and two unpublished studies. The
analysis paid particular attention to the relationship between age,
the drugdose administered, and treatment efficacy. The authors re-
port that treatment failure following DHA-P was highest in young
children (aged between one and five years), and conclude that this
is related to significant underdosing of both dihydroartemisinin
and piperaquine in this age group, and to different pharmacoki-
netics in young children. On this basis, some further dose opti-
mization of this combination is underway.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In Africa, DHA-P seems to reduce treatment failure compared to
AL6, although it should be noted that AL6 also performed above
the WHO standard of 95% cure rate in all these trials. DHA-P
therefore represents an effective alternativewith a simplifieddosing
regimen, and a longer post-treatment prophylactic effect.
In Asia, DHA-P appears to be as effective as the widely used
AS+MQ, and is better tolerated. This may promote DHA-P to
become the first line treatment option.
Implications for research
The efficacy of DHA-P is now well established. Future research
should concentrate on safety surveillance, particularly in infants
and pregnant women, and further appraisal of the potential effects
on cardiac conduction.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adam 2010 SDN
Methods Trial design: An open label RCT
Follow-up: Temperature and blood smears on days 1, 2, 3, 7, 14, 21, and 28. Haemo-
globin concentrations (Hb) measured on days 0 and 28
Adverse event monitoring: Participants requested to attend the health centre any time
they felt unwell. During follow-up participants were asked about the presence of adverse
effects that might be expected from treatment (for example, nausea, vomiting). These
were considered treatment-related if they had not been reported at the participant’s first
presentation
Participants Number of participants: 160
Inclusion criteria: Age≥ 6months, uncomplicatedP. falciparummono-infection, axillary
temperature > 37.5°C or a history of fever within the preceding 24 hrs, able to take oral
treatment, informed consent
Exclusion criteria: Severe or complicated malaria, severe concomitant pathology or other
illness needing medical follow-up incompatible with the trial, allergy to one of the trial
drugs, use of one of the trial drugs in the preceding 28 days, pregnancy
Interventions 1.DHA-P, fixeddose combination, 40mg/320mg adult tablets, 20mg/160mg children’s
tablets (Duo-Cotecxin: Beijing)
• 5 to 9 kg half an adult tablet (or 1 children’s tablet) each day for 3 days
• 10 to 19.9 kg 1 adult tablet (or 2 children’s tablets) each day for 3 days
• 20 to 40 kg 2 adult tablets (or 4 children’s tablets) each day for 3 days
• > 40 kg 3 adult tablets (or 6 children’s tablet) each day for 3 days
• (Equivalent to daily doses of about 2.4 mg dihydroartemisinin/kg and 20 mg
piperaquine/kg)
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novar-
tis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• ≥ 35 kg 4 tablets twice daily for 3 days
All doses were supervised.
Outcomes 1. ACPR at day 28, PCR-adjusted and PCR-unadjusted
2. Gametocyte carriage
3. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Sudan
Setting: Elmouraf health centre, Sinnar
Transmission: Unstable transmission
Resistance: “Multiple drug resistance”
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Adam 2010 SDN (Continued)
Dates: Dec 2009 to Feb 2010
Funding: Beijing Holley-Cotec Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block-randomization using a concealed
envelope system was used to allocate each
patient to one of the two treatment arms”.
Block size was unclear
Allocation concealment (selection bias) Unclear risk Used concealed envelopes, unclear if they
were sequentially numbered or opaque
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “all the slides were double-checked
blindly”.
Blinding for adverse events (performance
and detection bias)
High risk Trial described as “open”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (6.
3% DHA-P versus 7.5% AL6)
Selective reporting (reporting bias) Low risk The WHO recommends 42 day follow-up
in studies of AL6. Day 28 outcomes may
underestimate treatment failure with AL6
Other bias Unclear risk The role of the trial sponsor was not de-
scribed.
Agarwal 2013 KEN
Methods Trial design: An open label RCT
Follow-up: Followed up for 42 days and asked to return on days 1, 2, 3, 7, 14, 21, 28,
35, and 42 after enrolment or at any day if ill. Clinical assessment and blood smear at
each visit. Hb measured on days 0, 7, 14, 28, and 42
Adverse event monitoring: Not reported. “Adverse events investigated and addressed”
Participants Number of participants: 274
Inclusion criteria: Children aged 6 to 59 months with axillary temperature ≥ 37.5 °C
or history of fever in preceding 48 hrs, weight ≥ 5.0 kg, parasitaemia, residing within
10 km of Siaya District Hospital, written informed consent
Exclusion criteria: Lethargy, convulsions, persistent vomiting, inability to drink, signs
of severe malaria, severe anaemia (Hb < 5 g/dL), known hypersensitivity to trial drugs,
presence of chronic medical conditions, treatment with any anti-malarial in preceding
two weeks, previous enrolment in any malaria trial, severe malnutrition (weight-for-age
≤ 3 standard deviations below mean for gender according to WHO standards)
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Agarwal 2013 KEN (Continued)
Interventions 1. DHA-P, fixed dose combination, 20 mg/160 mg tablets (DuoCotexin: Beijing Holley-
Cotec)
• 5 to 6 kg: one half tablet daily
• 7 to 9 kg: one tablet daily
• 10 to 14 kg: two tablets on day 0 then one tablet on days 1 and 2
• 15 to 19 kg: two tablets daily
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novar-
tis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
All doses, except AL evening doses, administered under direct supervision
Outcomes 1. ACPR at days 28 and 42, PCR-unadjusted and PCR-adjusted
2. Mean change in Hb from baseline to day 28
3. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Kenya
Setting: district hospital in western Kenya
Transmission: Holoendemic with high transmission and two seasonal peaks, April to
July and November to December
Resistance: Not reported
Dates: Oct 2010 to Aug 2011
Funding: KEMRI/CDC Research and Public Health Collaboration, Beijing Holley-
Cotec provided DHA-P free of charge
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “children were block randomized in fixed
blocks of ten to treatment”
Allocation concealment (selection bias) Unclear risk None described.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “All microscopists were blinded to the
treatment arm”.
Blinding for adverse events (performance
and detection bias)
Unclear risk No other blinding reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Percentage withdrawn from analysis high
in both treatment groups (17.5% DHA-P
versus 18.2% AL)
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Agarwal 2013 KEN (Continued)
Selective reporting (reporting bias) Low risk All WHO outcomes reported.
Other bias Low risk No other forms of bias identified.
Arinaitwe 2009 UGA
Methods Trial design: An open label RCT
Follow-up: Blood smears taken on days 0, 2, 3, 7, 14, 21, and 28 after each episode and
any time they felt ill. Follow-up continued for up to one year
Adverse event monitoring: Clinicians assessed participants for adverse events using stan-
dardized criteria at each follow-up visit. Passive monitoring was carried out for up to 63
days after treatment. Adverse events were defined as any untoward medical occurrence,
regardless of its suspected relationship to the trial drugs, as per International Conference
of Harmonization guidelines. Adverse events were graded as mild, moderate, severe, or
life threatening
Participants Number of participants: 232, with 671 episodes of uncomplicated falciparum malaria
treated. All episodes treated were included in the analysis
Inclusion criteria: For enrolment in the trial cohort: age 6 weeks to 12 months, HIV
status of mother and child documented, living within a 30 km radius of the trial clinic,
currently breast-feeding if HIV exposed, and informed consent including consent to
come to the trial clinic for any illness and avoid medications given outside of the trial.
For randomization: uncomplicated malaria diagnosed by positive blood smear after doc-
umented fever of ≥ 38.0 °C or history of fever in the past 24 hrs, age ≥ 4 months,
weight ≥ 5 kg
Exclusion criteria: Active medical problems requiring inpatient evaluation. For with-
drawal from trial cohort: movement outside trial area, inability to tolerate trial drugs,
withdrawal of informed consent, inability to be located for > 60 days, or inability to
adhere to trial procedures and schedule
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Duocotecxin: Holley Pharm)
• Target daily dose 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg piperaquine
given in three equally divided daily doses to the nearest quarter tablet.
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novar-
tis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
Only the first daily dose supervised. Subsequent episodes of malaria occurring > 14 days
after a previous episode were treated with the assigned trial drug
Outcomes 1. Recurrent falciparum parasitaemia at day 28, 42, 63, PCR-unadjusted and PCR-
adjusted
2. Gametocyte carriage
3. Mean change in Hb from baseline to day 28
4. Adverse events
Not included in this review:
1. Incidence of malaria after randomization
2. Fever clearance
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3. Parasite clearance
Notes Country: Uganda
Setting: Enrolled from local antenatal clinics in Tororo
Transmission: High transmission
Resistance: Not reported
Dates: Aug 2007 to Jul 2008
Funding: Doris Duke Charitable Foundation and Puget Sound Partners in Global
Health. Holleypharm provided DHA-P free of charge
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was computer gener-
ated by an off-site investigator”
Allocation concealment (selection bias) Low risk “Sequentially numbered, sealed envelopes
containing the treatment group assign-
ments were prepared from the randomiza-
tion list. The study nurse assigned treat-
ment numbers sequentially and allocated
treatment by opening the envelope corre-
sponding to the treatment number”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk No blinding of microscopists reported, but
all slides were re-read by a second micro-
scopist, and a third microscopist resolved
discrepancies
Blinding for adverse events (performance
and detection bias)
High risk Described as “open-label”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar low drop out in both groups (1.7%
DHA-P versus 1.6% AL6)
Selective reporting (reporting bias) Low risk All listed outcomes reported.
Other bias Low risk This trial randomized individuals to an
ACT and then followed them up through
multiple treatment episodes. The data pre-
sented is for the all malaria episodes re-
ported during the trial period
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Ashley 2004a THA
Methods Trial design: A 3-arm RCT
Follow-up: All patients admitted to hospital for 28 days, oral temperature taken every 6
hrs, parasite counts 12-hourly until negative then daily for 28 days
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. All patients had full blood counts, urea,
electrolytes, creatinine, and liver function tests at days 0 and 7
Participants Number of participants: 134
Inclusion criteria: Age > 14 yrs, weight > 40 kg, symptoms of malaria, P. falciparum
parasitaemia, informed consent.
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, contraindication to mefloquine, treatment with mefloquine
in the previous 60 days, sulphonamides or 4-aminoquinolones present in urine on ad-
mission
Interventions 1. DHA-P, fixed dose combination (Artekin: Holleykin)
• Total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48
hrs
2. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses were supervised.
Outcomes 1. Cure rate at day 28, all reappearances of parasites presumed to be recrudescences
as patients hospitalized for duration
2. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low transmission
Resistance: Multiple-drug resistance
Dates: Jul 2002 to Apr 2003
Funding: Mahidol University, Tak Malaria Initiative Project, supported by Bill and
Melinda Gates Foundation, Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation was computer gener-
ated (STATA; version 7; Statacorp)”. Ran-
domized in blocks of six
Allocation concealment (selection bias) Unclear risk “The treatment allocation was concealed
in sealed envelopes labelled with the study
code”, unclear if these were sequentially
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Ashley 2004a THA (Continued)
numbered or opaque
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived”
Blinding for adverse events (performance
and detection bias)
Unclear risk No other blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar loss to follow-up in all groups (10.
6% DHA-P versus 11.9% AS+MQ)
Selective reporting (reporting bias) Low risk The WHO recommends 63 days follow-
up in studies of AS+MQ.Day 28 outcomes
are likely to underestimate treatment fail-
ure with AS+MQ and DHA-P
Other bias Low risk No other sources of bias identified.
Ashley 2004b THA
Methods Trial design: A RCT
Follow-up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. A subset of 55 patients in the DHA-P
group had full blood counts, urea, electrolyte, creatinine and liver function tests at days
0 and 7. Thirty-two patients from the DHA-P group also had ECG monitoring before
and after treatment
Participants Number of participants: 355
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum parasitaemia, informed
consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, contraindication to mefloquine, treatment with mefloquine
in the previous 60 days
Interventions 1. DHA-P, fixed dose combination (Artekin: Holleykin)
• Total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses at 0, 8, 24, and 48
hrs
2. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses were supervised.
Outcomes 1. Cure rate at day 63, PCR-adjusted and PCR-unadjusted
2. P. vivax during follow-up, and mean time to reappearance
3. Gametocyte development during follow-up
4. Mean haematocrit at days 0 and 7
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5. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Four clinics on the Thai-Myanmar border
Transmission: Unstable low and seasonal transmission
Resistance: Multiple-drug resistance
Dates: Jul 2002 to Apr 2003
Funding: Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation was computer gener-
ated (STATA; version 7; Statacorp)”. Ran-
domized in blocks of 9
Allocation concealment (selection bias) Unclear risk “The treatment allocation was concealed
in sealed envelopes labelled with the study
code”, unclear if these were sequentially
numbered or opaque
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived”
Blinding for adverse events (performance
and detection bias)
Unclear risk No other blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar losses to follow-up in all groups (12.
8% DHA-P versus 13.6% AS+MQ)
Selective reporting (reporting bias) Low risk All WHO outcomes reported.
Other bias Low risk No other sources of bias identified.
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Ashley 2005 THA
Methods Trial design: A 3-arm RCT
Follow-up: Temperature and blood smears daily until clearance of fever and parasites,
then weekly attendance for examination, symptom enquiry, malaria smear and haemat-
ocrit until day 63
Adverse event monitoring: Adverse events defined as signs or symptoms that occurred
or became more severe after treatment started. Symptoms were screened at each visit
Participants Number of participants: 499
Inclusion criteria: Age 1 to 65 yrs, symptomatic P. falciparum mono-infection or mixed
infections, informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% of
red blood cells parasitized, treatment with mefloquine in the previous 60 days
Interventions 1. DHA-P, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 4 divided doses at 0, 8, 24, and
48 hrs
2. DHA-P, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.4 mg/kg DHA and 51.2 mg/kg P in 3 divided doses at 0, 24, and 48
hrs
3. Artesunate plusmefloquine, loose combination (Artesunate:Guilin,Mequin: Atlantic)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervised.
Outcomes 1. Cure rate at day 63, PCR-adjusted and PCR-unadjusted
2. P. vivax during follow-up, and mean time to reappearance
3. Gametocyte development during follow-up
4. Mean haematocrit at days 0 and 7
5. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Six clinics on the Thai-Myanmar border
Transmission: Unstable low and seasonal transmission
Resistance: Multiple-drug resistance
Dates: Nov 2004 to Jun 2005
Funding: DnDi, European Union International Co-operation programme, Médecins
sans Frontières, WHO/TDR, Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation list was generated us-
ing STATA; version 7 (Stata)”. Random-
ized in blocks of nine
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Ashley 2005 THA (Continued)
Allocation concealment (selection bias) Unclear risk “The treatment allocation was concealed
in sealed envelopes labelled with the study
code”, unclear if these were sequentially
numbered or opaque
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Laboratory staff reading the blood smears
had no knowledge of the treatment re-
ceived”
Blinding for adverse events (performance
and detection bias)
Unclear risk No other blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low in all groups
(4.2% DHA-P versus 4.8% AS+MQ)
Selective reporting (reporting bias) Low risk AllWHOoutcomes reported.Twopatients
were considered to be early treatment fail-
ures by the reviewers and reclassified as
such. This was not clearly stated in the pa-
per
Other bias Low risk No other sources of bias identified.
Bassat 2009 AF
Methods Trial design: An open label RCT (non-inferiority).
Follow-up: Children were kept at the health facility for the three day treatment period,
and then returned on days 7, 14, 21, 28, 35, and 42, and any time symptoms occurred,
for clinical assessment and blood smears. Haematological and biochemical assessments
were carried out at enrolment, days 3, 28, and 42 and at clinician request
Adverse event monitoring: Monitoring and recording of adverse events was carried out
throughout the trial. A 12-lead ECG was performed at enrolment and on days 2 and 7
to assess any QT/QTc interval prolongation
Participants Number of participants: 1553
Inclusion criteria: Uncomplicated malaria, age 6 to 59 months, body weight > 5 kg, fever
(axillary temperature ≥ 37.5 °C) or history of fever in the preceding 24 hrs, microscop-
ically confirmed P. falciparum mono-infection, asexual parasite densities between 2,000
and 200,000/µL, informed consent
Exclusion criteria: severe malaria or other danger signs, acute malnutrition (weight for
height < 70% of the median National Center for Health Statistics/WHO reference), any
other concomitant illness or underlying disease, contra-indication to trial drugs, ongoing
antimalarial prophylaxis, ECG abnormality requiring urgent management
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets and 20 mg/160 mg tablets
(Eurartesim®, Sigma-Tau)
• Daily dose of 2.25 mg/kg dihydroartemisinin and 18 mg/kg piperaquine,
rounded up to the nearest half tablet
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Bassat 2009 AF (Continued)
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novar-
tis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
All doses were supervised.
Outcomes 1. Adequate clinical and parasitological response on days 14, 28, and 42, PCR-
adjusted and PCR-unadjusted
2. Gametocyte presence and clearance
3. Hb changes from baseline to day 28
4. Adverse events
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Burkina Faso, Kenya, Mozambique, Uganda, and Zambia
Setting: Four rural sites and one peri-urban site.
Transmission: Malaria mesoendemic at all sites. Two sites had high transmission in one
period of the year (Jun to Dec or Nov to May), three others had perennial malaria with
two sites having two peak seasons and one with marked seasonality (Oct to Apr)
Resistance: Documented resistance to chloroquine ranged from 35% in Burkina Faso to
81% in Uganda
Dates: Aug 2005 to Jul 2006
Funding: Medicine for Malaria Venture and Sigma-Tau I.F.R. SpA (Rome)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list stratified by country
was generated by an independent off site
contract research organisation”
Allocation concealment (selection bias) Low risk “Each treatment allocation concealed in
opaque sealed envelopes that were opened
only after the patient’s recruitment”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “assessment of the primary end-point were
made by staff blinded to the treatment as-
signment andbefore availability of the PCR
results”
Blinding for adverse events (performance
and detection bias)
High risk Described as ’open label’. ECG assessment
were interpreted in a blinded manner
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number excluded from primary analysis
similar between groups (7.5%DHA-P ver-
sus 9.7% AL6)
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Bassat 2009 AF (Continued)
Selective reporting (reporting bias) Low risk All outcomes listed in the trial protocol
were assessed.
Other bias Unclear risk “Employees of Sigma-Tau participated in
study design, data entry, collection and
analysis of data”. “An author independent
of the sponsor, Umberto D’Alessandro,
had access to the primary dataset and
takes responsibility for the analyses and
manuscript as a whole”
Grande 2007 PER
Methods Trial design: An open-label RCT
Follow-up: Days 0, 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56, and 63 or any other day they
became ill, for a clinical assessment and malaria film. PCV measurement day 0, 7, 14
and 63. P. vivax treated with CQ.
Adverse event monitoring: Assessed at each follow-up visit, an adverse event defined as
any unfavourable and unintended sign, symptom or disease temporally associated with
the drug administered. Complete blood count, liver, and renal function tests at days 0
and 7
Participants Number of participants: 522
Inclusion criteria: Age 5 to 60 yrs, fever > 37.5 °C or history of fever in the previous 24
hrs, P. falciparum mono-infection 1000 to 200,000/µL.
Exclusion criteria: Pregnancy or lactation, severe malaria, any concomitant illness or
underlying disease, contraindication to any of the trial drugs, history of treatment with
mefloquine in the previous 60 days or chloroquine, primaquine or quinine in previous
14 days
Interventions 1. DHA-P, fixed dose combination (Artekin: Holleykin)
• Total dose: 6.3 mg/kg DHA and 50.4 mg/kg PQP in 3 divided doses, given once
daily for 3 days
2. Artesunate plusmefloquine, loose combination (Artesunate: Guilin, Lariam:Hoffman
La-Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses were supervised.
Outcomes 1. Day 63 cure rate PCR-adjusted and PCR-unadjusted
2. P. vivax during follow-up
3. Gametocyte prevalence at day 0, 7, 14, 21, and 28
4. Gametocyte development during follow-up
5. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
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Notes Country: Peru
Setting: Nine rural health posts
Transmission: Low malaria transmission
Resistance: High CQ and SP resistance
Dates: July 2003 to July 2005
Funding: Directorate-General for Development and Cooperation of the Belgian Gov-
ernment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized in blocks of 10”. No further
details given.
Allocation concealment (selection bias) Low risk “Sealed opaque envelopes were opened
only after the final decision to recruit the
patient had been made”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar loss to follow-up in both groups (8.
7% DHA-P versus 5.9% AS+MQ)
Selective reporting (reporting bias) Low risk All WHO outcomes reported.
Other bias Low risk No other sources of bias identified.
Hasugian 2007 IDN
Methods Trial design: An open label RCT
Follow-up: Daily until fever and parasites cleared then weekly until day 42, for a physical
examination, a symptom questionnaire and malaria film. Hb measured on days 0, 7, and
28
Adverse event monitoring: Assessed at each follow-up visit
Participants Number of participants: 340
Inclusion criteria: Age > 1 yr, weight > 5 kg, slide confirmed malaria (P. falciparum, P.
vivax or both), fever or history of fever in the preceding 48 hrs
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severe malaria, > 4%
red blood cells parasitized, concomitant disease that required hospital admission
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Interventions 1. DHA-P, fixed dose combination (Artekin: Holley)
• Total dose: 6.75 mg/kg DHA and 54 mg/kg PQP in 3 divided doses given once
daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax:Guilin, Flavoquine: Aven-
tis)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervised
Outcomes 1. Parasitological failure on days 42 and 28, PCR-adjusted and PCR-unadjusted
2. Parasitological failure with P. vivax on days 42 and 28
3. Gametocyte carriage after treatment
4. Anaemia at days 0, 7, and 28
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Indonesia
Setting: Rural clinics
Transmission: Unstable
Resistance: Chloroquine and SP resistance
Dates: Jul 2005 to Dec 2005
Funding: Wellcome Trust - National Health and Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list was generated in
blocks of 20 by an independent statistician”
Allocation concealment (selection bias) Low risk “Treatment allocation concealed in an
opaque, sealed envelope that was opened
once the patient had been enrolled”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “All slides were read by a certified micro-
scopist who was blinded to treatment allo-
cation”
Blinding for adverse events (performance
and detection bias)
High risk An open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk The primary outcomedata are unpublished
data including only participants with P. fal-
ciparum mono or co-infection at baseline.
High losses to follow-up in both groups at
day 42 (21% DHA-P versus 24.5 % AL6),
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moderate at day 28 (16.6% DHA-P versus
18.8 % AL6)
Selective reporting (reporting bias) Low risk All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Janssens 2007 KHM
Methods Trial design: An open label RCT
Follow-up: Monitored daily until fever and parasites cleared then weekly to day 63.
Temperature, symptom questionnaire, malaria film, and haematocrit at each visit
Adverse event monitoring: An adverse event defined as any new sign or symptom ap-
pearing after treatment started. At each visit a symptom questionnaire was completed
Participants Number of participants: 464
Inclusion criteria: Age > 1 yr, axillary temp > 37.5 °C or history of fever, signs and
symptoms of uncomplicated malaria, P. falciparum mono or mixed infections, written
informed consent
Exclusion criteria: Pregnancy or lactation, signs or symptoms of severe malaria, > 4% red
blood cells parasitized, a history of convulsions or neuropsychiatric disorder, treatment
with mefloquine in the past 60 days
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Adult total dose: 6 mg/kg DHA and 48 mg/kg P in 4 divided doses, given at 0, 8,
24, and 48 hrs
• Children total dose: 6.4 mg/kg DHA + 51.2 mg/kg P in 4 divided doses, given at
0, 8, 24, 48 hrs
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilin, Mefloquine:
Mepha)
• Adults: 100 mg AS plus 500 mg MQ twice daily on day 0, then 200 mg AS once
daily on day 1 and day 2
• Children: AS 4 mg/kg once daily for 3 days plus 25 mg/kg MQ split into 2 doses
on day 0
All doses supervised.
Outcomes 1. Cure rate at days 63, 42, and 28, PCR-adjusted and PCR-unadjusted
2. P. vivax parasitaemia during follow-up
3. Mean haematocrit at day 0 and 63
4. Adverse effects
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Cambodia
Setting: Rural health centres and outreach malaria clinics
Transmission: Low and seasonal
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Janssens 2007 KHM (Continued)
Resistance: Multiple-drug resistance
Dates: Oct 2002 to March 2003
Funding: Médecins sans Frontières
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated randomisation
(STATA version 8, Statacorp)”
Allocation concealment (selection bias) Unclear risk “Treatment allocations were concealed in
sealed envelopes”. No further details
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up balanced and low in
both groups (9.3% DHA-P versus 10%
AS+MQ)
Selective reporting (reporting bias) Low risk All WHO outcomes reported.
Other bias Low risk No other sources of bias identified.
Kamya 2007 UGA
Methods Trial design: A single blind (outcome assessors) RCT
Follow-up: Standardized history and examination and malaria film on days 0, 1, 2, 3,
7, 14, 21, 28, 35, 42 and any other day they felt unwell. Hb measured at day 0 and
day 42 or day of failure. Anaemia was treated with ferrous sulphate and anthelminthics
according to IMCI guidelines
Adverse event monitoring: Assessed for any new or worsening event at each visit. An
adverse event defined as any untoward medical occurrence, irrespective of its suspected
relationship to the trial medications
Participants Number of participants: 509
Inclusion criteria: Age 6 months to 10 yrs, weight > 5 kg, axillary temp > 37.5 °C or
history of fever in the past 24 hrs, P. falciparum mono-infection 2000 to 200,000/µL,
informed consent
Exclusion criteria: Danger signs or signs of severe malaria, evidence of concomitant
febrile illness, history of serious side effects to trial medication
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Interventions 1. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
2. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Duocotexin: HolleyPharm)
• Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 divided doses, given once daily
for 3 days
• Plus placebo tablet in the evening to simulate twice daily dosing
All doses supervised. All participants received a glass of milk after each dose
Outcomes 1. Risk of treatment failure at day 42, PCR-adjusted and unadjusted
2. Non falciparum species during follow-up
3. Gametocyte development during follow-up
4. Mean increase in Hb at last day of follow-up
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Rural health centre
Transmission: Perennial holoendemic malaria with very high transmission intensity
Resistance: Not reported
Dates: Mar 2006 to July 2006
Funding:USCentres forDisease Control,MalariaConsortiumDrugman,DFID,DHA-
P supplied by HolleyPharm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list was computer gener-
ated by an off-site investigator”
Allocation concealment (selection bias) Low risk “Sequentially numbered, sealed envelopes
containing the treatment group assign-
ments were prepared from the randomisa-
tion list”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Study physicians and laboratory person-
nel involved in assessing outcomes were
blinded to treatment assignments”
Blinding for adverse events (performance
and detection bias)
Low risk Placebos were used to blind participants to
treatment allocation. Trial physicians were
also blinded
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Kamya 2007 UGA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (0.
9% AL6 versus 0.9% DHA-P). A large
number of participants were excluded after
randomization for failing to meet the entry
criteria
Selective reporting (reporting bias) Low risk All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Karema 2006 RWA
Methods Trial design: A 3-arm open label RCT
Follow-up: History, clinical signs and symptoms, and malaria film on days 0, 1, 2, 3, 7,
14, 21, and 28 and any other day they felt unwell. PCV measured at days 0 and 14
Adverse eventmonitoring: An adverse event defined as any unfavourable and unintended
sign associated temporally with the use of the drug administered. Differential WBC
count (and liver function tests at 1 site only) assessed at days 0 and 14
Participants Number of participants: 762
Inclusion criteria: Age 12 to 59 months, weight > 10 kg, axillary temp > 37.5 °C or
history of fever in the preceding 24 hrs, P. falciparummono-infection 2000 to 200,000/
µL.
Exclusion criteria: Severe malaria, any other concomitant illness or underlying disease,
known allergy to trial drugs, clear history of adequate antimalarial treatment in the
previous 72 hrs, PCV < 15%
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleypharm)
• Total dose: DHA 4.8 to 9.3 mg/kg + P 38.4 to 73.8 mg/kg in 3 divided doses,
given once daily for 3 days
2. Artesunate plus amodiaquine, loose combination (Arsumax: Sanofi)
• AS 4 mg/kg once daily for 3 days
• AQ 10 mg/kg once daily for 3 days
All doses supervised
Outcomes 1. ACPR at day 28, PCR-adjusted and PCR-unadjusted
2. Gametocyte prevalence during follow-up
3. Mean PCV at baseline and day 14
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Rwanda
Setting: Peri-urban and rural health centres
Transmission: Not reported
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Resistance: Not reported
Dates: Oct 2003 to Apr 2004
Funding: Belgian Development Co-operation in collaboration with the Prince Leopold
Institute of Tropical Medicine. DHA-P provided by Holleypharm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomly allocated in blocks of 15“,
computer generated sequence (information
from author)
Allocation concealment (selection bias) Unclear risk ”Allocation of treatment was concealed un-
til final recruitment’. No further details
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Laboratory technicians reading malaria
slides did not know the treatment received”
Blinding for adverse events (performance
and detection bias)
High risk An open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very low losses to follow-up in all groups
(0.8% DHA-P versus 0.4% AS+AQ)
Selective reporting (reporting bias) Low risk All WHO outcomes reported. Day 28
outcomes may underestimate failure with
DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Karunajeewa 2008 PNG
Methods Trial design: A 4-arm open label RCT
Follow-up: Standardized follow-up including temperature and malaria film on days 0,
1, 2, 3, 7, 14, 28, and 42. Drug levels assayed on day 7
Adverse event monitoring: None described
Participants Number of participants: 372
Inclusion criteria: Age 0.5 to 5 yrs, axillary temp > 37.5 °C or history of fever in the
preceding 24 hrs, > 1000/µL asexual P. falciparum or > 250/µL asexual P. vivax,P. ovale,
or P. malariae, informed consent
Exclusion criteria: Features of severe malaria, evidence of another infection or coexisting
condition including malnutrition, intake of trial drug in previous 14 days
Interventions 1. Artesunate plus sulfadoxine-pyrimethamine, loose combination (Sanofi-Aventis,
Roche)
• AS 4 mg/kg once daily for 3 days
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Karunajeewa 2008 PNG (Continued)
• SP 25/1.25 mg/kg once on the first day
2. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Beijing Holley-Cotec)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
3. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Novartis),
given with milk
• A 1.7 mg/kg twice daily for 3 days
• L 10 mg/kg twice daily for 3 day
All doses supervised except the evening dose of AL6
Outcomes 1. ACPR (P. falciparum) at days 28 and 42, PCR-adjusted and PCR-unadjusted
2. ACPR (P. vivax) at day 42
3. Gametocyte prevalence during follow-up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
3. Drug levels day 7
Notes Country: Papua New Guinea
Setting: Health centres
Transmission: Holoendemic
Resistance: CQ and SP
Dates: Apr 2005 to Jul 2007
Funding: WHOWestern Pacific Region, Rotary against Malaria in Papua New Guinea,
National Health and Medical Research Council of Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomised assign-
ment with blocks of 24 for each site”
Allocation concealment (selection bias) Unclear risk Not described.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk Microscopists were unaware of treatment
assignments.
Blinding for adverse events (performance
and detection bias)
High risk An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate losses to follow-up in all groups
(11.5% AS+SP versus 13.0% DHA-P ver-
sus 14.2% AL6)
Selective reporting (reporting bias) Low risk All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life
43Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Karunajeewa 2008 PNG (Continued)
Other bias Low risk No other sources of bias identified.
Krudsood 2007 THA
Methods Trial design: An open label RCT
Follow-up: Blood smears every 12 hrs until found to be negative and daily for 28 days.
Haematological and biochemical samples, and urine examined on day 0, 1 and 3 and
weekly for the 4 weeks trial period
Adverse eventmonitoring: Regular physical examinationswere conducted and assessment
was done using non-suggestive questioning by investigators
Participants Number of participants: 191
Inclusion criteria: Male and female patients with uncomplicated malaria confirmed by
positive falciparum asexual blood smear, age ≥ 13 years, body weight ≥ 35kg, ability to
take oral medication, agreement to stay in hospital for at least 28 days, informed consent
Exclusion criteria: Pregnant or lactating women, severe malaria per WHO criteria, vom-
iting not allowing oral medication, concomitant systemic disease or disorder other than
malaria requiring therapy, history of ingestion of antimalarials in preceding 14 days or
with sulphonamides or 4-aminoquinolones in urine
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleypharm)
• Daily dose: DHA 2.0 mg/kg + P 15 mg/kg, given once daily for 3 days
2. Artemether-lumefantrine, fixed dose combination (Coartem: Novartis)
• Daily dose: A 1.6 mg/kg + L 9.6 mg/kg, given twice daily for 3 days
All doses supervised
Outcomes 1. Cure rate at day 28, PCR-unadjusted
2. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Thailand
Setting: Hospital for tropical diseases
Transmission: “No known malaria transmission”
Resistance: Some resistance to P. falciparum reported in Southeast Asia reported
Dates: Nov 2005 to June 2006
Funding: Mahidol University Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported in the trial.
Allocation concealment (selection bias) Unclear risk Not reported.
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Krudsood 2007 THA (Continued)
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk Blinding of microscopists not reported.
Blinding for adverse events (performance
and detection bias)
High risk Trial is ’open-label’.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up in one treatment group
was high (15.5% DHA-P versus 13.8%
AL6)
Selective reporting (reporting bias) Low risk All listed outcomes are reported.
Other bias Low risk No other sources of bias identified.
Mayxay 2006 LAO
Methods Trial design: An open label RCT
Follow-up: Temperature was measured every 6 hrs and patient reviewed daily until fever
and parasites cleared then weekly until day 42 or anytime they felt unwell. At each visit
a malaria film and haematocrit measurement was taken
Adverse event monitoring: Potential adverse events were recorded at each visit
Participants Number of participants: 220
Inclusion criteria: Age > 1 year, axillary temp > 37.5 °C or history of fever in the previous
3 days, P. falciparum mono-infection 1000 to 200,00/µL, were likely to stay in hospital
until parasite clearance and complete 42 days follow-up, informed consent
Exclusion criteria: Pregnancy or lactation, signs of severe malaria, antimalarials in the
previous 3 days, contraindications to the trial drugs
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
2. Artesunate plus mefloquine, loose combination (Artesunate: Guilin, Lariam: Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 15 mg base/kg on day 1 and 10 mg base/kg on day 2
All doses supervised.
Outcomes 1. Cure rate at day 42, PCR-adjusted and PCR-unadjusted
2. P. vivax during follow-up
3. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
3. Gametocyte carriage after treatment
Notes Country: Lao People’s Democratic Republic (Laos)
Setting: District clinic
Transmission: Not reported
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Resistance: Not reported
Dates: May 2004 to Sept 2004
Funding: Western Pacific Regional office of WHO, Wellcome Trust of Great Britain,
Artekin provided by Holleykin Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized in blocks of 10”. No further
details given.
Allocation concealment (selection bias) Low risk “The treatment choice was kept in a sealed
opaque envelope, which was opened only
after the decision to recruit”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open-label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (3.
6% DHA-P versus 1.8% AS+MQ)
Selective reporting (reporting bias) Low risk The WHO recommends 63 days follow-
up in studies of AS+MQ.Day 42 outcomes
are likely to overestimate the efficacy of the
two drugs
Other bias Low risk No other sources of bias identified.
Mens 2008 KEN
Methods Trial design: An open label RCT
Follow-up: Malaria film and Hb level on days 0, 1, 2, 3, 7, 14, and 28, plus QT-NASBA
for detection of sub-microscopic gametocytaemia
Adverse event monitoring: Adverse events were recorded at each visit in the case record
form. An adverse event defined as any unfavourable and unintended sign
Participants Number of participants: 146
Inclusion criteria: Age 6 months to 12 years, axillary temp > 37.5 °C or history of fever,
P. falciparum mono-infection 1000 to 200,000/µL, informed consent
Exclusion criteria: Severe malaria, any other underlying illness
Interventions 1. DHA-P, fixed dose combination, 20 mg/160 mg tablets (Sigma-Tau)
• 4 to 7 kg ½ tablet once daily for 3 days
• 7 to 13 kg 1 tablet once daily for 3 days
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• 13 to 24 kg 2 tablets once daily for 3 days
• 24 to 35 kg 4 tablets once daily for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20/120 mg tablets (Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
All doses supervised and given with a glass of milk.
Outcomes 1. Recurrent parasitaemia at day 28, PCR-adjusted and PCR-unadjusted
2. Gametocyte prevalence during follow-up
3. Mean Hb at day 28
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Kenya
Setting: Health centre
Transmission: High transmission
Resistance: Not reported
Dates: Apr 2007 to Jul 2007
Funding: The Knowledge and Innovation Fund, Koninklijk Instituut voor de Tropen/
Royal Tropical Institute. DHA-P provided free of charge by Sigma-Tau
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer generated randomisation
list”.
Allocation concealment (selection bias) Unclear risk None described.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk Microscopists were blinded to treatment al-
location.
Blinding for adverse events (performance
and detection bias)
Unclear risk No other blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (8.
2% DHA-P versus 8.2% AL6)
Selective reporting (reporting bias) Low risk TheWHOrecommends 42 days follow-up
in studies of AL6. Day 28 outcomes may
underestimate treatment failure with AL6
and DHA-P
Other bias Low risk No other sources of bias identified.
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Ratcliff 2007 IDN
Methods Trial design: An open-label RCT
Follow-up: A symptom questionnaire, physical examination, malaria film and Hb mea-
surement daily until fever and parasites cleared then weekly to day 42
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number of participants: 774
Inclusion criteria: Weight > 10 kg, fever or a history of fever in the preceding 48 hrs,
slide confirmed malaria (P. falciparum, P. vivax or mixed infections)
Exclusion criteria: Pregnancy or lactation, danger signs or signs of severity, parasitaemia
> 4%, concomitant disease requiring hospital admission
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Total dose: DHA 6.75 mg/kg + P 54 mg/kg in 3 divided doses, given once daily
for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 10 to 15 kg 1 tablet twice daily for 3 days
• 15 to 25 kg 2 tablets twice daily for 3 days
• 25 to 35 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
Only the first dose of each day was supervised. All participants advised to take each dose
with a biscuit or milk
Outcomes 1. Parasitological failure at days 42 and 28, PCR-adjusted and PCR-unadjusted
2. P. vivax during follow-up
3. Gametocyte carriage after treatment
4. Anaemia during follow-up
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
Notes Country: Indonesia
Setting: Rural outpatient clinics
Transmission: Unstable
Resistance: Multiple-drug resistance
Dates: Jul 2004 to Jun 2005
Funding: Wellcome Trust UK and National Health and Medical Research Council Aus-
tralia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list was generated in
blocks of 20 patients by an independent
statistician”
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Ratcliff 2007 IDN (Continued)
Allocation concealment (selection bias) Low risk “With each treatment allocation concealed
in an opaque sealed envelope”. No further
details given
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk The microscopists were blinded to treat-
ment allocation.
Blinding for adverse events (performance
and detection bias)
High risk An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk The primary outcomedata are unpublished
data including only participants with P.
falciparum mono or co-infection at base-
line. Losses to follow-up were high in both
groups at day 42 (28.4 % DHA-P versus
25.6%AL6) andmoderate at day 28 (19%
DHA-P versus 17.6% AL6)
Selective reporting (reporting bias) Low risk All WHO outcomes reported. Day 42
outcomes may underestimate failure with
DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Sawa 2013 KEN
Methods Trial design: RCT
Follow-up: Clinical assessment on days 1, 2, 3, 7, 14, 28, and 42 and any other time
when child became ill. Blood smears taken on all follow-up days except day 1
Adverse event monitoring: Not reported
Participants Number of participants: 298
Inclusion criteria:Microscopically confirmedP. falciparum infectionwith asexual parasite
density of 1,000 to 200,000 parasites/µL, tympanic temperature of≥ 37.5 °C or history
of fever in preceding 24 hrs, age 6 months to 10 years, informed consent
Exclusion criteria: Hb level of < 5 g/dL, presence of any other Plasmodium species,
presence of other febrile disease, severe malaria, history of adverse events with trial drugs
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Duocotexin: Holley Pharm)
• Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 equally divided doses, given
once daily for 3 days
• Dose rounded off to nearest half tablet
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• Half tablet per 5 kg body weight
• Dose rounded to nearest half tablet
All doses were supervised. All participants advised to take each dose with fatty food to
facilitate absorption
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Outcomes 1. Parasitological efficacy at days 42 and 28, PCR-adjusted and PCR-unadjusted
2. Gametocyte carriage after treatment
Not included in the review:
1. Malaria transmission to mosquitoes
Notes Country: Kenya
Setting: Community setting
Transmission: Moderate transmission intensity
Resistance: None reported
Dates: Apr to Jun 2009
Funding: Grants from the European Community’s Seventh Framework Programme and
the Bill and Melinda Gates Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was generated for dif-
ferent age strata (<2 years, 2-5 years, and 5-
10 years), using MS Excel”
Allocation concealment (selection bias) Unclear risk Allocation concealment is not reported.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Except for those involved in administering
medication, all staff members engaged in
the trial were blinded to the treatment arm
to which each child was assigned”
Blinding for adverse events (performance
and detection bias)
Low risk All staff blinded were except those admin-
istering drugs.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low number of patients without outcomes
in both groups (DHA-P 7.6%, AL6 5.2%)
Selective reporting (reporting bias) Low risk All WHO outcomes are reported.
Other bias Low risk No other sources of bias identified.
Smithuis 2006 MMR
Methods Trial design: A 4-arm open-label RCT
Follow-up: A symptom questionnaire, malaria film, and gametocyte count on days 0, 1,
2, 3, 7, 14, 21, 28, 35, and 42. Hb was measured on days 0 and 28
Adverse event monitoring: A symptom questionnaire at each visit
Participants Number of participants: 652
Inclusion criteria: Age > 1 year, axillary temperature > 37.5 °C or history of fever in
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the previous 48 hrs, P. falciparum mono-infection 500 to 100,000 parasites/µL or co-
infection with P. vivax, informed consent.
Exclusion criteria: Pregnancy, signs of severe malaria, signs or symptoms of other diseases,
history of taking mefloquine in the previous 2 months or any other antimalarial in the
previous 48 hrs, history of psychiatric disease
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Supervised
2. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Total dose: DHA 6.3 mg/kg + P 50.4 mg/kg in 3 divided doses, given once daily
for 3 days
• Unsupervised
3. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Supervised
4. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Unsupervised
Outcomes 1. Failure Rate at days 42 and 28, 42 PCR-unadjusted and PCR-adjusted
2. P. vivax during follow-up and median time to appearance
3. Gametocyte carriage at days 0, 7, 14, 21, and 28
4. Mean change in Hb from day 0 to day 28
5. Adverse events
Not included in the review:
1. Fever clearance
2. Parasite clearance
3. New gametocyte appearance at day 7 and day 14
Notes Country: Myanmar
Setting: Rural village tracts
Transmission: Seasonal with peaks in the monsoon season Nov to Jan and sometimes in
the early monsoon, May to June
Resistance: Very high rates of CQ and SP resistance
Dates: Nov 2003 to Feb 2004
Funding: Médecins sans Frontières (Holland)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Unmarked and sealed envelopes, contain-
ing the treatment allocation were drawn
from a box
Allocation concealment (selection bias) Unclear risk “Unmarked and sealed envelopes”. No fur-
ther details given.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very low losses to follow-up in both groups.
Selective reporting (reporting bias) Low risk The WHO recommends 63 days follow-
up in studies of AS+MQ.Day 42 outcomes
are likely to overestimate the efficacy of the
two drugs
Other bias Low risk No other sources of bias identified.
Smithuis 2010 MMR
Methods Trial design: A 5-arm open-label RCT
Follow-up: Assessment done weekly for 9 weeks and at any other time they became ill.
Hb was only measured on day 63
Adverse event monitoring: Specific procedures not reported.
Participants Number of participants: 811
Inclusion criteria: Acute uncomplicatedmalaria (parasite density 500 - 200,000 parasites/
µL) or mixed infection, weight > 5 kg, age > 6 months, informed consent
Exclusion criteria: Pregnancy, severe malaria, severe acute malnutrition (weight-for-
height below 70% of median with or without symmetrical peripheral oedema), history
of antimalarial treatment within preceding 48 hrs, history of taking mefloquine in past
8 weeks, known history of hypersensitivity to trial drugs
Interventions 1.DHA-P, fixed dose combination, 40mg/320mg adult tablets, 20mg/160mg children’s
tablets
• DHA 2.5 mg/kg + P 20 mg/kg daily, given once daily for 3 days
• Supervised
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120mg tablets
• A 3.3 mg/kg + L 19.8 mg/kg daily, twice daily for 3 days
• Only first dose was supervised
• Patients were advised to take some fatty food. Mothers were encouraged to
breastfeed treated infants before each dose
3. Artesunate amodiaquine, fixed dose combination, 25 mg/67.5mg tablets, 50 mg/135
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mg tablets, 100 mg/270mg tablets
• AS 4 mg/kg + AQ 10.8 mg base/kg daily, once daily for 3 days
• Supervised
4. Artesunate plus mefloquine, fixed dose combination, 25 mg/55 mg tablets, 100mg/
220mg tablets
• AS 4 mg/kg + MQ 8.8 mg/kg daily, once daily for 3 days
• Supervised
5. Artesunate plus mefloquine, loose combination
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 0
• Supervised
• Dose rounded off to nearest quarter tablet
For children, tablets were crushed and syrup added.
Outcomes 1. Recurrence of P. falciparum after antimalarial treatment on days 28 and 63 PCR-
unadjusted and PCR-adjusted
2. P. vivax during follow-up and median time to appearance
3. Gametocyte carriage at days 0, 7, 14, 21, and 28
4. Mean change in Hb from day 0 to day 28
5. Adverse events
Not included in the review:
1. New gametocyte appearance at day 7
2. Gametocyte carriage after single dose of primaquine
Notes Country: Myanmar
Setting: Three clinics in Rakhine state
Transmission: Seasonal and generally low
Resistance: No resistance reported
Dates: Dec 2008 to Mar 2009
Funding: Médecins sans Frontières (Holland) and the Wellcome Trust Mahidol Univer-
sity Oxford Tropical Medicine Research Programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random assignment was achieved by pa-
tients drawing an envelope from a box after
enrolment”
Allocation concealment (selection bias) Unclear risk “Treatment allocations were put in sealed
envelopes in blocks of 50 for each age-
group”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Microscopists examining blood films were
unaware of treatment allocation”
Blinding for adverse events (performance
and detection bias)
High risk Described as “open-label”.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in each treatment
group (AA 3.2%, AL6 5.6%, AM-F 4.1%,
AM-L 7.5%, DP 3.7%)
Selective reporting (reporting bias) Unclear risk Some WHO outcomes are not reported
(for example, LTF, ETF).
Other bias Low risk No other sources of bias identified.
Tangpukdee 2005 THA
Methods Trial design: An open label RCT
Follow-up: The patients were admitted to hospital for 28 days. Clinical evaluation and
parasite counts were performed 12-hourly until parasites cleared then daily for 28 days
Adverse event monitoring: Assessed daily using non-suggestive questioning. Side effects
were defined as signs and symptoms which occurred or became more severe after treat-
ment started. Routine haematology, biochemistry, and urinalysis were conducted and
baseline and weekly during follow-up
Participants Number of participants: 180
Inclusion criteria: Age >14 years, weight > 40 kg, P. falciparum on blood smear, ability
to take oral medicines, agree to stay in hospital for 28 days, informed consent
Exclusion criteria: Pregnancy or lactation, severe malaria, severe vomiting, concomi-
tant systemic diseases, other antimalarials in the previous 14 days or the presence of
sulphonamides or 4-aminoquinolones in the urine
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Total dose: DHA 6 mg/kg + P 45 mg/kg in 3 divided doses, given once daily for 3
days
2. Artesunate plus mefloquine, loose combination
• AS 4 mg/kg once daily for 3 days
• MQ 8 mg/kg once daily for 3 days
All doses supervised
Outcomes 1. Cure rate at day 28. PCR analysis not performed as all patients hospitalised for
duration of follow-up, so all recurrent parasitaemias presumed to be recrudescence
2. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Thailand
Setting: Bangkok Hospital for Tropical Diseases
Transmission: Low
Resistance: Multiple-drug resistance
Dates: Not given
Funding: Mahidol University Research Grant, Artekin supplied by Holleykin Pharma-
ceuticals
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly treated at a ratio of 1:2”. No
further details given
Allocation concealment (selection bias) Unclear risk None described.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were low and simi-
lar between groups (10.8% DHA-P versus
10% AS+MQ)
Selective reporting (reporting bias) Low risk Day 28 outcomes may overestimate the ef-
ficacy of drugs with long half-lives such as
AS+MQ and DHA-P
Other bias Low risk No other sources of bias identified.
The 4ABC Study 2011 AF
Methods Trial design: An open label multicenter RCT
Follow-up: The patients were admitted to hospital for 3 days in some facilities while in
some, they were kept for only 1h to check for vomiting. They were asked to return on
days 3, 7, 14, 21, and 28. Clinical assessment and blood smears taken at each visit and
when clinically judged to be necessary. Haematological samples were taken at enrolment
and on days 3, 7, 14, and 28. Samples for biochemistry tests (liver and renal function)
were taken at enrolment and on days 7 and 28
Adverse event monitoring: Monitored throughout the trial. Method of monitoring not
specified
Participants Number of participants: 4116
Inclusion criteria: Suspected uncomplicated malaria, age 6 to 59 months, body weight
> 5 kg, microscopically confirmed P. falciparum mono-infection with asexual parasite
density between 2,000 and 200,000/µL, fever (axillary temperature≥ 37.5 °C) or history
of fever in preceding 24 hrs, Hb ≥ 7.0 g/dL, informed consent
Exclusion criteria: Participation in another investigational drug trial in previous 30 days,
known hypersensitivity to study drugs, severe malaria or other danger signs for example
not able to breast-feed or drunk, vomiting (more than twice in 24 hrs), recent history of
convulsions (more than once in 24 hrs), unconscious state, unable to stand or sit, severe
malnutrition (weight for height < 70% of median National Center for Health Statistics/
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The 4ABC Study 2011 AF (Continued)
WHO reference) or other concomitant illness or underlying disease, contra-indication
to receive trial drugs, or ongoing prophylaxis with drugs having antimalarial activity
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg adult tablets, 20 mg/160 mg paedi-
atric tablets (Eurartesim®: Sigma Tau)
• DHA 2.25 mg/kg + P 18 mg/kg daily, given once daily for 3 days
• Dose rounded off to nearest half tablet
2. Artemether-lumefantrine, fixed dose combination (Coartem: Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• Administered with a fatty food (for example, milk or groundnuts)
3. Artesunate-amodiaquine, fixed dose combination, 25 mg/67.5 mg tablets, 50 mg/135
mg tablets, 100 mg/270 mg tablets (Coarsucam: Sanofi Aventis)
• AS 2.8-5.5 mg/kg + AQ 7.5-15 mg/kg, given once daily for 3 days
• < 9 kg 1 tablet of 25 mg/67.5 mg formulation per day
• 9 to 17.9kg 1 tablet of 50 mg/135 mg formulation per day
• 18 to 35.9kg 1 tablet of 100 mg/270 mg formulation per day
All doses supervised.
Outcomes 1. ACPR at day 28, PCR-unadjusted and PCR-adjusted
2. ACPR at day 63, PCR-unadjusted and PCR-adjusted
3. Presence and clearance of gametocytes
4. Hb changes from baseline to days 3, 7, 14, and 28
5. Adverse events
Not included in the review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Seven sub-Saharan African countries (Burkina Faso, Gabon, Nigeria, Rwanda,
Uganda, Zambia, and Mozambique)
Setting: We were unable to identify the trial sites as rural, urban or health facilities
Transmission: Varied across trial regions. Trial regions in Gabon and Nigeria had peren-
nial andhighmalaria transmission; trial regions in Burkina Faso andRwanda had seasonal
but high transmission; trial regions inZambia included areas with seasonal, mesoendemic
transmission; trial regions in Mozambique had perennial, mesoendemic transmission;
Jinja and Tororo trial regions in Uganda had perennial, low transmission while Mbarara
in Uganda had mesoendemic transmission.
Resistance: All sites had notable CQ and SP resistance. CQ resistance ranged from 24%
in Burkina Faso to 100% in Gabon while SP resistance ranged from 4% in Burkina Faso
to 49% in Jinja, Uganda.
Dates: Jul 2007 to Jun 2009
Funding: European Developing Countries Clinical Trials Partnership (EDCTP) and the
Medicine for Malaria Venture (MMV)
Risk of bias
Bias Authors’ judgement Support for judgement
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The 4ABC Study 2011 AF (Continued)
Random sequence generation (selection
bias)
Low risk “A randomization list was produced for
each recruiting site by the National In-
stitute for Health Research Medicines for
Children Research Network Clinical Trials
Unit, University of Liverpool, UK”
Allocation concealment (selection bias) Low risk “Each treatment allocation concealed in
opaque sealed envelopes that were opened
only after the patient’s recruitment”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk Trial is described as “open-label” but the
clinician or other staff following up the pa-
tient and assessing the end points blinded
to the treatment assignment whenever pos-
sible
Blinding for adverse events (performance
and detection bias)
Low risk “the clinician or other staff followingup the
patient and assessing the endpoints blinded
to the treatment assignment whenever pos-
sible”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low loss to follow-up in each treatment
group (3.5% ASAQ, 2.5% DHA-P, 2.4%
AL6)
Selective reporting (reporting bias) Low risk All WHO outcomes are reported.
Other bias Low risk No other sources of bias identified.
Tran 2004 VNM
Methods Trial design: An open label RCT
Follow-up: Malaria film on days 0, 2, and 7. Participants followed up to day 56 but
further details not described
Adverse event monitoring: Not described
Participants Number of participants: 243
Inclusion criteria: Age > 2 yrs, microscopically confirmed uncomplicated P. falciparum
malaria
Exclusion criteria: Pregnancy, evidence of organ dysfunction, unable to tolerate oral
medication, unable to return for follow-up, resident in Dac O for > 2 years
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin)
• Adults: 2 tablets at 0, 6, 24, and 48 hrs
• Children < 15 yrs: 1 tablet at 0, 6, 24, and 48 hrs
2. Artesunate plusmefloquine, loose combination (artesunate:Guilin, Lariam:Hoffman-
La Roche)
• AS 4 mg/kg once daily for 3 days
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• MQ 25 mg base/kg as 2 divided doses 6 hrs apart on day 3
Outcomes 1. Parasitological failure at days 42 and 28, PCR-adjusted and PCR-unadjusted
2. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Vietnam
Setting: Health station
Transmission: Low and seasonal
Resistance: Multiple-drug resistance
Dates: Nov 2001 to Mar 2002
Funding: Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated one of
three treatments in a ratio of 2:2:1”. No
further details given
Allocation concealment (selection bias) Unclear risk “Drugs were kept in identically numbered
opaque envelopes”. No further details
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk No comment on blinding of laboratory
staff.
Blinding for adverse events (performance
and detection bias)
High risk An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There were no losses to follow-up”.
Selective reporting (reporting bias) Unclear risk It is unclear from the paper whether it is
only clinical failure that is being reported
Other bias Low risk No other sources of bias identified.
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Valecha 2010 AS
Methods Trial design: An open-label (non-inferiority) RCT
Follow-up: Particiopants were managed as outpatients unless local practice dictated oth-
erwise (some centres used hospital stays of between 3 and 28 days). Outpatients were
asked to return on days 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56, and 63, and any time they
felt unwell. Blood smears were performed at each visit
Adverse event monitoring: Blood and urine samples were taken for analysis on days 0,
28, 63 (if abnormal on day 28) and on the day of any recurrent parasitaemia. Twelve-
lead ECGs were performed at days 0, 2, 7, 28 (if abnormal on day 7), 63 and on the day
of any recurrent parasitaemia
Participants Number of participants: 1150
Inclusion criteria: Age 3 months to 65 years (≥18 years in India), P. falciparum mono-
infection (80 to 200,000 parasites/µL) or mixed infection, weight ≥ 5 kg, fever (≥ 37.
5 °C) or history of fever, informed consent
Exclusion criteria: Severe malaria, treatment with MQ in the 60 days before screening,
treatment with DHA-P in the 3 months before screening, > 4% parasitised red blood
cells, pregnancy or lactation
Interventions 1. DHA-P, fixed dose combination, adult tablets 40 mg/320 mg, child tablets 20 mg/
160 mg (Eurartesim®: Sigma Tau)
• One dose daily for 3 days
• 2.25 mg/kg DHA and 18 mg/kg piperaquine per dose
• Dose rounded up to the nearest half tablet
2. Artesunate plus mefloquine, loose dose combination, AS 50mg tablets, MQ 250 mg
tablets (Mepha Ltd)
• AS 4mg/kg once daily for 3 days
• MQ none on day 0, then 15 mg/kg once on day 1 and 10 mg/kg once on day 2
All doses supervised.
Outcomes 1. Cure rate at days 28, 42, and 63, PCR corrected and uncorrected
2. Mean change in Hb day 0 to day 63
3. Gametocyte carriage
4. Person-gametocyte-weeks
5. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Thailand (six sites), Laos (two centres), and India (three centres)
Setting: Hospitals and research units.
Transmission: Varied across trial regions. Trial regions in Thailand had unstable, low and
seasonal malaria transmission; trial regions in Laos had seasonal transmission with a peak
just after the heavy rainy months of July to August; trial regions in India included areas
with perennial transmission, perennial transmission with a seasonal peak from June to
September, and transmission active in post monsoon months
Resistance: All sites had notable CQ resistance (estimates of 28 day treatment failure at
the Indian sites ranged from 32% to 67% between 2002 and 2007). The Thai sites also
had multi-drug resistant P. falciparum.
Dates: Jun 2005 to Feb 2007.
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Valecha 2010 AS (Continued)
Funding: Medicines for Malaria Venture, Sigma Tau, and Oxford University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation list was generated by
an external contract research organisation
(MDSPharmaServices) using the planpro-
cedure of SAS (Cary, NC, USA)”
Allocation concealment (selection bias) Unclear risk “Randomisation was conducted under
blinded conditions: the blind to the inves-
tigator and patient in the randomisation
process was maintained by the use of sealed
envelopes”
Envelopes are not described as opaque.
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Evaluation of the PCR test results was
blinded”.
Blinding for adverse events (performance
and detection bias)
High risk Trial is described as “open label”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Proportion of participants not completing
the trial was low in both groups (6.6%
DHA-P versus 6.0% AS+MQ)
Selective reporting (reporting bias) Low risk All listed outcomes reported.
Other bias High risk “A committee representing members of the
DHA-PQP Joint Development Team and
trial site Principal Investigators developed
the protocol. Sigma Tau conducted the
study, collected and analysed data. All au-
thors had access to the primary data and
take responsibility for data reporting accu-
racy and completeness. The corresponding
author had responsibility for the final deci-
sion to submit for publication”
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Yavo 2011 AF
Methods Trial design: An open-label (non-inferiority) RCT
Follow-up: Clinical and physical assessment and blood smears taken on follow-up days
1, 2, 3, 4, 7, 14, 21, and 28 after swallowing first antimalarial. Haematological and
biochemical assessment conducted at baseline and on day 4
Adverse event monitoring: Recorded on the case report forms and graded as mild, mod-
erate or severe
Participants Number of participants: 384
Inclusion criteria: At least 2 years of age, P. falciparummono-infection with parasitaemia
from 2,000 to 200,000/µL of blood in Cameroon and Côte d’Ivoire and 1,000 to 100,
000/µL of blood in Sénégal, fever with axillary temperature≥ 37.5 °C, written informed
consent
Exclusion criteria: History of side-effects to trial drugs, evidence of concomitant febrile
illness, severe malaria or danger signs, treatment with 4-amino quinolones, SP, MG or
halofantrine in previous 7 days or quinine, artemisinin or cyclins in previous 3 days,
pregnancy or nursing, ongoing antimalarial treatment
Interventions 1. DHA-P, fixed dose combination, 40mg/320 mg tablets (Duocotecxin: BeijingHolley-
Cotect Pharmaceutical Co.)
• One dose daily for 3 days
• 5 to 9 kg half tablet
• 10 to 14 kg ¾ tablet
• 15 to 19 kg 1 tablet
• 20 to 24 kg 1¼ tablets
• 25 to 29 kg 1 ½ tablets
• 30 to 34 kg 1 ¾ tablets
• 35 to 39 kg 2 tablets
• 40 to 44 kg 2 ¼ tablets
• 45 to 49 kg 2 ½ tablets
• ≥ 50 kg 3 tablets
• Dose rounded up to the nearest quarter tablet
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novar-
tis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
All doses supervised.
Outcomes 1. ACPR at day 28, PCR-adjusted and PCR-unadjusted
2. Mean change in Hb day 0 to day 63
3. Change in gametocyte carrier status
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Senegal, Côte d’Ivoire, Cameroon
Setting: health facilities
Transmission: Not reported
61Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Yavo 2011 AF (Continued)
Resistance: “CQ and SP resistance reported in most parts of the continent”
Dates: November 2006 to May 2008
Funding: Beijing Holley-Cotec Pharmaceutical Co. Ltd which also supplied DHA-P
free of charge
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “In each study site computer generated ran-
domization codes were prepared by an in-
dependent individual”
Allocation concealment (selection bias) Low risk “These codes were enclosed in sequentially
numbered opaque sealed envelopes, each of
which contained the treatment allocation”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Unclear risk Blinding of microscopists not described.
Blinding for adverse events (performance
and detection bias)
High risk Trial described as “open label”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low percentage of patients without out-
comes (3.0% in DHA-P and 2.1% in AL6)
Selective reporting (reporting bias) Low risk All WHO outcomes are reported. Day
28 outcomes may underestimate effect of
DHA-P
Other bias Low risk No other sources of bias identified.
Yeka 2008 UGA
Methods Trial design: A single blind RCT
Follow-up: Standardized history, physical exam, and malaria film on days 0, 1, 2, 3, 7,
14, 21, 28, 35, and 42 and any other day they were unwell. Hb on days 0 and 42 or the
day of failure. Anaemia was treated with ferrous sulphate and anthelmintics according
to IMCI guidelines
Adverse event monitoring: Assessed at each visit including neurological examination.
Adverse events described as any untoward medical occurrence
Participants Number of participants: 461
Inclusion criteria: Age 6 months to 10 yrs, weight > 5 kg, axillary temp > 37.5 °C or
history of fever in the previous 24 hrs, P. falciparum mono-infection 2000 to 200,000/
µL, informed consent
Exclusion criteria: Danger signs or evidence of severe malaria, concomitant febrile illness,
history of serious side effects to the trial medications
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Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Duocotexin: HolleyPharm)
• Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 divided doses, given once daily
for 3 days
• Plus placebo in the evenings to simulate twice daily dosing
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
All doses supervised and given with a glass of milk
Outcomes 1. ACPR at day 42, PCR-adjusted and PCR-unadjusted
2. Gametocytes development during follow-up
3. Mean increase in Hb at last day of follow-up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
Notes Country: Uganda
Setting: Health centre
Transmission: Moderate transmission
Resistance: Not stated
Dates: Aug 2006 to Apr 2007
Funding: CDC, DfID, DHA-P supplied by Holleypharm, AL6 supplied by Uganda
Ministry of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation list was computer gener-
ated by an off-site investigator”
Allocation concealment (selection bias) Low risk “Sealed opaque envelopes containing the
study number and assigned treatment were
secured in a locked cabinet”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
Low risk “Only the study nurse was aware of as-
signments. All other study personnel were
blinded”
Blinding for adverse events (performance
and detection bias)
Low risk “Patients were not informed of their treat-
ment regimen”. “Only the study nurse was
aware of assignments and adverse events as-
sessed by clinicians. All other study person-
nel were blinded”
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Yeka 2008 UGA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (1.
4% DHA-P versus 1.5% AL6)
Selective reporting (reporting bias) Low risk AllWHO outcomes reported. Day 42 out-
comesmay underestimate treatment failure
with DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Zongo 2007 BFA
Methods Trial design: A 3-arm RCT
Follow-up: A standardized history, examination, and malaria film on days 0, 1, 2, 3, 7,
14, 21, 28, 35, and 42. Hbmeasured on days 0 and 42 or day of clinical failure. Children
with Hb < 10 g/dL were treated with ferrous sulphate and antihelminthic treatment
Adverse event monitoring: Assessed at each visit. Adverse events defined as untoward
medical occurrences
Participants Number of participants: 580
Inclusion criteria: Age > 6 months, weight > 5 kg, axillary temp > 37.5 °C or history of
fever in the last 24 hrs, P. falciparummono-infection 2000 to 200,000/µL, the ability to
participate in 42 days follow-up, informed consent
Exclusion criteria: Danger signs or signs of severe malaria, history of serious adverse
effects related to trial medications, evidence of concomitant febrile illness, antimalarial
use other than chloroquine in previous two weeks, Hb < 5 g/dL
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets (Duocotexin: HolleyPharm)
• Total dose: DHA 6.4 mg/kg + PQP 51.2 mg/kg in 3 divided doses, given once
daily for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem:
Novartis)
• 5 to 14 kg 1 tablet twice daily for 3 days
• 15 to 24 kg 2 tablets twice daily for 3 days
• 25 to 34 kg 3 tablets twice daily for 3 days
• > 35 kg 4 tablets twice daily for 3 days
3. Amodiaquine plus sulfadoxine-pyrimethamine, loose combination (Flavoquine: Aven-
tis, Fansidar: Roche)
• AQ 10 mg/kg once daily on days 0 and 1, then 5 mg/kg once on day 2
• SP 25/1.25 mg/kg on day 0
All doses supervised
Outcomes 1. Risk of treatment failure at days 42 and 28, PCR-adjusted and PCR-unadjusted
2. Gametocyte development during follow-up
3. Hb (mean g/dL) on day 0 and last day of follow-up
4. Adverse events
Not included in this review:
1. Fever clearance
2. Parasite clearance
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Notes Country: Burkino Faso
Setting: Health dispensaries
Transmission: Holoendemic, transmission principally in the rainy season May to Oct
Resistance: Not reported
Dates: Not reported
Funding: Doris Duke Charitable Foundation, Holley Cotec Pharmaceuticals, Interna-
tional Atomic Energy Agency, National Budget of the Institut de Recherche en Sciences
de la Sante
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly assigned on the basis of a com-
puter-generated code provided by an off-
site investigator”
Allocation concealment (selection bias) Low risk “Referred for treatment allocation by a
study nurse not involved in enrolment or
assessment of treatment outcomes”
Blinding formicroscopy outcomes (perfor-
mance bias and detection bias)
High risk “The study was not blinded”.
Blinding for adverse events (performance
and detection bias)
High risk As above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in all groups (8%
DHA-P versus 6.4% AL6 versus 8.2%
AQ+SP)
Selective reporting (reporting bias) Low risk AllWHO outcomes reported. Day 42 out-
comesmay underestimate treatment failure
with DHA-P due to its long half-life
Other bias Low risk No other sources of bias identified.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chinh 2009 Comparison not relevant to this review: two fixed-dose combinations of DHA-P were compared
Guo 1990 Conference presentation. Comparison not relevant to this review: artesunate versus piperaquine
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Gupta 2010 Molecular genotyping analysis based on Kamya 2007 UGA and Yeka 2008 UGA. Contains no new efficacy data.
Karema 2005 Conference presentation of Karema 2006 RWA.
Somé 2010 Polymorphism selection analysis based on Zongo 2007a BFA. Contains no new efficacy data
Song 2011 KHM Comparison not relevant to this review: DHA-P-phosphate (2 day dosage) versus artemether-lumefantrine
Sutanto 2013 Comparison not relevant to this review: DHA-P + primaquine versus DHA-P
Tarning 2008 Pharmacokinetic analysis based on Ashley 2005 THA. Contains no new efficacy data.
Thanh 2009 Quasi-RCT.
Tjitra 2012 Comparison not relevant to this review: Artemisinin-naphthoquine versus DHA-P
Tran 2012 Comparison not relevant to this review: AS monotherapy versus DHA-P
Verret 2011 Nutritional status analysis based on Arinaitwe 2009 UGA. Contains no new efficacy data.
Wang 2008 Quasi-RCT.
Yeka 2013 A comparison of DHA-P versus artemether-lumefantrine as rescue treatments based on The 4ABC Study 2011
AF. Contains no new efficacy data.
Characteristics of studies awaiting assessment [ordered by study ID]
Borrmann 2011 KEN (a)
Methods Trial design: A non-inferiority RCT
Follow-up: Clinical assessment and blood smears taken on days 0, 1, 2, and 3 then weekly until day 63 and finally
on day 84
Adverse event monitoring: Monitoring done on days 0, 1, 2, and 3 then weekly until day 63 and finally on day 84
Participants Number of participants: 474
Inclusion criteria: Uncomplicated malaria, age 6 to 59 months, body weight ≥ 5kg, microscopically confirmed
falciparum mono-infection with asexual parasite density of 2,000 to 200,000 µL, reported or documented axillary
temperature ≥ 37.5 °C, informed consent
Exclusion criteria: Known allergies, severe malaria or danger signs, ECG abnormalities that require urgent manage-
ment, participation in another investigational drug study within previous 30 days
Interventions 1. DHA-P, fixed dose combination, 40 mg/320 mg tablets and 20 mg/160 mg tablets (Eurartesim®, Sigma-Tau)
• Daily dose of 2.25 mg/kg dihydroartemisinin and 18 mg/kg piperaquine, given once daily for 3 days, rounded
up to the nearest half tablet
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg (Coartem: Novartis)
• A 2 mg/kg twice daily for 3 days
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Borrmann 2011 KEN (a) (Continued)
• L 12 mg/kg twice daily for 3 days
All doses were supervised.
Outcomes 1. 28-day cure rate, PCR-adjusted and PCR-unadjusted
2. Risk of recrudescent primary or secondary (re-) infections
3. Gametocyte carrier rate
4. Hb recovery
Not included in this review:
1. Fever clearance time
2. Parasite clearance time
Notes Country: Kenya
Setting: One hospital site.
Transmission: Perennial with peaks trailing two typical annual rainy seasons
Resistance: None reported
Dates: Sep 2005 to Apr 2008
Funding: DFG and MMV grants, European Developing Countries Clinical Trials Partnership (EDCTP) and the
Wellcome Trust
Characteristics of ongoing studies [ordered by study ID]
Tekete 2012 AF
Trial name or title EDCTP Longitudinal study
Methods Trial design: An open-label RCT
Follow-up: Patients will receive same study drug for subsequent episodes of uncomplicated malaria for up to
2 years after first randomization. Haematology, biochemistry and clinical safety will be assessed over this two
year period
Participants Number of participants: 4032
Inclusion criteria: Acute uncomplicated malaria, age > 6 months, weight≥ 5 kg with no clinical sign of severe
malnutrition, axillary temp > 37.5 °C, oral/rectal/tympanic temperature > 38 °C or history of fever in the
last 24 hrs, microscopically confirmed P. falciparum with parasite density less than 200,000/µL, ability to
swallow oral medication, no documented malaria treatment in preceding 2 weeks or 4 weeks for re-inclusion,
the ability to participate in the scheduled follow-up visits, written informed consent
Exclusion criteria: Signs and symptoms of severe/complicated malaria, severe vomiting (more than 3 times in
preceding 24hrs) or inability to tolerate oral medication, severe diarrhoea (3 or more watery stools per day),
known history of clinically significant disorders such as cardiovascular (QTc interval > 450 ms), respiratory
(including active tuberculosis), history of jaundice, renal, hepatic, gastrointestinal, immunological (including
active HIV), neurological, endocrine, or other major psychiatric disorders, history of convulsions or other
abnormality (including recent head trauma), Hb < 7 g/dL, concomitant febrile illness, hypersensitivity to
study drugs, use of any other antimalarial in preceding 2 weeks before enrolment, pregnant or lactating
women, known or suspected chronic alcohol abuse, active Hepatitis A, B or C, liver function tests > 2 times
upper limit of normal, known significant renal impairment indicated by serum creatinine more than 1.5 x
ULN
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Tekete 2012 AF (Continued)
Interventions 1. DHA-P, fixed dose combination, adult tablets 40 mg/320 mg, child tablets 20 mg/160 mg (Eurartesim®:
Sigma Tau)
• One dose daily for 3 days
2. Artemether-lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem: Novartis)
• Dose based on body weight between 2 to 4 tablets/day
• Children given dispersible tablets
• Once daily for 3 days
3. Artesunate-Amodiaquine, fixed dose combination, 3 strengths: 25 mg/67.5 mg, 50 mg/135 mg, 100 mg/
270 mg (Winthrop: Sanofi-aventis)
• Once daily for 3 days
4, Artesunate-Amodiaquine, fixed dose combination (Pyramax: Shin Poong)
• Dose based on body weight between 1 to 4 tablets/sachets per day
• Once daily for 3 days
Outcomes 1. Incidence rate of malaria
2. Repeated treatment safety over 2 years
3. Efficacy of study drugs according to WHO guidelines
Starting date 01 June 2011
Contact information Principal investigator - Dr Abdoulaye Djimde - adjimde@mrtcbko.org
Notes Country: Burkino Faso (2 centres), Mali (1 centre), Guinea (1 centre)
Dates: 01 June 2011 to 29 June 2014
Funding: Medicines for Malaria Venture and European & Developing Countries Clinical Trials Partnership
(EDCTP)
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D A T A A N D A N A L Y S E S
Comparison 1. Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure (P. falciparum) Day
28 PCR-unadjusted
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Asia 8 3487 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.28, 3.72]
2 Total failure (P. falciparum) Day
28 PCR-adjusted
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Asia 8 3482 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.21, 0.80]
3 Total failure (P. falciparum) Day
42 PCR-unadjusted
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Asia 7 3421 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.54, 1.50]
4 Total failure (P. falciparum) Day
42 PCR-adjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Asia 6 2901 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.26, 0.88]
5 Total failure (P. falciparum) Day
63 PCR-unadjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Asia 5 2715 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.69, 1.03]
5.2 South America 1 445 Risk Ratio (M-H, Fixed, 95% CI) 6.19 [1.40, 27.35]
6 Total failure (P. falciparum) Day
63 PCR-adjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Asia 5 2500 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.30, 0.84]
6.2 South America 1 435 Risk Ratio (M-H, Fixed, 95% CI) 9.55 [0.52, 176.35]
7 Gametocyte carriage 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Gametocyte carriage day 0 3 2322 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.66, 1.73]
7.2 Gametocyte carriage day 7 3 2270 Risk Ratio (M-H, Random, 95% CI) 1.99 [1.57, 2.51]
7.3 Gametocyte carriage day
14
3 2249 Risk Ratio (M-H, Random, 95% CI) 5.11 [3.26, 7.99]
7.4 Gametocyte carriage day
21
3 2218 Risk Ratio (M-H, Random, 95% CI) 9.44 [0.80, 110.80]
7.5 Gametocyte carriage day
28
3 2199 Risk Ratio (M-H, Random, 95% CI) 9.55 [1.80, 50.61]
8 Gametocyte development (in
those negative at baseline)
3 1234 Risk Ratio (M-H, Fixed, 95% CI) 3.06 [1.13, 8.33]
9 Serious adverse events (including
deaths)
8 3522 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.59, 2.42]
10 Other adverse events:
Gastrointestinal
10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Early vomiting 9 4114 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.71, 1.15]
10.2 Nausea 9 4531 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.60, 0.78]
10.3 Vomiting 5 2744 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.47, 0.75]
10.4 Anorexia 6 3497 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.73, 1.02]
10.5 Diarrhoea 5 2217 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.05, 2.04]
10.6 Abdominal pain 7 3887 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.82, 1.20]
11 Other adverse events:
Neuro-psychiatric
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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11.1 Headache 4 2039 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.64, 1.00]
11.2 Dizziness 9 4531 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.66, 0.78]
11.3 Sleeplessness 6 2551 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.40, 0.60]
11.4 Fatigue 2 872 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.23, 0.73]
11.5 Nightmares 1 220 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.69]
11.6 Anxiety 1 522 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.03, 0.33]
11.7 Blurred vision 1 464 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.24, 1.02]
11.8 Tinnitus 1 220 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.13, 1.24]
12 Other adverse events:
Cardio-respiratory
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Palpitations 3 1175 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.45, 0.82]
12.2 Cough 1 1148 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.54, 1.19]
12.3 Dyspnoea 1 220 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.08, 1.06]
12.4 Prolonged QT interval
(reported as adverse events)
1 1148 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.72, 2.24]
12.5 Prolonged QT interval
(Bazett’s correction)
1 1148 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [1.20, 3.49]
12.6 Prolonged QT interval
(Fridericia’s correction)
1 1148 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.52, 1.52]
13 Other adverse events:
Musculoskeletal/
dermatological
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Arthralgia 1 1148 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.60, 1.65]
13.2 Myalgia 1 1148 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.63, 1.70]
13.3 Urticaria 2 719 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.15, 2.35]
13.4 Pruritis 2 872 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.26, 1.60]
13.5 Rash 1 220 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.09]
14 Sensitivity analysis: Total failure
Day 63 PCR-unadjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Total failure (P.
falciparum) Day 63
PCR-unadjusted
4 1627 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.52, 1.70]
14.2 Total failure Day 63
PCR-unadjusted (losses to
follow-up included as failures)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.65, 1.38]
14.3 Total failure Day 63
PCR-unadjusted (losses to
follow-up included as successes)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.52, 1.68]
15 Sensitivity analysis: Total failure
Day 63 PCR-adjusted
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Total failure (P.
falciparum) Day 63
PCR-adjusted
4 1497 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.17, 1.83]
15.2 Total failure Day 63
PCR-adjusted (indeterminate
PCR included as failures)
4 1508 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.32, 1.39]
15.3 Total failure Day 63
PCR-adjusted (new infections
included as successes)
4 1627 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.35]
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15.4 Total failure Day 63
PCR-adjusted (losses to
follow-up included as failures)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
15.5 Total failure Day 63
PCR-adjusted (losses to
follow-up included as successes)
4 1801 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.33]
Comparison 2. Dihydroartemisinin-piperaquine dose analysis: 3 dose versus 4 dose regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure PCR-unadjusted 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
1.1 Day 63 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
2 Total failure PCR-adjusted 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
2.1 Day 63 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
Comparison 3. Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure Day 28
PCR-unadjusted
8 3644 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.25, 2.41]
1.1 DHA-P 4 doses 4 1075 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.10, 3.14]
1.2 DHA-P 3 doses 5 2569 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.19, 5.07]
2 Total failure Day 28
PCR-adjusted
8 3633 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.15, 1.65]
2.1 DHA-P 4 doses 4 1067 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.10, 6.11]
2.2 DHA-P 3 doses 5 2566 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.94]
3 Total failure Day 42
PCR-unadjusted
7 3578 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.51, 1.31]
3.1 DHA-P 4 doses 3 957 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.50, 1.28]
3.2 DHA-P 3 doses 5 2621 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.40, 1.99]
4 Total failure Day 42
PCR-adjusted
6 3046 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.20, 1.18]
4.1 DHA-P 4 doses 3 903 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.14, 2.82]
4.2 DHA-P 3 doses 4 2143 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.12, 1.48]
5 Total failure Day 63
PCR-unadjusted
6 3317 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.62, 1.40]
5.1 DHA-P 4 doses 3 1019 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.10]
5.2 DHA-P 3 doses 4 2298 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.52, 2.90]
6 Total failure Day 63
PCR-adjusted
6 3072 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.28, 1.15]
6.1 DHA-P 4 doses 3 908 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.17, 1.04]
6.2 DHA-P 3 doses 4 2164 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.26, 2.77]
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Comparison 4. Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure (P. falciparum) Day
28 PCR-unadjusted
13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Africa 9 6200 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.30, 0.39]
1.2 Asia and Oceania 4 1143 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.64, 1.47]
2 Total failure (P. falciparum) Day
28 PCR-adjusted
12 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 9 5417 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.29, 0.62]
2.2 Asia and Oceania 3 925 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [0.81, 5.03]
3 Total failure (P. falciparum) Day
42 PCR-unadjusted
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Africa 7 3301 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.53, 0.67]
3.2 Asia and Oceania 2 572 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.65, 1.17]
4 Total failure (P. falciparum) Day
42 PCR-adjusted
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Africa 7 2559 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.41, 0.81]
4.2 Asia and Oceania 2 468 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.75, 3.83]
5 Total failure (P. falciparum) Day
63 PCR-unadjusted
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Africa 2 3200 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.65, 0.78]
5.2 Asia 1 323 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.47, 1.88]
6 Total failure (P. falciparum) Day
63 PCR-adjusted
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Africa 2 2097 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.50, 1.04]
6.2 Asia 1 298 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.01]
7 Gametocyte development (in
those negative at baseline)
6 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Gametocyte carriage 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Gametocyte carriage day 1
to 14
4 1537 Risk Ratio (M-H, Fixed, 95% CI) 4.32 [1.48, 12.63]
8.2 Gametocyte carriage day
15 to 28
4 1516 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.06, 0.72]
8.3 Gametocyte carriage day
29 to 42
2 650 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.13, 0.61]
9 Anaemia 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Mean haemoglobin (g/dL)
at baseline
8 6599 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.09, 0.01]
9.2 Mean haemoglobin (g/dL)
at day 28
1 134 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.03, 0.75]
9.3 Mean haemoglobin (g/dL)
at day 42
1 375 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.02, 0.62]
9.4 Mean change in
haemoglobin (g/dL) from
baseline to day 28
2 2185 Mean Difference (IV, Fixed, 95% CI) 0.19 [0.03, 0.34]
9.5 Mean change in
haemoglobin (g/dL) from
baseline to day 42
2 835 Mean Difference (IV, Fixed, 95% CI) 0.26 [0.00, 0.51]
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10 Serious adverse events
(including deaths)
9 7246 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.93, 2.68]
11 Other adverse events:
Gastrointestinal
12 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Early vomiting 4 2969 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.00, 2.83]
11.2 Vomiting 9 6761 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.89, 1.20]
11.3 Nausea 2 547 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.36, 3.76]
11.4 Diarrhoea 7 4889 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.81, 1.09]
11.5 Abdominal pain 5 911 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.65, 1.08]
11.6 Anorexia 5 3834 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.80, 1.08]
12 Other adverse events:
Neuro-psychiatric
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Headache 2 309 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.90, 1.63]
12.2 Sleeplessness 2 547 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.69, 6.16]
12.3 Dizziness 2 547 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.67, 4.15]
12.4 Sleepiness 1 384 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.12, 69.49]
12.5 Weakness 5 1812 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.89, 1.27]
13 Other adverse events:
Cardio-respiratory
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Cough 5 4342 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.95, 1.09]
13.2 Coryza 2 832 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.89, 1.07]
13.3 Prolonged QTc interval
(reported as adverse events)
1 1548 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.51, 1.90]
13.4 Prolonged QTc interval
(Bazett’s correction)
1 1548 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.91, 1.92]
13.5 Prolonged QTc interval
(Fridericia’s correction)
1 1548 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.09, 10.81]
14 Other adverse events:
Musculoskeletal/
dermatological
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Pruritis 5 2033 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.03, 2.92]
14.2 Face oedema 1 384 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.12, 69.49]
Comparison 5. Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure (P. falciparum) Day
28 PCR-unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Africa 2 2800 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.41, 0.59]
1.2 Asia 2 482 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.18, 0.77]
2 Total failure (P. falciparum) Day
28 PCR-adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 2 2486 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.42, 1.06]
2.2 Asia 2 466 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.40]
3 Total failure (P. falciparum) Day
42 PCR-unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Asia 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]
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4 Total failure (P. falciparum) Day
42 PCR-adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Asia 1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]
5 Total failure (P. falciparum) Day
63 PCR-unadjusted
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Africa 1 2292 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.86, 1.07]
5.2 Asia 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.27, 0.89]
6 Total failure (P. falciparum) Day
63 PCR-adjusted
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Africa 1 1506 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.85, 3.83]
6.2 Asia 1 278 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.59]
7 Serious adverse events (including
deaths)
2 2805 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.19, 0.87]
8 Other adverse events:
Gastrointestinal
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Early vomiting 2 650 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.44, 1.56]
8.2 Vomiting 1 2471 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.62, 1.01]
8.3 Nausea 1 316 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.62, 1.61]
8.4 Diarrhoea 2 2787 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.83, 1.27]
8.5 Abdominal pain 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.51, 1.65]
8.6 Anorexia 2 2787 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.72, 1.13]
9 Other adverse events:
Neuro-psychiatric
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Headache 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.14, 6.75]
9.2 Sleeplessness 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.44, 1.41]
10 Other adverse events:
Cardio-respiratory
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Cough 1 2471 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.91, 1.15]
10.2 Palpitations 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.58, 1.35]
Comparison 6. Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total failure (P. falciparum) Day
28 PCR-unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oceania 1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.62, 1.64]
2 Total failure (P. falciparum) Day
28 PCR-adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oceania 1 195 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.46, 2.22]
3 Total failure (P. falciparum) Day
42 PCR-unadjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Oceania 1 215 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.45]
4 Total failure (P. falciparum) Day
42 PCR-adjusted
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Oceania 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.39, 1.51]
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Analysis 1.1. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
1 Total failure (P. falciparum) Day 28 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 1 Total failure (P. falciparum) Day 28 PCR-unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Asia
Tran 2004 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Janssens 2007 KHM 2/195 2/207 1.06 [ 0.15, 7.46 ]
Ashley 2004a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Smithuis 2006 MMR 6/319 0/316 12.88 [ 0.73, 227.64 ]
Ashley 2005 THA 5/318 13/157 0.19 [ 0.07, 0.52 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Valecha 2010 AS 6/667 17/336 0.18 [ 0.07, 0.45 ]
Smithuis 2010 MMR 5/154 2/296 4.81 [ 0.94, 24.48 ]
Subtotal (95% CI) 1985 1502 1.02 [ 0.28, 3.72 ]
Total events: 26 (DHA-P), 34 (AS+MQ)
Heterogeneity: Tau2 = 1.99; Chi2 = 23.41, df = 6 (P = 0.00067); I2 =74%
Test for overall effect: Z = 0.02 (P = 0.98)
0.005 0.1 1 10 200
Favours DHA-P Favours AS+MQ
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Analysis 1.2. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
2 Total failure (P. falciparum) Day 28 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 2 Total failure (P. falciparum) Day 28 PCR-adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Tran 2004 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Ashley 2004a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Janssens 2007 KHM 2/195 1/206 2.11 [ 0.19, 23.11 ]
Smithuis 2006 MMR 2/315 0/316 5.02 [ 0.24, 104.06 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Ashley 2005 THA 2/315 7/151 0.14 [ 0.03, 0.65 ]
Valecha 2010 AS 1/667 8/336 0.06 [ 0.01, 0.50 ]
Smithuis 2010 MMR 0/149 1/310 0.69 [ 0.03, 16.86 ]
Subtotal (95% CI) 1973 1509 0.41 [ 0.21, 0.80 ]
Total events: 9 (DHA-P), 17 (AS+MQ)
Heterogeneity: Chi2 = 11.72, df = 6 (P = 0.07); I2 =49%
Test for overall effect: Z = 2.60 (P = 0.0094)
0.002 0.1 1 10 500
Favours DHA-P Favours AS+MQ
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Analysis 1.3. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
3 Total failure (P. falciparum) Day 42 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 3 Total failure (P. falciparum) Day 42 PCR-unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Asia
Tran 2004 VNM 16/166 7/77 15.5 % 1.06 [ 0.45, 2.47 ]
Janssens 2007 KHM 9/195 9/207 14.7 % 1.06 [ 0.43, 2.62 ]
Mayxay 2006 LAO 4/106 5/108 9.9 % 0.82 [ 0.23, 2.95 ]
Smithuis 2006 MMR 6/319 1/316 4.8 % 5.94 [ 0.72, 49.09 ]
Ashley 2005 THA 16/318 19/157 19.1 % 0.42 [ 0.22, 0.79 ]
Valecha 2010 AS 39/667 34/336 22.7 % 0.58 [ 0.37, 0.90 ]
Smithuis 2010 MMR 8/150 7/299 13.3 % 2.28 [ 0.84, 6.16 ]
Subtotal (95% CI) 1921 1500 100.0 % 0.90 [ 0.54, 1.50 ]
Total events: 98 (DHA-P), 82 (AS+MQ)
Heterogeneity: Tau2 = 0.24; Chi2 = 14.44, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 0.39 (P = 0.70)
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Analysis 1.4. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
4 Total failure (P. falciparum) Day 42 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 4 Total failure (P. falciparum) Day 42 PCR-adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Tran 2004 VNM 2/152 1/71 5.2 % 0.93 [ 0.09, 10.13 ]
Janssens 2007 KHM 3/189 2/200 7.4 % 1.59 [ 0.27, 9.39 ]
Mayxay 2006 LAO 1/103 1/104 3.8 % 1.01 [ 0.06, 15.93 ]
Smithuis 2006 MMR 2/315 0/315 1.9 % 5.00 [ 0.24, 103.73 ]
Ashley 2005 THA 2/304 7/145 36.1 % 0.14 [ 0.03, 0.65 ]
Valecha 2010 AS 5/667 9/336 45.6 % 0.28 [ 0.09, 0.83 ]
Subtotal (95% CI) 1730 1171 100.0 % 0.48 [ 0.26, 0.88 ]
Total events: 15 (DHA-P), 20 (AS+MQ)
Heterogeneity: Chi2 = 8.06, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 2.36 (P = 0.018)
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Analysis 1.5. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
5 Total failure (P. falciparum) Day 63 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 5 Total failure (P. falciparum) Day 63 PCR-unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Janssens 2007 KHM 18/195 22/207 12.9 % 0.87 [ 0.48, 1.57 ]
Ashley 2004b THA 26/154 29/151 17.7 % 0.88 [ 0.54, 1.42 ]
Ashley 2005 THA 29/318 27/157 21.8 % 0.53 [ 0.33, 0.86 ]
Valecha 2010 AS 86/718 53/358 42.7 % 0.81 [ 0.59, 1.11 ]
Smithuis 2010 MMR 14/152 12/305 4.8 % 2.34 [ 1.11, 4.94 ]
Subtotal (95% CI) 1537 1178 100.0 % 0.84 [ 0.69, 1.03 ]
Total events: 173 (DHA-P), 143 (AS+MQ)
Heterogeneity: Chi2 = 10.77, df = 4 (P = 0.03); I2 =63%
Test for overall effect: Z = 1.64 (P = 0.10)
2 South America
Grande 2007 PER 12/219 2/226 100.0 % 6.19 [ 1.40, 27.35 ]
Subtotal (95% CI) 219 226 100.0 % 6.19 [ 1.40, 27.35 ]
Total events: 12 (DHA-P), 2 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
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Analysis 1.6. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
6 Total failure (P. falciparum) Day 63 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 6 Total failure (P. falciparum) Day 63 PCR-adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Janssens 2007 KHM 4/181 5/190 12.8 % 0.84 [ 0.23, 3.08 ]
Ashley 2004b THA 3/131 9/131 23.7 % 0.33 [ 0.09, 1.20 ]
Ashley 2005 THA 3/292 7/137 25.1 % 0.20 [ 0.05, 0.77 ]
Valecha 2010 AS 11/667 10/336 35.0 % 0.55 [ 0.24, 1.29 ]
Smithuis 2010 MMR 2/140 2/295 3.4 % 2.11 [ 0.30, 14.80 ]
Subtotal (95% CI) 1411 1089 100.0 % 0.50 [ 0.30, 0.84 ]
Total events: 23 (DHA-P), 33 (AS+MQ)
Heterogeneity: Chi2 = 4.92, df = 4 (P = 0.30); I2 =19%
Test for overall effect: Z = 2.61 (P = 0.0092)
2 South America
Grande 2007 PER 4/211 0/224 100.0 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 211 224 100.0 % 9.55 [ 0.52, 176.35 ]
Total events: 4 (DHA-P), 0 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 1.7. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
7 Gametocyte carriage.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 7 Gametocyte carriage
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gametocyte carriage day 0
Smithuis 2006 MMR 137/327 103/325 1.32 [ 1.08, 1.62 ]
Grande 2007 PER 35/262 43/260 0.81 [ 0.54, 1.22 ]
Valecha 2010 AS 0/767 0/381 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1356 966 1.07 [ 0.66, 1.73 ]
Total events: 172 (DHA-P), 146 (AS+MQ)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.48, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Gametocyte carriage day 7
Smithuis 2006 MMR 118/322 58/318 2.01 [ 1.53, 2.64 ]
Grande 2007 PER 17/256 9/256 1.89 [ 0.86, 4.16 ]
Valecha 2010 AS 59/749 15/369 1.94 [ 1.11, 3.37 ]
Subtotal (95% CI) 1327 943 1.99 [ 1.57, 2.51 ]
Total events: 194 (DHA-P), 82 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 5.74 (P < 0.00001)
3 Gametocyte carriage day 14
Smithuis 2006 MMR 84/318 17/318 4.94 [ 3.00, 8.13 ]
Grande 2007 PER 10/253 1/253 10.00 [ 1.29, 77.54 ]
Valecha 2010 AS 30/742 3/365 4.92 [ 1.51, 16.01 ]
Subtotal (95% CI) 1313 936 5.11 [ 3.26, 7.99 ]
Total events: 124 (DHA-P), 21 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 7.14 (P < 0.00001)
4 Gametocyte carriage day 21
Smithuis 2006 MMR 26/316 0/310 52.00 [ 3.18, 849.49 ]
Grande 2007 PER 1/247 1/250 1.01 [ 0.06, 16.09 ]
Valecha 2010 AS 16/733 0/362 16.32 [ 0.98, 271.26 ]
Subtotal (95% CI) 1296 922 9.44 [ 0.80, 110.80 ]
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 43 (DHA-P), 1 (AS+MQ)
Heterogeneity: Tau2 = 2.71; Chi2 = 4.68, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.79 (P = 0.074)
5 Gametocyte carriage day 28
Smithuis 2006 MMR 6/318 0/314 12.84 [ 0.73, 226.91 ]
Grande 2007 PER 3/243 0/249 7.17 [ 0.37, 138.12 ]
Valecha 2010 AS 9/722 0/353 9.30 [ 0.54, 159.38 ]
Subtotal (95% CI) 1283 916 9.55 [ 1.80, 50.61 ]
Total events: 18 (DHA-P), 0 (AS+MQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
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Analysis 1.8. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
8 Gametocyte development (in those negative at baseline).
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 8 Gametocyte development (in those negative at baseline)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2004b THA 3/168 2/163 37.4 % 1.46 [ 0.25, 8.60 ]
Ashley 2005 THA 9/310 1/153 24.6 % 4.44 [ 0.57, 34.74 ]
Grande 2007 PER 8/227 2/213 38.0 % 3.75 [ 0.81, 17.48 ]
Total (95% CI) 705 529 100.0 % 3.06 [ 1.13, 8.33 ]
Total events: 20 (DHA-P), 5 (AS+MQ)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
9 Serious adverse events (including deaths).
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 9 Serious adverse events (including deaths)
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Janssens 2007 KHM (1) 0/228 0/236 0.0 [ 0.0, 0.0 ]
Ashley 2004b THA (2) 1/179 0/176 2.95 [ 0.12, 71.93 ]
Ashley 2004a THA (3) 0/67 0/67 0.0 [ 0.0, 0.0 ]
Mayxay 2006 LAO (4) 0/110 1/110 0.33 [ 0.01, 8.09 ]
Ashley 2005 THA (5) 11/333 4/166 1.37 [ 0.44, 4.24 ]
Grande 2007 PER (6) 0/262 3/260 0.14 [ 0.01, 2.73 ]
Tangpukdee 2005 THA 0/120 0/60 0.0 [ 0.0, 0.0 ]
Valecha 2010 AS (7) 12/767 3/381 1.99 [ 0.56, 7.00 ]
Total (95% CI) 2066 1456 1.20 [ 0.59, 2.42 ]
Total events: 24 (DHA-P), 11 (AS+MQ)
Heterogeneity: Chi2 = 3.60, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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all deemed related to drug: 1 anaemia, 1 convulsion, 1 encephalitis)
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(1) Janssens 2007 KHM: No serious adverse events reported
(2) Ashley 2004b THA: One death occurred following DHA-P. No Other serious adverse events reported.
(3) Ashley 2004a: No serious adverse events reported
(4) Mayxay 2006 LAO: One severe neuropsychiatric reaction in AS+MQ group
(5) Ashley 2005 THA: All serious adverse events except one case of severe vomiting after AS+MQ were judged to be unrelated or unlikely to be due to the study
treatment
(6) Grande 2007 PER: Three serious drug related events with AS+MQ requiring stopping treatment (encephalopathy, anxiety and arrhythmia, palpitations and chest pain)
(7) Valecha 2010 AS: For DHA-P six SAE deemed related to drug: 2 cases of anemia, 1 viral infection, 1 Wolf-Parkinson-White synrome, 1 convulsion, 1 encephalitis), for
AS+MQ three SAE,
Analysis 1.10. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
10 Other adverse events: Gastrointestinal.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 10 Other adverse events: Gastrointestinal
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Early vomiting
Ashley 2004a THA (1) 0/67 0/67 0.0 [ 0.0, 0.0 ]
Ashley 2004b THA (2) 9/179 5/177 1.78 [ 0.61, 5.21 ]
Ashley 2005 THA (3) 8/333 6/166 0.66 [ 0.23, 1.88 ]
Grande 2007 PER (4) 10/262 11/260 0.90 [ 0.39, 2.09 ]
Janssens 2007 KHM (5) 56/228 67/236 0.87 [ 0.64, 1.17 ]
Smithuis 2006 MMR (6) 8/156 10/162 0.83 [ 0.34, 2.05 ]
Smithuis 2010 MMR (7) 10/161 25/330 0.82 [ 0.40, 1.67 ]
Tangpukdee 2005 THA (8) 0/120 0/60 0.0 [ 0.0, 0.0 ]
Valecha 2010 AS (9) 4/769 0/381 4.46 [ 0.24, 82.72 ]
Subtotal (95% CI) 2275 1839 0.91 [ 0.71, 1.15 ]
Total events: 105 (DHA-P), 124 (AS+MQ)
Heterogeneity: Chi2 = 3.21, df = 6 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
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(. . . Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Nausea
Ashley 2004b THA 16/179 26/176 0.61 [ 0.34, 1.09 ]
Ashley 2005 THA 37/333 22/166 0.84 [ 0.51, 1.37 ]
Grande 2007 PER 126/262 156/260 0.80 [ 0.68, 0.94 ]
Janssens 2007 KHM 15/228 29/236 0.54 [ 0.29, 0.97 ]
Mayxay 2006 LAO 6/110 24/110 0.25 [ 0.11, 0.59 ]
Smithuis 2006 MMR 39/327 65/325 0.60 [ 0.41, 0.86 ]
Smithuis 2010 MMR 28/161 63/330 0.91 [ 0.61, 1.36 ]
Tangpukdee 2005 THA 5/120 4/60 0.63 [ 0.17, 2.24 ]
Valecha 2010 AS 22/767 26/381 0.42 [ 0.24, 0.73 ]
Subtotal (95% CI) 2487 2044 0.68 [ 0.60, 0.78 ]
Total events: 294 (DHA-P), 415 (AS+MQ)
Heterogeneity: Chi2 = 15.98, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 5.85 (P < 0.00001)
3 Vomiting
Ashley 2004b THA 8/179 14/176 0.56 [ 0.24, 1.31 ]
Ashley 2005 THA 23/333 18/166 0.64 [ 0.35, 1.15 ]
Grande 2007 PER 53/262 73/260 0.72 [ 0.53, 0.98 ]
Mayxay 2006 LAO 3/110 11/110 0.27 [ 0.08, 0.95 ]
Valecha 2010 AS 19/767 24/381 0.39 [ 0.22, 0.71 ]
Subtotal (95% CI) 1651 1093 0.59 [ 0.47, 0.75 ]
Total events: 106 (DHA-P), 140 (AS+MQ)
Heterogeneity: Chi2 = 4.95, df = 4 (P = 0.29); I2 =19%
Test for overall effect: Z = 4.39 (P = 0.000011)
4 Anorexia
Grande 2007 PER 111/262 112/260 0.98 [ 0.81, 1.20 ]
Janssens 2007 KHM 15/228 26/236 0.60 [ 0.32, 1.10 ]
Mayxay 2006 LAO 10/110 17/110 0.59 [ 0.28, 1.23 ]
Smithuis 2006 MMR 10/327 19/325 0.52 [ 0.25, 1.11 ]
Smithuis 2010 MMR 22/161 46/330 0.98 [ 0.61, 1.57 ]
Valecha 2010 AS 38/767 21/381 0.90 [ 0.54, 1.51 ]
Subtotal (95% CI) 1855 1642 0.86 [ 0.73, 1.02 ]
Total events: 206 (DHA-P), 241 (AS+MQ)
Heterogeneity: Chi2 = 6.12, df = 5 (P = 0.29); I2 =18%
Test for overall effect: Z = 1.77 (P = 0.076)
5 Diarrhoea
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Study or subgroup DHA-P AS+MQ Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2004b THA 12/179 8/176 1.47 [ 0.62, 3.52 ]
Ashley 2005 THA 33/333 8/166 2.06 [ 0.97, 4.35 ]
Mayxay 2006 LAO 8/110 9/110 0.89 [ 0.36, 2.22 ]
Smithuis 2006 MMR 11/327 9/325 1.21 [ 0.51, 2.89 ]
Smithuis 2010 MMR 20/161 27/330 1.52 [ 0.88, 2.62 ]
Subtotal (95% CI) 1110 1107 1.46 [ 1.05, 2.04 ]
Total events: 84 (DHA-P), 61 (AS+MQ)
Heterogeneity: Chi2 = 2.13, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
6 Abdominal pain
Ashley 2004b THA 22/179 8/176 2.70 [ 1.24, 5.91 ]
Ashley 2005 THA 28/333 13/166 1.07 [ 0.57, 2.02 ]
Grande 2007 PER 73/262 79/260 0.92 [ 0.70, 1.20 ]
Mayxay 2006 LAO 12/110 18/110 0.67 [ 0.34, 1.32 ]
Smithuis 2006 MMR 3/327 0/325 6.96 [ 0.36, 134.16 ]
Smithuis 2010 MMR 19/161 49/330 0.79 [ 0.48, 1.30 ]
Valecha 2010 AS 40/767 20/381 0.99 [ 0.59, 1.68 ]
Subtotal (95% CI) 2139 1748 0.99 [ 0.82, 1.20 ]
Total events: 197 (DHA-P), 187 (AS+MQ)
Heterogeneity: Chi2 = 10.45, df = 6 (P = 0.11); I2 =43%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 31.62, df = 5 (P = 0.00), I2 =84%
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(1) Ashley 2004a: ’Early vomiting’
(2) Ashley 2004b: Vomiting of drug dose
(3) Ashley 2005: Vomiting of drug dose
(4) Grande 2007: Vomiting within 1 hour of dose
(5) Janssens 2007: Vomiting on day 0
(6) Smithius 2006: Vomiting within 1 hour of dose
(7) Smithius: Vomiting in first 24 hours
(8) Tangpukdee 2005: Vomiting due to study drug
(9) Valecha 2010: Excluded due to persistent vomiting
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Analysis 1.11. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
11 Other adverse events: Neuro-psychiatric.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 11 Other adverse events: Neuro-psychiatric
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache
Mayxay 2006 LAO 11/110 30/110 22.1 % 0.37 [ 0.19, 0.69 ]
Smithuis 2010 MMR 2/161 0/330 0.2 % 10.22 [ 0.49, 211.56 ]
Tangpukdee 2005 THA 4/120 2/60 2.0 % 1.00 [ 0.19, 5.31 ]
Valecha 2010 AS 138/767 77/381 75.7 % 0.89 [ 0.69, 1.14 ]
Subtotal (95% CI) 1158 881 100.0 % 0.80 [ 0.64, 1.00 ]
Total events: 155 (DHA-P), 109 (AS+MQ)
Heterogeneity: Chi2 = 9.22, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Dizziness
Ashley 2004b THA 25/179 34/176 5.1 % 0.72 [ 0.45, 1.16 ]
Ashley 2005 THA 37/333 28/166 5.5 % 0.66 [ 0.42, 1.04 ]
Grande 2007 PER 185/262 218/260 32.3 % 0.84 [ 0.77, 0.93 ]
Janssens 2007 KHM 9/228 26/236 3.8 % 0.36 [ 0.17, 0.75 ]
Mayxay 2006 LAO 12/110 39/110 5.8 % 0.31 [ 0.17, 0.56 ]
Smithuis 2006 MMR 104/327 144/325 21.3 % 0.72 [ 0.59, 0.88 ]
Smithuis 2010 MMR 87/161 215/330 20.8 % 0.83 [ 0.70, 0.98 ]
Tangpukdee 2005 THA 4/120 3/60 0.6 % 0.67 [ 0.15, 2.88 ]
Valecha 2010 AS 11/767 24/381 4.7 % 0.23 [ 0.11, 0.46 ]
Subtotal (95% CI) 2487 2044 100.0 % 0.72 [ 0.66, 0.78 ]
Total events: 474 (DHA-P), 731 (AS+MQ)
Heterogeneity: Chi2 = 35.76, df = 8 (P = 0.00002); I2 =78%
Test for overall effect: Z = 7.94 (P < 0.00001)
3 Sleeplessness
Ashley 2004b THA 15/179 28/176 10.9 % 0.53 [ 0.29, 0.95 ]
Ashley 2005 THA 42/333 26/166 13.4 % 0.81 [ 0.51, 1.27 ]
Grande 2007 PER 27/262 98/260 37.9 % 0.27 [ 0.19, 0.40 ]
Janssens 2007 KHM 16/228 36/236 13.6 % 0.46 [ 0.26, 0.81 ]
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Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mayxay 2006 LAO 17/110 31/110 11.9 % 0.55 [ 0.32, 0.93 ]
Smithuis 2010 MMR 18/161 49/330 12.4 % 0.75 [ 0.45, 1.25 ]
Subtotal (95% CI) 1273 1278 100.0 % 0.49 [ 0.40, 0.60 ]
Total events: 135 (DHA-P), 268 (AS+MQ)
Heterogeneity: Chi2 = 16.29, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 7.13 (P < 0.00001)
4 Fatigue
Mayxay 2006 LAO 13/110 28/110 82.3 % 0.46 [ 0.25, 0.85 ]
Smithuis 2006 MMR 1/327 6/325 17.7 % 0.17 [ 0.02, 1.37 ]
Subtotal (95% CI) 437 435 100.0 % 0.41 [ 0.23, 0.73 ]
Total events: 14 (DHA-P), 34 (AS+MQ)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.01 (P = 0.0026)
5 Nightmares
Mayxay 2006 LAO 1/110 11/110 100.0 % 0.09 [ 0.01, 0.69 ]
Subtotal (95% CI) 110 110 100.0 % 0.09 [ 0.01, 0.69 ]
Total events: 1 (DHA-P), 11 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.021)
6 Anxiety
Grande 2007 PER 3/262 29/260 100.0 % 0.10 [ 0.03, 0.33 ]
Subtotal (95% CI) 262 260 100.0 % 0.10 [ 0.03, 0.33 ]
Total events: 3 (DHA-P), 29 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
7 Blurred vision
Janssens 2007 KHM 10/228 21/236 100.0 % 0.49 [ 0.24, 1.02 ]
Subtotal (95% CI) 228 236 100.0 % 0.49 [ 0.24, 1.02 ]
Total events: 10 (DHA-P), 21 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
8 Tinnitus
Mayxay 2006 LAO 4/110 10/110 100.0 % 0.40 [ 0.13, 1.24 ]
Subtotal (95% CI) 110 110 100.0 % 0.40 [ 0.13, 1.24 ]
Total events: 4 (DHA-P), 10 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 32.52, df = 7 (P = 0.00), I2 =78%
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Analysis 1.12. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
12 Other adverse events: Cardio-respiratory.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 12 Other adverse events: Cardio-respiratory
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Palpitations
Janssens 2007 KHM 9/228 23/236 23.2 % 0.41 [ 0.19, 0.86 ]
Mayxay 2006 LAO 7/110 23/110 23.6 % 0.30 [ 0.14, 0.68 ]
Smithuis 2010 MMR 32/161 79/330 53.2 % 0.83 [ 0.58, 1.20 ]
Subtotal (95% CI) 499 676 100.0 % 0.61 [ 0.45, 0.82 ]
Total events: 48 (DHA-P), 125 (AS+MQ)
Heterogeneity: Chi2 = 6.78, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 3.26 (P = 0.0011)
2 Cough
Valecha 2010 AS 60/767 37/381 100.0 % 0.81 [ 0.54, 1.19 ]
Subtotal (95% CI) 767 381 100.0 % 0.81 [ 0.54, 1.19 ]
Total events: 60 (DHA-P), 37 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 Dyspnoea
Mayxay 2006 LAO 3/110 10/110 100.0 % 0.30 [ 0.08, 1.06 ]
Subtotal (95% CI) 110 110 100.0 % 0.30 [ 0.08, 1.06 ]
Total events: 3 (DHA-P), 10 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
4 Prolonged QT interval (reported as adverse events)
Valecha 2010 AS (1) 41/767 16/381 100.0 % 1.27 [ 0.72, 2.24 ]
Subtotal (95% CI) 767 381 100.0 % 1.27 [ 0.72, 2.24 ]
Total events: 41 (DHA-P), 16 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
5 Prolonged QT interval (Bazett’s correction)
Valecha 2010 AS 66/767 16/381 100.0 % 2.05 [ 1.20, 3.49 ]
Subtotal (95% CI) 767 381 100.0 % 2.05 [ 1.20, 3.49 ]
Total events: 66 (DHA-P), 16 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
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Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Prolonged QT interval (Fridericia’s correction)
Valecha 2010 AS 36/767 20/381 100.0 % 0.89 [ 0.52, 1.52 ]
Subtotal (95% CI) 767 381 100.0 % 0.89 [ 0.52, 1.52 ]
Total events: 36 (DHA-P), 20 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 20.02, df = 5 (P = 0.00), I2 =75%
0.05 0.2 1 5 20
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(1) Defined as >450 ms in children and adult men and > 470 ms in adult women on day 2.
Analysis 1.13. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
13 Other adverse events: Musculoskeletal/dermatological.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 13 Other adverse events: Musculoskeletal/dermatological
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Arthralgia
Valecha 2010 AS 42/767 21/381 100.0 % 0.99 [ 0.60, 1.65 ]
Subtotal (95% CI) 767 381 100.0 % 0.99 [ 0.60, 1.65 ]
Total events: 42 (DHA-P), 21 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Myalgia
Valecha 2010 AS 46/767 22/381 100.0 % 1.04 [ 0.63, 1.70 ]
Subtotal (95% CI) 767 381 100.0 % 1.04 [ 0.63, 1.70 ]
Total events: 46 (DHA-P), 22 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
3 Urticaria
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Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashley 2005 THA 3/333 0/166 11.8 % 3.50 [ 0.18, 67.36 ]
Mayxay 2006 LAO 1/110 5/110 88.2 % 0.20 [ 0.02, 1.68 ]
Subtotal (95% CI) 443 276 100.0 % 0.59 [ 0.15, 2.35 ]
Total events: 4 (DHA-P), 5 (AS+MQ)
Heterogeneity: Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.75 (P = 0.45)
4 Pruritis
Mayxay 2006 LAO 4/110 11/110 95.6 % 0.36 [ 0.12, 1.11 ]
Smithuis 2006 MMR 3/327 0/325 4.4 % 6.96 [ 0.36, 134.16 ]
Subtotal (95% CI) 437 435 100.0 % 0.65 [ 0.26, 1.60 ]
Total events: 7 (DHA-P), 11 (AS+MQ)
Heterogeneity: Chi2 = 3.51, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.93 (P = 0.35)
5 Rash
Mayxay 2006 LAO 0/110 1/110 100.0 % 0.33 [ 0.01, 8.09 ]
Subtotal (95% CI) 110 110 100.0 % 0.33 [ 0.01, 8.09 ]
Total events: 0 (DHA-P), 1 (AS+MQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 1.67, df = 4 (P = 0.80), I2 =0.0%
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Analysis 1.14. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
14 Sensitivity analysis: Total failure Day 63 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 14 Sensitivity analysis: Total failure Day 63 PCR-unadjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total failure (P. falciparum) Day 63 PCR-unadjusted
Ashley 2004b THA 26/154 29/151 30.6 % 0.88 [ 0.54, 1.42 ]
Janssens 2007 KHM 18/195 22/207 27.7 % 0.87 [ 0.48, 1.57 ]
Ashley 2005 THA 29/318 27/157 30.4 % 0.53 [ 0.33, 0.86 ]
Grande 2007 PER 12/219 2/226 11.3 % 6.19 [ 1.40, 27.35 ]
Subtotal (95% CI) 886 741 100.0 % 0.94 [ 0.52, 1.70 ]
Total events: 85 (DHA-P), 80 (AS+MQ)
Heterogeneity: Tau2 = 0.24; Chi2 = 10.50, df = 3 (P = 0.01); I2 =71%
Test for overall effect: Z = 0.21 (P = 0.83)
2 Total failure Day 63 PCR-unadjusted (losses to follow-up included as failures)
Ashley 2004b THA 51/179 54/176 27.4 % 0.93 [ 0.67, 1.28 ]
Janssens 2007 KHM 38/215 45/230 25.0 % 0.90 [ 0.61, 1.33 ]
Ashley 2005 THA 43/332 36/166 24.6 % 0.60 [ 0.40, 0.89 ]
Grande 2007 PER 45/252 27/251 23.1 % 1.66 [ 1.06, 2.59 ]
Subtotal (95% CI) 978 823 100.0 % 0.95 [ 0.65, 1.38 ]
Total events: 177 (DHA-P), 162 (AS+MQ)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.26, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Total failure Day 63 PCR-unadjusted (losses to follow-up included as successes)
Ashley 2004b THA 26/179 29/176 30.6 % 0.88 [ 0.54, 1.43 ]
Janssens 2007 KHM 18/215 22/230 27.7 % 0.88 [ 0.48, 1.59 ]
Ashley 2005 THA 29/332 27/166 30.5 % 0.54 [ 0.33, 0.88 ]
Grande 2007 PER 12/252 2/251 11.1 % 5.98 [ 1.35, 26.43 ]
Subtotal (95% CI) 978 823 100.0 % 0.94 [ 0.52, 1.68 ]
Total events: 85 (DHA-P), 80 (AS+MQ)
Heterogeneity: Tau2 = 0.23; Chi2 = 10.06, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.22 (P = 0.82)
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Analysis 1.15. Comparison 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine, Outcome
15 Sensitivity analysis: Total failure Day 63 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Dihydroartemisinin-piperaquine versus Artesunate plus mefloquine
Outcome: 15 Sensitivity analysis: Total failure Day 63 PCR-adjusted
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total failure (P. falciparum) Day 63 PCR-adjusted
Ashley 2004b THA 3/131 9/131 29.7 % 0.33 [ 0.09, 1.20 ]
Janssens 2007 KHM 4/181 5/190 29.5 % 0.84 [ 0.23, 3.08 ]
Ashley 2005 THA 3/292 7/137 28.8 % 0.20 [ 0.05, 0.77 ]
Grande 2007 PER 4/211 0/224 12.0 % 9.55 [ 0.52, 176.35 ]
Subtotal (95% CI) 815 682 100.0 % 0.57 [ 0.17, 1.83 ]
Total events: 14 (DHA-P), 21 (AS+MQ)
Heterogeneity: Tau2 = 0.78; Chi2 = 6.94, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Total failure Day 63 PCR-adjusted (indeterminate PCR included as failures)
Ashley 2004b THA 7/135 10/132 35.1 % 0.68 [ 0.27, 1.74 ]
Janssens 2007 KHM 4/181 6/191 24.2 % 0.70 [ 0.20, 2.45 ]
Ashley 2005 THA 6/295 8/138 30.9 % 0.35 [ 0.12, 0.99 ]
Grande 2007 PER 4/211 1/225 9.8 % 4.27 [ 0.48, 37.86 ]
Subtotal (95% CI) 822 686 100.0 % 0.67 [ 0.32, 1.39 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.28, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 1.08 (P = 0.28)
3 Total failure Day 63 PCR-adjusted (new infections included as successes)
Ashley 2004b THA 7/154 10/151 35.8 % 0.69 [ 0.27, 1.76 ]
Janssens 2007 KHM 4/195 6/207 23.8 % 0.71 [ 0.20, 2.47 ]
Ashley 2005 THA 6/318 8/157 31.1 % 0.37 [ 0.13, 1.05 ]
Grande 2007 PER 4/219 1/226 9.3 % 4.13 [ 0.47, 36.64 ]
Subtotal (95% CI) 886 741 100.0 % 0.67 [ 0.34, 1.35 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.12; Chi2 = 3.96, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.11 (P = 0.27)
4 Total failure Day 63 PCR-adjusted (losses to follow-up included as failures)
Ashley 2004b THA 32/179 35/176 29.3 % 0.90 [ 0.58, 1.38 ]
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Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Janssens 2007 KHM 24/215 29/230 24.6 % 0.89 [ 0.53, 1.47 ]
Ashley 2005 THA 20/332 17/166 19.2 % 0.59 [ 0.32, 1.09 ]
Grande 2007 PER 37/252 26/251 26.9 % 1.42 [ 0.89, 2.27 ]
Subtotal (95% CI) 978 823 100.0 % 0.93 [ 0.67, 1.30 ]
Total events: 113 (DHA-P), 107 (AS+MQ)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.22, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 0.41 (P = 0.68)
5 Total failure Day 63 PCR-adjusted (losses to follow-up included as successes)
Ashley 2004b THA 7/179 10/176 36.1 % 0.69 [ 0.27, 1.77 ]
Janssens 2007 KHM 4/215 6/230 23.6 % 0.71 [ 0.20, 2.49 ]
Ashley 2005 THA 6/332 8/166 31.3 % 0.38 [ 0.13, 1.06 ]
Grande 2007 PER 4/252 1/251 9.0 % 3.98 [ 0.45, 35.40 ]
Subtotal (95% CI) 978 823 100.0 % 0.67 [ 0.34, 1.33 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.80, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 1.14 (P = 0.25)
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Analysis 2.1. Comparison 2 Dihydroartemisinin-piperaquine dose analysis: 3 dose versus 4 dose regimen,
Outcome 1 Total failure PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Dihydroartemisinin-piperaquine dose analysis: 3 dose versus 4 dose regimen
Outcome: 1 Total failure PCR-unadjusted
Study or subgroup DHA-P (4 doses) DHA-P (3 doses) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 63
Ashley 2005 THA 18/155 11/163 100.0 % 1.72 [ 0.84, 3.53 ]
Total (95% CI) 155 163 100.0 % 1.72 [ 0.84, 3.53 ]
Total events: 18 (DHA-P (4 doses)), 11 (DHA-P (3 doses))
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Dihydroartemisinin-piperaquine dose analysis: 3 dose versus 4 dose regimen,
Outcome 2 Total failure PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Dihydroartemisinin-piperaquine dose analysis: 3 dose versus 4 dose regimen
Outcome: 2 Total failure PCR-adjusted
Study or subgroup DHA-P (4 doses) DHA-P (3 doses) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 63
Ashley 2005 THA 1/138 2/154 100.0 % 0.56 [ 0.05, 6.09 ]
Total (95% CI) 138 154 100.0 % 0.56 [ 0.05, 6.09 ]
Total events: 1 (DHA-P (4 doses)), 2 (DHA-P (3 doses))
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 1 Total failure Day 28 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 1 Total failure Day 28 PCR-unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2004a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2005 THA 2/155 13/157 0.16 [ 0.04, 0.68 ]
Janssens 2007 KHM 2/195 2/207 1.06 [ 0.15, 7.46 ]
Tran 2004 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 575 500 0.56 [ 0.10, 3.14 ]
Total events: 5 (DHA-P), 15 (ASMQ)
Heterogeneity: Tau2 = 1.18; Chi2 = 4.12, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.66 (P = 0.51)
2 DHA-P 3 doses
Ashley 2005 THA 3/163 13/157 0.22 [ 0.06, 0.77 ]
Smithuis 2006 MMR 6/319 0/316 12.88 [ 0.73, 227.64 ]
Smithuis 2010 MMR 5/154 2/296 4.81 [ 0.94, 24.48 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Valecha 2010 AS 6/667 17/336 0.18 [ 0.07, 0.45 ]
Subtotal (95% CI) 1410 1159 0.98 [ 0.19, 5.07 ]
Total events: 21 (DHA-P), 32 (ASMQ)
Heterogeneity: Tau2 = 2.52; Chi2 = 19.65, df = 4 (P = 0.00059); I2 =80%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 1985 1659 0.78 [ 0.25, 2.41 ]
Total events: 26 (DHA-P), 47 (ASMQ)
Heterogeneity: Tau2 = 1.68; Chi2 = 23.45, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
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Analysis 3.2. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 2 Total failure Day 28 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 2 Total failure Day 28 PCR-adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2004a THA 1/59 0/59 3.00 [ 0.12, 72.18 ]
Ashley 2005 THA 1/154 7/151 0.14 [ 0.02, 1.12 ]
Janssens 2007 KHM 2/195 1/206 2.11 [ 0.19, 23.11 ]
Tran 2004 VNM 0/166 0/77 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 574 493 0.79 [ 0.10, 6.11 ]
Total events: 4 (DHA-P), 8 (ASMQ)
Heterogeneity: Tau2 = 1.62; Chi2 = 3.99, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 0.22 (P = 0.82)
2 DHA-P 3 doses
Ashley 2005 THA 1/161 7/151 0.13 [ 0.02, 1.08 ]
Smithuis 2006 MMR 2/315 0/316 5.02 [ 0.24, 104.06 ]
Smithuis 2010 MMR 0/149 1/310 0.69 [ 0.03, 16.86 ]
Tangpukdee 2005 THA 1/107 0/54 1.53 [ 0.06, 36.89 ]
Valecha 2010 AS 1/667 8/336 0.06 [ 0.01, 0.50 ]
Subtotal (95% CI) 1399 1167 0.39 [ 0.08, 1.94 ]
Total events: 5 (DHA-P), 16 (ASMQ)
Heterogeneity: Tau2 = 1.48; Chi2 = 7.33, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 1973 1660 0.50 [ 0.15, 1.65 ]
Total events: 9 (DHA-P), 24 (ASMQ)
Heterogeneity: Tau2 = 1.20; Chi2 = 12.01, df = 7 (P = 0.10); I2 =42%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 3.3. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 3 Total failure Day 42 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 3 Total failure Day 42 PCR-unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2005 THA 10/155 19/157 15.4 % 0.53 [ 0.26, 1.11 ]
Janssens 2007 KHM 9/195 9/207 12.9 % 1.06 [ 0.43, 2.62 ]
Tran 2004 VNM 16/166 7/77 13.7 % 1.06 [ 0.45, 2.47 ]
Subtotal (95% CI) 516 441 42.1 % 0.80 [ 0.50, 1.28 ]
Total events: 35 (DHA-P), 35 (ASMQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 DHA-P 3 doses
Ashley 2005 THA 6/163 19/157 13.1 % 0.30 [ 0.12, 0.74 ]
Mayxay 2006 LAO 4/106 5/108 8.6 % 0.82 [ 0.23, 2.95 ]
Smithuis 2006 MMR 6/319 1/316 4.1 % 5.94 [ 0.72, 49.09 ]
Smithuis 2010 MMR 8/150 7/299 11.7 % 2.28 [ 0.84, 6.16 ]
Valecha 2010 AS 39/667 34/336 20.3 % 0.58 [ 0.37, 0.90 ]
Subtotal (95% CI) 1405 1216 57.9 % 0.89 [ 0.40, 1.99 ]
Total events: 63 (DHA-P), 66 (ASMQ)
Heterogeneity: Tau2 = 0.53; Chi2 = 13.49, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 1921 1657 100.0 % 0.82 [ 0.51, 1.31 ]
Total events: 98 (DHA-P), 101 (ASMQ)
Heterogeneity: Tau2 = 0.23; Chi2 = 15.74, df = 7 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 3.4. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 4 Total failure Day 42 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 4 Total failure Day 42 PCR-adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2005 THA 1/146 7/145 13.4 % 0.14 [ 0.02, 1.14 ]
Janssens 2007 KHM 3/189 2/200 16.8 % 1.59 [ 0.27, 9.39 ]
Tran 2004 VNM 2/152 1/71 10.9 % 0.93 [ 0.09, 10.13 ]
Subtotal (95% CI) 487 416 41.2 % 0.62 [ 0.14, 2.82 ]
Total events: 6 (DHA-P), 10 (ASMQ)
Heterogeneity: Tau2 = 0.69; Chi2 = 3.24, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.62 (P = 0.54)
2 DHA-P 3 doses
Ashley 2005 THA 1/158 7/145 13.4 % 0.13 [ 0.02, 1.05 ]
Mayxay 2006 LAO 1/103 1/104 8.6 % 1.01 [ 0.06, 15.93 ]
Smithuis 2006 MMR 2/315 0/315 7.3 % 5.00 [ 0.24, 103.73 ]
Valecha 2010 AS 5/667 9/336 29.4 % 0.28 [ 0.09, 0.83 ]
Subtotal (95% CI) 1243 900 58.8 % 0.43 [ 0.12, 1.48 ]
Total events: 9 (DHA-P), 17 (ASMQ)
Heterogeneity: Tau2 = 0.57; Chi2 = 4.56, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 1730 1316 100.0 % 0.49 [ 0.20, 1.18 ]
Total events: 15 (DHA-P), 27 (ASMQ)
Heterogeneity: Tau2 = 0.39; Chi2 = 8.31, df = 6 (P = 0.22); I2 =28%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 3.5. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 5 Total failure Day 63 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 5 Total failure Day 63 PCR-unadjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2004b THA 26/154 29/151 17.1 % 0.88 [ 0.54, 1.42 ]
Ashley 2005 THA 18/155 27/157 15.8 % 0.68 [ 0.39, 1.17 ]
Janssens 2007 KHM 18/195 22/207 15.2 % 0.87 [ 0.48, 1.57 ]
Subtotal (95% CI) 504 515 48.0 % 0.81 [ 0.59, 1.10 ]
Total events: 62 (DHA-P), 78 (ASMQ)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 DHA-P 3 doses
Ashley 2005 THA 11/163 27/157 14.0 % 0.39 [ 0.20, 0.76 ]
Grande 2007 PER 12/219 2/226 5.6 % 6.19 [ 1.40, 27.35 ]
Smithuis 2010 MMR 14/152 12/305 12.7 % 2.34 [ 1.11, 4.94 ]
Valecha 2010 AS 86/718 53/358 19.7 % 0.81 [ 0.59, 1.11 ]
Subtotal (95% CI) 1252 1046 52.0 % 1.22 [ 0.52, 2.90 ]
Total events: 123 (DHA-P), 94 (ASMQ)
Heterogeneity: Tau2 = 0.60; Chi2 = 19.24, df = 3 (P = 0.00024); I2 =84%
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 1756 1561 100.0 % 0.93 [ 0.62, 1.40 ]
Total events: 185 (DHA-P), 172 (ASMQ)
Heterogeneity: Tau2 = 0.19; Chi2 = 19.96, df = 6 (P = 0.003); I2 =70%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 3.6. Comparison 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus
mefloquine), Outcome 6 Total failure Day 63 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 3 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome: 6 Total failure Day 63 PCR-adjusted
Study or subgroup DHA-P ASMQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 DHA-P 4 doses
Ashley 2004b THA 3/131 9/131 17.7 % 0.33 [ 0.09, 1.20 ]
Ashley 2005 THA 1/138 7/137 9.0 % 0.14 [ 0.02, 1.14 ]
Janssens 2007 KHM 4/181 5/190 17.5 % 0.84 [ 0.23, 3.08 ]
Subtotal (95% CI) 450 458 44.2 % 0.42 [ 0.17, 1.04 ]
Total events: 8 (DHA-P), 21 (ASMQ)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.31, df = 2 (P = 0.31); I2 =13%
Test for overall effect: Z = 1.88 (P = 0.060)
2 DHA-P 3 doses
Ashley 2005 THA 2/154 7/137 13.9 % 0.25 [ 0.05, 1.20 ]
Grande 2007 PER 4/211 0/224 5.1 % 9.55 [ 0.52, 176.35 ]
Smithuis 2010 MMR 2/140 2/295 10.0 % 2.11 [ 0.30, 14.80 ]
Valecha 2010 AS 11/667 10/336 26.8 % 0.55 [ 0.24, 1.29 ]
Subtotal (95% CI) 1172 992 55.8 % 0.85 [ 0.26, 2.77 ]
Total events: 19 (DHA-P), 19 (ASMQ)
Heterogeneity: Tau2 = 0.73; Chi2 = 6.32, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 1622 1450 100.0 % 0.57 [ 0.28, 1.15 ]
Total events: 27 (DHA-P), 40 (ASMQ)
Heterogeneity: Tau2 = 0.29; Chi2 = 9.09, df = 6 (P = 0.17); I2 =34%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.87, df = 1 (P = 0.35), I2 =0.0%
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Analysis 4.1. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 1
Total failure (P. falciparum) Day 28 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 1 Total failure (P. falciparum) Day 28 PCR-unadjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Bassat 2009 AF (1) 72/986 89/482 17.2 % 0.40 [ 0.30, 0.53 ]
Mens 2008 KEN 0/67 1/67 0.2 % 0.33 [ 0.01, 8.04 ]
Zongo 2007 BFA 4/172 36/178 5.1 % 0.11 [ 0.04, 0.32 ]
Yavo 2011 AF (2) 2/191 5/183 0.7 % 0.38 [ 0.08, 1.95 ]
Arinaitwe 2009 UGA 39/345 109/315 16.4 % 0.33 [ 0.23, 0.46 ]
Sawa 2013 KEN 0/137 10/147 1.5 % 0.05 [ 0.00, 0.86 ]
The 4ABC Study 2011 AF (3) 134/1378 334/1171 52.1 % 0.34 [ 0.28, 0.41 ]
Adam 2010 SDN 0/75 1/74 0.2 % 0.33 [ 0.01, 7.95 ]
Agarwal 2013 KEN 20/116 45/116 6.5 % 0.44 [ 0.28, 0.70 ]
Subtotal (95% CI) 3467 2733 100.0 % 0.34 [ 0.30, 0.39 ]
Total events: 271 (DHA-P), 630 (AL6)
Heterogeneity: Chi2 = 8.59, df = 8 (P = 0.38); I2 =7%
Test for overall effect: Z = 15.93 (P < 0.00001)
2 Asia and Oceania
Ratcliff 2007 IDN 6/233 13/218 34.6 % 0.43 [ 0.17, 1.12 ]
Krudsood 2007 THA 1/82 0/81 1.3 % 2.96 [ 0.12, 71.70 ]
Karunajeewa 2008 PNG 25/111 20/113 51.1 % 1.27 [ 0.75, 2.15 ]
Smithuis 2010 MMR 5/154 5/151 13.0 % 0.98 [ 0.29, 3.32 ]
Subtotal (95% CI) 580 563 100.0 % 0.97 [ 0.64, 1.47 ]
Total events: 37 (DHA-P), 38 (AL6)
Heterogeneity: Chi2 = 4.29, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 21.88, df = 1 (P = 0.00), I2 =95%
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(1) Bassat 2009 was conducted in Burkino Faso, Kenya, Mozambique, Uganda and Zambia
(2) Yavo 2011 was conducted in Senegal, Cote d’Ivoire and Cameroon
(3) The 4ABC study was conducted in Burkina Faso, Gabon, Nigeria, Zambia, Rwanda, Uganda and Mozambique
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Analysis 4.2. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 2
Total failure (P. falciparum) Day 28 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 2 Total failure (P. falciparum) Day 28 PCR-adjusted
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Bassat 2009 AF (1) 14/937 11/400 0.54 [ 0.25, 1.19 ]
Mens 2008 KEN 0/67 0/66 0.0 [ 0.0, 0.0 ]
Zongo 2007 BFA 4/172 6/148 0.57 [ 0.17, 1.99 ]
Yavo 2011 AF (2) 1/190 2/180 0.47 [ 0.04, 5.18 ]
Arinaitwe 2009 UGA 1/307 3/208 0.23 [ 0.02, 2.16 ]
The 4ABC Study 2011 AF (3) 24/1268 41/878 0.41 [ 0.25, 0.67 ]
Sawa 2013 KEN 0/137 2/139 0.20 [ 0.01, 4.19 ]
Adam 2010 SDN 0/75 1/74 0.33 [ 0.01, 7.95 ]
Agarwal 2013 KEN 1/97 3/74 0.25 [ 0.03, 2.40 ]
Subtotal (95% CI) 3250 2167 0.42 [ 0.29, 0.62 ]
Total events: 45 (DHA-P), 69 (AL6)
Heterogeneity: Chi2 = 1.40, df = 7 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
2 Asia and Oceania
Ratcliff 2007 IDN 2/229 2/207 0.90 [ 0.13, 6.36 ]
Karunajeewa 2008 PNG 11/97 3/96 3.63 [ 1.04, 12.60 ]
Smithuis 2010 MMR 0/149 1/147 0.33 [ 0.01, 8.01 ]
Subtotal (95% CI) 475 450 2.01 [ 0.81, 5.03 ]
Total events: 13 (DHA-P), 6 (AL6)
Heterogeneity: Chi2 = 2.74, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 9.54, df = 1 (P = 0.00), I2 =90%
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(1) Bassat 2009 was conducted in Burkino Faso, Kenya, Mozambique, Uganda and Zambia
(2) Yavo 2011 was conducted in Senegal, Cote d’Ivoire and Cameroon
(3) The 4ABC study was conducted in Burkina Faso, Gabon, Nigeria, Zambia, Rwanda, Uganda and Mozambique
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Analysis 4.3. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 3
Total failure (P. falciparum) Day 42 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 3 Total failure (P. falciparum) Day 42 PCR-unadjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Kamya 2007 UGA 90/207 108/197 20.6 % 0.79 [ 0.65, 0.97 ]
Bassat 2009 AF (1) 200/973 147/467 36.9 % 0.65 [ 0.54, 0.78 ]
Zongo 2007 BFA 13/172 55/176 10.1 % 0.24 [ 0.14, 0.43 ]
Yeka 2008 UGA 21/207 46/177 9.2 % 0.39 [ 0.24, 0.63 ]
Arinaitwe 2009 UGA 16/114 33/108 6.3 % 0.46 [ 0.27, 0.79 ]
Sawa 2013 KEN 5/134 30/145 5.4 % 0.18 [ 0.07, 0.45 ]
Agarwal 2013 KEN 52/113 62/111 11.6 % 0.82 [ 0.64, 1.07 ]
Subtotal (95% CI) 1920 1381 100.0 % 0.60 [ 0.53, 0.67 ]
Total events: 397 (DHA-P), 481 (AL6)
Heterogeneity: Chi2 = 34.72, df = 6 (P<0.00001); I2 =83%
Test for overall effect: Z = 8.97 (P < 0.00001)
2 Asia and Oceania
Ratcliff 2007 IDN 19/195 26/161 41.8 % 0.60 [ 0.35, 1.05 ]
Karunajeewa 2008 PNG 42/107 40/109 58.2 % 1.07 [ 0.76, 1.50 ]
Subtotal (95% CI) 302 270 100.0 % 0.87 [ 0.65, 1.17 ]
Total events: 61 (DHA-P), 66 (AL6)
Heterogeneity: Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 5.66, df = 1 (P = 0.02), I2 =82%
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(1) Bassat 2009 was conducted in Burkino Faso, Kenya, Mozambique, Uganda and Zambia
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Analysis 4.4. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 4
Total failure (P. falciparum) Day 42 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 4 Total failure (P. falciparum) Day 42 PCR-adjusted
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Kamya 2007 UGA 13/130 28/117 0.42 [ 0.23, 0.77 ]
Bassat 2009 AF (1) 41/814 17/337 1.00 [ 0.58, 1.73 ]
Zongo 2007 BFA 4/163 7/128 0.45 [ 0.13, 1.50 ]
Yeka 2008 UGA 4/190 10/141 0.30 [ 0.10, 0.93 ]
Arinaitwe 2009 UGA 0/98 0/75 0.0 [ 0.0, 0.0 ]
Sawa 2013 KEN 0/129 4/119 0.10 [ 0.01, 1.88 ]
Agarwal 2013 KEN 4/65 4/53 0.82 [ 0.21, 3.11 ]
Subtotal (95% CI) 1589 970 0.58 [ 0.41, 0.81 ]
Total events: 66 (DHA-P), 70 (AL6)
Heterogeneity: Chi2 = 7.97, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Asia and Oceania
Ratcliff 2007 IDN 3/179 3/138 0.77 [ 0.16, 3.76 ]
Karunajeewa 2008 PNG 12/77 5/74 2.31 [ 0.85, 6.23 ]
Subtotal (95% CI) 256 212 1.69 [ 0.75, 3.83 ]
Total events: 15 (DHA-P), 8 (AL6)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 5.68, df = 1 (P = 0.02), I2 =82%
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(1) Bassat 2009 was conducted in Burkino Faso, Kenya, Mozambique, Uganda and Zambia
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Analysis 4.5. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 5
Total failure (P. falciparum) Day 63 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 5 Total failure (P. falciparum) Day 63 PCR-unadjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Arinaitwe 2009 UGA 46/351 110/320 16.2 % 0.38 [ 0.28, 0.52 ]
The 4ABC Study 2011 AF (1) 503/1369 550/1160 83.8 % 0.77 [ 0.71, 0.85 ]
Subtotal (95% CI) 1720 1480 100.0 % 0.71 [ 0.65, 0.78 ]
Total events: 549 (DHA-P), 660 (AL6)
Heterogeneity: Chi2 = 18.97, df = 1 (P = 0.00001); I2 =95%
Test for overall effect: Z = 7.54 (P < 0.00001)
2 Asia
Smithuis 2010 MMR 14/161 15/162 100.0 % 0.94 [ 0.47, 1.88 ]
Subtotal (95% CI) 161 162 100.0 % 0.94 [ 0.47, 1.88 ]
Total events: 14 (DHA-P), 15 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
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(1) The 4ABC study was conducted in Burkina Faso, Gabon, Nigeria, Zambia, Rwanda, Uganda and Mozambique
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Analysis 4.6. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 6
Total failure (P. falciparum) Day 63 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 6 Total failure (P. falciparum) Day 63 PCR-adjusted
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Arinaitwe 2009 UGA 8/313 4/214 7.7 % 1.37 [ 0.42, 4.48 ]
The 4ABC Study 2011 AF (1) 45/911 49/659 92.3 % 0.66 [ 0.45, 0.98 ]
Subtotal (95% CI) 1224 873 100.0 % 0.72 [ 0.50, 1.04 ]
Total events: 53 (DHA-P), 53 (AL6)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.75 (P = 0.080)
2 Asia
Smithuis 2010 MMR 2/149 2/149 100.0 % 1.00 [ 0.14, 7.01 ]
Subtotal (95% CI) 149 149 100.0 % 1.00 [ 0.14, 7.01 ]
Total events: 2 (DHA-P), 2 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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(1) The 4ABC study was conducted in Burkina Faso, Gabon, Nigeria, Zambia, Rwanda, Uganda and Mozambique
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Analysis 4.7. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 7
Gametocyte development (in those negative at baseline).
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 7 Gametocyte development (in those negative at baseline)
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kamya 2007 UGA 9/170 18/156 0.46 [ 0.21, 0.99 ]
Zongo 2007 BFA 7/184 3/188 2.38 [ 0.63, 9.08 ]
Yeka 2008 UGA 9/201 21/179 0.38 [ 0.18, 0.81 ]
Mens 2008 KEN 10/64 3/61 3.18 [ 0.92, 11.00 ]
Arinaitwe 2009 UGA 9/321 1/294 8.24 [ 1.05, 64.67 ]
Adam 2010 SDN 0/76 0/74 0.0 [ 0.0, 0.0 ]
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Analysis 4.8. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 8
Gametocyte carriage.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 8 Gametocyte carriage
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gametocyte carriage day 1 to 14
Kamya 2007 UGA 5/170 2/156 2.29 [ 0.45, 11.65 ]
Yeka 2008 UGA 4/201 1/179 3.56 [ 0.40, 31.58 ]
Arinaitwe 2009 UGA 10/351 1/320 9.12 [ 1.17, 70.82 ]
Adam 2010 SDN 0/80 0/80 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 802 735 4.32 [ 1.48, 12.63 ]
Total events: 19 (DHA-P), 4 (AL6)
Heterogeneity: Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Gametocyte carriage day 15 to 28
Kamya 2007 UGA 0/168 5/150 0.08 [ 0.00, 1.46 ]
Yeka 2008 UGA 1/200 7/178 0.13 [ 0.02, 1.02 ]
Arinaitwe 2009 UGA 1/351 0/320 2.74 [ 0.11, 66.92 ]
Adam 2010 SDN 0/75 0/74 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 794 722 0.21 [ 0.06, 0.72 ]
Total events: 2 (DHA-P), 12 (AL6)
Heterogeneity: Chi2 = 3.12, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 2.47 (P = 0.013)
3 Gametocyte carriage day 29 to 42
Kamya 2007 UGA 4/159 11/123 0.28 [ 0.09, 0.86 ]
Yeka 2008 UGA 4/194 13/174 0.28 [ 0.09, 0.83 ]
Subtotal (95% CI) 353 297 0.28 [ 0.13, 0.61 ]
Total events: 8 (DHA-P), 24 (AL6)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
0.005 0.1 1 10 200
Favours DHA-P Favours AL6
109Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 4.9. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome 9
Anaemia.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 9 Anaemia
Study or subgroup DHA-P AL6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean haemoglobin (g/dL) at baseline
Bassat 2009 AF 1038 89.23 (18.15) 510 90.59 (18.2) 0.1 % -1.36 [ -3.29, 0.57 ]
Kamya 2007 UGA 211 9.5 (1.9) 210 9.7 (1.8) 1.8 % -0.20 [ -0.55, 0.15 ]
Yeka 2008 UGA 215 9.9 (2.1) 199 9.9 (1.9) 1.5 % 0.0 [ -0.39, 0.39 ]
Zongo 2007 BFA 187 10.1 (2.4) 188 10.2 (2) 1.1 % -0.10 [ -0.55, 0.35 ]
Mens 2008 KEN 73 6.33 (1.29) 73 6.28 (1.27) 1.3 % 0.05 [ -0.37, 0.47 ]
Arinaitwe 2009 UGA 351 9.9 (1.5) 320 9.8 (1.5) 4.4 % 0.10 [ -0.13, 0.33 ]
The 4ABC Study 2011 AF 1475 9.4 (1.5) 1226 9.2 (1.5) 17.4 % 0.20 [ 0.09, 0.31 ]
Smithuis 2010 MMR 161 11.3 (0.24) 162 11.4 (0.27) 72.4 % -0.10 [ -0.16, -0.04 ]
Subtotal (95% CI) 3711 2888 100.0 % -0.04 [ -0.09, 0.01 ]
Heterogeneity: Chi2 = 25.93, df = 7 (P = 0.00052); I2 =73%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Mean haemoglobin (g/dL) at day 28
Mens 2008 KEN 67 7.15 (1.07) 67 6.79 (1.24) 100.0 % 0.36 [ -0.03, 0.75 ]
Subtotal (95% CI) 67 67 100.0 % 0.36 [ -0.03, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
3 Mean haemoglobin (g/dL) at day 42
Zongo 2007 BFA 187 11.6 (1.6) 188 11.3 (1.6) 100.0 % 0.30 [ -0.02, 0.62 ]
Subtotal (95% CI) 187 188 100.0 % 0.30 [ -0.02, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
4 Mean change in haemoglobin (g/dL) from baseline to day 28
Bassat 2009 AF 1020 1.7 (1.82) 494 1.43 (1.85) 60.9 % 0.27 [ 0.07, 0.47 ]
Arinaitwe 2009 UGA 351 0.62 (1.68) 320 0.56 (1.58) 39.1 % 0.06 [ -0.19, 0.31 ]
Subtotal (95% CI) 1371 814 100.0 % 0.19 [ 0.03, 0.34 ]
Heterogeneity: Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 2.39 (P = 0.017)
5 Mean change in haemoglobin (g/dL) from baseline to day 42
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Study or subgroup DHA-P AL6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kamya 2007 UGA 211 1.9 (1.8) 210 1.5 (1.8) 53.3 % 0.40 [ 0.06, 0.74 ]
Yeka 2008 UGA 215 1.75 (1.8) 199 1.66 (2) 46.7 % 0.09 [ -0.28, 0.46 ]
Subtotal (95% CI) 426 409 100.0 % 0.26 [ 0.00, 0.51 ]
Heterogeneity: Chi2 = 1.46, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.99 (P = 0.046)
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Analysis 4.10. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome
10 Serious adverse events (including deaths).
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 10 Serious adverse events (including deaths)
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ratcliff 2007 IDN 1/379 2/375 0.49 [ 0.05, 5.43 ]
Kamya 2007 UGA 4/211 2/210 1.99 [ 0.37, 10.75 ]
Bassat 2009 AF 18/1038 5/510 1.77 [ 0.66, 4.74 ]
Zongo 2007 BFA 0/187 0/188 0.0 [ 0.0, 0.0 ]
Yeka 2008 UGA 5/215 2/199 2.31 [ 0.45, 11.79 ]
Mens 2008 KEN 1/73 0/73 3.00 [ 0.12, 72.45 ]
Arinaitwe 2009 UGA 3/351 1/320 2.74 [ 0.29, 26.16 ]
The 4ABC Study 2011 AF 10/1468 6/1225 1.39 [ 0.51, 3.82 ]
Agarwal 2013 KEN 1/113 2/111 0.49 [ 0.05, 5.34 ]
Total (95% CI) 4035 3211 1.58 [ 0.93, 2.68 ]
Total events: 43 (DHA-P), 20 (AL6)
Heterogeneity: Chi2 = 2.60, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome
11 Other adverse events: Gastrointestinal.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 11 Other adverse events: Gastrointestinal
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Early vomiting
Ratcliff 2007 IDN (1) 11/379 10/375 42.9 % 1.09 [ 0.47, 2.53 ]
Bassat 2009 AF (2) 22/1038 4/510 22.9 % 2.70 [ 0.94, 7.80 ]
Zongo 2007 BFA (3) 7/196 3/197 12.8 % 2.35 [ 0.62, 8.94 ]
Agarwal 2013 KEN (4) 7/137 5/137 21.4 % 1.40 [ 0.46, 4.30 ]
Subtotal (95% CI) 1750 1219 100.0 % 1.69 [ 1.00, 2.83 ]
Total events: 47 (DHA-P), 22 (AL6)
Heterogeneity: Chi2 = 2.13, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
2 Vomiting
Krudsood 2007 THA 4/82 0/82 0.2 % 9.00 [ 0.49, 164.53 ]
Bassat 2009 AF 71/1038 35/510 16.1 % 1.00 [ 0.67, 1.47 ]
Kamya 2007 UGA 65/210 65/211 22.2 % 1.00 [ 0.75, 1.34 ]
Mens 2008 KEN 11/73 9/73 3.1 % 1.22 [ 0.54, 2.77 ]
Yeka 2008 UGA 35/213 35/198 12.4 % 0.93 [ 0.61, 1.42 ]
Yavo 2011 AF 4/197 0/187 0.2 % 8.55 [ 0.46, 157.64 ]
Arinaitwe 2009 UGA 23/351 20/320 7.2 % 1.05 [ 0.59, 1.87 ]
The 4ABC Study 2011 AF 123/1468 102/1225 38.1 % 1.01 [ 0.78, 1.29 ]
Smithuis 2010 MMR 2/161 2/162 0.7 % 1.01 [ 0.14, 7.06 ]
Subtotal (95% CI) 3793 2968 100.0 % 1.03 [ 0.89, 1.20 ]
Total events: 338 (DHA-P), 268 (AL6)
Heterogeneity: Chi2 = 4.65, df = 8 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
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Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Nausea
Krudsood 2007 THA 4/82 3/81 59.5 % 1.32 [ 0.30, 5.70 ]
Yavo 2011 AF 2/197 2/187 40.5 % 0.95 [ 0.14, 6.67 ]
Subtotal (95% CI) 279 268 100.0 % 1.17 [ 0.36, 3.76 ]
Total events: 6 (DHA-P), 5 (AL6)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
4 Diarrhoea
Krudsood 2007 THA 3/82 1/81 0.3 % 2.96 [ 0.31, 27.90 ]
Kamya 2007 UGA 19/210 25/211 8.2 % 0.76 [ 0.43, 1.34 ]
Mens 2008 KEN 9/73 7/73 2.3 % 1.29 [ 0.51, 3.27 ]
Yeka 2008 UGA 26/213 23/198 7.9 % 1.05 [ 0.62, 1.78 ]
Arinaitwe 2009 UGA 79/351 86/320 29.6 % 0.84 [ 0.64, 1.09 ]
Yavo 2011 AF 4/197 2/187 0.7 % 1.90 [ 0.35, 10.24 ]
The 4ABC Study 2011 AF 166/1468 142/1225 51.0 % 0.98 [ 0.79, 1.20 ]
Subtotal (95% CI) 2594 2295 100.0 % 0.94 [ 0.81, 1.09 ]
Total events: 306 (DHA-P), 286 (AL6)
Heterogeneity: Chi2 = 3.65, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
5 Abdominal pain
Kamya 2007 UGA 20/45 19/36 24.2 % 0.84 [ 0.54, 1.32 ]
Krudsood 2007 THA 8/82 5/81 5.8 % 1.58 [ 0.54, 4.63 ]
Mens 2008 KEN 23/73 26/73 29.8 % 0.88 [ 0.56, 1.40 ]
Yeka 2008 UGA 17/74 24/63 29.7 % 0.60 [ 0.36, 1.02 ]
Yavo 2011 AF 9/197 9/187 10.6 % 0.95 [ 0.39, 2.34 ]
Subtotal (95% CI) 471 440 100.0 % 0.84 [ 0.65, 1.08 ]
Total events: 77 (DHA-P), 83 (AL6)
Heterogeneity: Chi2 = 2.99, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
6 Anorexia
Krudsood 2007 THA 4/82 4/81 1.4 % 0.99 [ 0.26, 3.82 ]
Kamya 2007 UGA 91/210 90/211 31.3 % 1.02 [ 0.82, 1.27 ]
Mens 2008 KEN 8/73 10/73 3.5 % 0.80 [ 0.33, 1.91 ]
Yeka 2008 UGA 47/213 49/198 17.7 % 0.89 [ 0.63, 1.27 ]
The 4ABC Study 2011 AF 130/1468 121/1225 46.0 % 0.90 [ 0.71, 1.13 ]
Subtotal (95% CI) 2046 1788 100.0 % 0.93 [ 0.80, 1.08 ]
Total events: 280 (DHA-P), 274 (AL6)
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Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.89, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 6.80, df = 5 (P = 0.24), I2 =27%
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(1) Ratcliff 2007: Vomiting within the first hour after drug administration.
(2) Bassat 2009: Excluded due to persistent vomiting on day 0
(3) Zongo 2007b: Repeated vomiting on day 0.
(4) Agarwal 2013 KEN: Vomiting the first dose.
Analysis 4.12. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome
12 Other adverse events: Neuro-psychiatric.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 12 Other adverse events: Neuro-psychiatric
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache
Krudsood 2007 THA 8/82 5/81 12.0 % 1.58 [ 0.54, 4.63 ]
Mens 2008 KEN 43/73 37/73 88.0 % 1.16 [ 0.86, 1.56 ]
Subtotal (95% CI) 155 154 100.0 % 1.21 [ 0.90, 1.63 ]
Total events: 51 (DHA-P), 42 (AL6)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Sleeplessness
Krudsood 2007 THA 9/82 3/81 66.2 % 2.96 [ 0.83, 10.55 ]
Yavo 2011 AF 0/197 1/187 33.8 % 0.32 [ 0.01, 7.72 ]
Subtotal (95% CI) 279 268 100.0 % 2.07 [ 0.69, 6.16 ]
Total events: 9 (DHA-P), 4 (AL6)
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Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 1.63, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.31 (P = 0.19)
3 Dizziness
Krudsood 2007 THA 7/82 5/81 71.0 % 1.38 [ 0.46, 4.18 ]
Yavo 2011 AF 5/197 2/187 29.0 % 2.37 [ 0.47, 12.08 ]
Subtotal (95% CI) 279 268 100.0 % 1.67 [ 0.67, 4.15 ]
Total events: 12 (DHA-P), 7 (AL6)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
4 Sleepiness
Yavo 2011 AF 1/197 0/187 100.0 % 2.85 [ 0.12, 69.49 ]
Subtotal (95% CI) 197 187 100.0 % 2.85 [ 0.12, 69.49 ]
Total events: 1 (DHA-P), 0 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
5 Weakness
Kamya 2007 UGA 103/210 85/211 56.4 % 1.22 [ 0.98, 1.51 ]
Krudsood 2007 THA 9/82 7/81 4.7 % 1.27 [ 0.50, 3.25 ]
Yeka 2008 UGA 28/213 27/198 18.6 % 0.96 [ 0.59, 1.58 ]
Mens 2008 KEN 19/73 30/73 20.0 % 0.63 [ 0.39, 1.02 ]
Arinaitwe 2009 UGA 1/351 0/320 0.3 % 2.74 [ 0.11, 66.92 ]
Subtotal (95% CI) 929 883 100.0 % 1.06 [ 0.89, 1.27 ]
Total events: 160 (DHA-P), 149 (AL6)
Heterogeneity: Chi2 = 6.75, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 2.89, df = 4 (P = 0.58), I2 =0.0%
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Analysis 4.13. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome
13 Other adverse events: Cardio-respiratory.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 13 Other adverse events: Cardio-respiratory
Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
Arinaitwe 2009 UGA 177/351 153/320 18.0 % 1.05 [ 0.90, 1.23 ]
Kamya 2007 UGA 133/210 136/211 15.2 % 0.98 [ 0.85, 1.13 ]
Mens 2008 KEN 16/73 17/73 1.9 % 0.94 [ 0.52, 1.72 ]
The 4ABC Study 2011 AF 470/1468 387/1225 47.4 % 1.01 [ 0.91, 1.13 ]
Yeka 2008 UGA 164/213 150/198 17.5 % 1.02 [ 0.91, 1.13 ]
Subtotal (95% CI) 2315 2027 100.0 % 1.02 [ 0.95, 1.09 ]
Total events: 960 (DHA-P), 843 (AL6)
Heterogeneity: Chi2 = 0.50, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Coryza
Kamya 2007 UGA 121/210 127/211 44.9 % 0.96 [ 0.82, 1.12 ]
Yeka 2008 UGA 159/213 150/198 55.1 % 0.99 [ 0.88, 1.10 ]
Subtotal (95% CI) 423 409 100.0 % 0.97 [ 0.89, 1.07 ]
Total events: 280 (DHA-P), 277 (AL6)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Prolonged QTc interval (reported as adverse events)
Bassat 2009 AF (1) 26/1038 13/510 100.0 % 0.98 [ 0.51, 1.90 ]
Subtotal (95% CI) 1038 510 100.0 % 0.98 [ 0.51, 1.90 ]
Total events: 26 (DHA-P), 13 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 Prolonged QTc interval (Bazett’s correction)
Bassat 2009 AF 94/1038 35/510 100.0 % 1.32 [ 0.91, 1.92 ]
Subtotal (95% CI) 1038 510 100.0 % 1.32 [ 0.91, 1.92 ]
Total events: 94 (DHA-P), 35 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
5 Prolonged QTc interval (Fridericia’s correction)
Bassat 2009 AF 2/1038 1/510 100.0 % 0.98 [ 0.09, 10.81 ]
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Study or subgroup DHA-P AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1038 510 100.0 % 0.98 [ 0.09, 10.81 ]
Total events: 2 (DHA-P), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 2.60, df = 4 (P = 0.63), I2 =0.0%
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(1) Defined as QTc > 450 ms on day 2.
Analysis 4.14. Comparison 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine, Outcome
14 Other adverse events: Musculoskeletal/dermatological.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 4 Dihydroartemisinin-piperaquine versus Artemether-lumefantrine
Outcome: 14 Other adverse events: Musculoskeletal/dermatological
Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pruritis
Arinaitwe 2009 UGA 0/351 0/320 0.0 [ 0.0, 0.0 ]
Kamya 2007 UGA 22/210 14/211 1.58 [ 0.83, 3.00 ]
Mens 2008 KEN 4/73 3/73 1.33 [ 0.31, 5.75 ]
Yavo 2011 AF 3/197 1/187 2.85 [ 0.30, 27.14 ]
Yeka 2008 UGA 8/213 3/198 2.48 [ 0.67, 9.21 ]
Subtotal (95% CI) 1044 989 1.74 [ 1.03, 2.92 ]
Total events: 37 (DHA-P), 21 (AL6)
Heterogeneity: Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
2 Face oedema
Yavo 2011 AF 1/197 0/187 2.85 [ 0.12, 69.49 ]
Subtotal (95% CI) 197 187 2.85 [ 0.12, 69.49 ]
Total events: 1 (DHA-P), 0 (AL6)
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Study or subgroup DHA-P AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 5.1. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 1 Total failure (P. falciparum) Day 28 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 1 Total failure (P. falciparum) Day 28 PCR-unadjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2006 RWA 24/250 45/251 16.6 % 0.54 [ 0.34, 0.85 ]
The 4ABC Study 2011 AF 134/1371 189/928 83.4 % 0.48 [ 0.39, 0.59 ]
Subtotal (95% CI) 1621 1179 100.0 % 0.49 [ 0.41, 0.59 ]
Total events: 158 (DHA-P), 234 (AS+AQ)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 7.47 (P < 0.00001)
2 Asia
Hasugian 2007 IDN 5/94 9/84 37.0 % 0.50 [ 0.17, 1.42 ]
Smithuis 2010 MMR 5/154 16/150 63.0 % 0.30 [ 0.11, 0.81 ]
Subtotal (95% CI) 248 234 100.0 % 0.38 [ 0.18, 0.77 ]
Total events: 10 (DHA-P), 25 (AS+AQ)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 5.2. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 2 Total failure (P. falciparum) Day 28 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 2 Total failure (P. falciparum) Day 28 PCR-adjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
Karema 2006 RWA 10/236 16/222 39.7 % 0.59 [ 0.27, 1.27 ]
The 4ABC Study 2011 AF 24/1269 20/759 60.3 % 0.72 [ 0.40, 1.29 ]
Subtotal (95% CI) 1505 981 100.0 % 0.67 [ 0.42, 1.06 ]
Total events: 34 (DHA-P), 36 (AS+AQ)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Asia
Hasugian 2007 IDN 1/90 6/81 33.3 % 0.15 [ 0.02, 1.22 ]
Smithuis 2010 MMR 0/149 12/146 66.7 % 0.04 [ 0.00, 0.66 ]
Subtotal (95% CI) 239 227 100.0 % 0.08 [ 0.01, 0.40 ]
Total events: 1 (DHA-P), 18 (AS+AQ)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Chi2 = 6.03, df = 1 (P = 0.01), I2 =83%
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Analysis 5.3. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 3 Total failure (P. falciparum) Day 42 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 3 Total failure (P. falciparum) Day 42 PCR-unadjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Hasugian 2007 IDN 5/86 14/66 100.0 % 0.27 [ 0.10, 0.72 ]
Subtotal (95% CI) 86 66 100.0 % 0.27 [ 0.10, 0.72 ]
Total events: 5 (DHA-P), 14 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours DHA-P Favours AS+AQ
Analysis 5.4. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 4 Total failure (P. falciparum) Day 42 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 4 Total failure (P. falciparum) Day 42 PCR-adjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Asia
Hasugian 2007 IDN 1/82 7/59 100.0 % 0.10 [ 0.01, 0.81 ]
Subtotal (95% CI) 82 59 100.0 % 0.10 [ 0.01, 0.81 ]
Total events: 1 (DHA-P), 7 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours DHA-P Favours AS+AQ
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Analysis 5.5. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 5 Total failure (P. falciparum) Day 63 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 5 Total failure (P. falciparum) Day 63 PCR-unadjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
The 4ABC Study 2011 AF 483/1372 337/920 100.0 % 0.96 [ 0.86, 1.07 ]
Subtotal (95% CI) 1372 920 100.0 % 0.96 [ 0.86, 1.07 ]
Total events: 483 (DHA-P), 337 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 Asia
Smithuis 2010 MMR 14/154 28/150 100.0 % 0.49 [ 0.27, 0.89 ]
Subtotal (95% CI) 154 150 100.0 % 0.49 [ 0.27, 0.89 ]
Total events: 14 (DHA-P), 28 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 4.75, df = 1 (P = 0.03), I2 =79%
0.01 0.1 1 10 100
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Analysis 5.6. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 6 Total failure (P. falciparum) Day 63 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 6 Total failure (P. falciparum) Day 63 PCR-adjusted
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Africa
The 4ABC Study 2011 AF 25/914 9/592 100.0 % 1.80 [ 0.85, 3.83 ]
Subtotal (95% CI) 914 592 100.0 % 1.80 [ 0.85, 3.83 ]
Total events: 25 (DHA-P), 9 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 Asia
Smithuis 2010 MMR 2/142 14/136 100.0 % 0.14 [ 0.03, 0.59 ]
Subtotal (95% CI) 142 136 100.0 % 0.14 [ 0.03, 0.59 ]
Total events: 2 (DHA-P), 14 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Chi2 = 9.41, df = 1 (P = 0.00), I2 =89%
0.01 0.1 1 10 100
Favours DHA-P Favours AS+AQ
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Analysis 5.7. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 7 Serious adverse events (including deaths).
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 7 Serious adverse events (including deaths)
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hasugian 2007 IDN 0/168 3/166 16.5 % 0.14 [ 0.01, 2.71 ]
The 4ABC Study 2011 AF 10/1468 15/1003 83.5 % 0.46 [ 0.21, 1.01 ]
Total (95% CI) 1636 1169 100.0 % 0.40 [ 0.19, 0.87 ]
Total events: 10 (DHA-P), 18 (AS+AQ)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours DHA-P Favours AS+AQ
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Analysis 5.8. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 8 Other adverse events: Gastrointestinal.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 8 Other adverse events: Gastrointestinal
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Early vomiting
Hasugian 2007 IDN (1) 7/168 13/166 64.7 % 0.53 [ 0.22, 1.30 ]
Smithuis 2010 MMR (2) 10/161 7/155 35.3 % 1.38 [ 0.54, 3.52 ]
Subtotal (95% CI) 329 321 100.0 % 0.83 [ 0.44, 1.56 ]
Total events: 17 (DHA-P), 20 (AS+AQ)
Heterogeneity: Chi2 = 2.06, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Vomiting
The 4ABC Study 2011 AF 123/1468 106/1003 100.0 % 0.79 [ 0.62, 1.01 ]
Subtotal (95% CI) 1468 1003 100.0 % 0.79 [ 0.62, 1.01 ]
Total events: 123 (DHA-P), 106 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
3 Nausea
Smithuis 2010 MMR 28/161 27/155 100.0 % 1.00 [ 0.62, 1.61 ]
Subtotal (95% CI) 161 155 100.0 % 1.00 [ 0.62, 1.61 ]
Total events: 28 (DHA-P), 27 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Diarrhoea
The 4ABC Study 2011 AF 166/1468 112/1003 88.5 % 1.01 [ 0.81, 1.27 ]
Smithuis 2010 MMR 20/161 17/155 11.5 % 1.13 [ 0.62, 2.08 ]
Subtotal (95% CI) 1629 1158 100.0 % 1.03 [ 0.83, 1.27 ]
Total events: 186 (DHA-P), 129 (AS+AQ)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
5 Abdominal pain
Smithuis 2010 MMR 19/161 20/155 100.0 % 0.91 [ 0.51, 1.65 ]
Subtotal (95% CI) 161 155 100.0 % 0.91 [ 0.51, 1.65 ]
Total events: 19 (DHA-P), 20 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
0.1 0.2 0.5 1 2 5 10
Favours DHA-P Favours AS+AQ
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(. . . Continued)
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Anorexia
The 4ABC Study 2011 AF 130/1468 94/1003 79.1 % 0.94 [ 0.73, 1.22 ]
Smithuis 2010 MMR 22/161 29/155 20.9 % 0.73 [ 0.44, 1.21 ]
Subtotal (95% CI) 1629 1158 100.0 % 0.90 [ 0.72, 1.13 ]
Total events: 152 (DHA-P), 123 (AS+AQ)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 2.67, df = 5 (P = 0.75), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours DHA-P Favours AS+AQ
(1) Vomited at least one dose of medication
(2) Vomiting in first 24h
Analysis 5.9. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 9 Other adverse events: Neuro-psychiatric.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 9 Other adverse events: Neuro-psychiatric
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache
Smithuis 2010 MMR 2/161 2/155 100.0 % 0.96 [ 0.14, 6.75 ]
Subtotal (95% CI) 161 155 100.0 % 0.96 [ 0.14, 6.75 ]
Total events: 2 (DHA-P), 2 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Sleeplessness
Smithuis 2010 MMR 18/161 22/155 100.0 % 0.79 [ 0.44, 1.41 ]
Subtotal (95% CI) 161 155 100.0 % 0.79 [ 0.44, 1.41 ]
Total events: 18 (DHA-P), 22 (AS+AQ)
0.01 0.1 1 10 100
Favours DHA-P Favours AS+AQ
(Continued . . . )
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(. . . Continued)
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
0.01 0.1 1 10 100
Favours DHA-P Favours AS+AQ
Analysis 5.10. Comparison 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine,
Outcome 10 Other adverse events: Cardio-respiratory.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 5 Dihydroartemisinin-piperaquine versus Artesunate plus amodiaquine
Outcome: 10 Other adverse events: Cardio-respiratory
Study or subgroup DHA-P AS+AQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough
The 4ABC Study 2011 AF 470/1468 314/1003 100.0 % 1.02 [ 0.91, 1.15 ]
Subtotal (95% CI) 1468 1003 100.0 % 1.02 [ 0.91, 1.15 ]
Total events: 470 (DHA-P), 314 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Palpitations
Smithuis 2010 MMR 32/161 35/155 100.0 % 0.88 [ 0.58, 1.35 ]
Subtotal (95% CI) 161 155 100.0 % 0.88 [ 0.58, 1.35 ]
Total events: 32 (DHA-P), 35 (AS+AQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 6.1. Comparison 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-
pyrimethamine, Outcome 1 Total failure (P. falciparum) Day 28 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-pyrimethamine
Outcome: 1 Total failure (P. falciparum) Day 28 PCR-unadjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2008 PNG 25/111 25/112 100.0 % 1.01 [ 0.62, 1.64 ]
Subtotal (95% CI) 111 112 100.0 % 1.01 [ 0.62, 1.64 ]
Total events: 25 (DHA-P), 25 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 6.2. Comparison 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-
pyrimethamine, Outcome 2 Total failure (P. falciparum) Day 28 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-pyrimethamine
Outcome: 2 Total failure (P. falciparum) Day 28 PCR-adjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2008 PNG 11/97 11/98 100.0 % 1.01 [ 0.46, 2.22 ]
Subtotal (95% CI) 97 98 100.0 % 1.01 [ 0.46, 2.22 ]
Total events: 11 (DHA-P), 11 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
0.01 0.1 1 10 100
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Analysis 6.3. Comparison 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-
pyrimethamine, Outcome 3 Total failure (P. falciparum) Day 42 PCR-unadjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-pyrimethamine
Outcome: 3 Total failure (P. falciparum) Day 42 PCR-unadjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2008 PNG 42/107 41/108 100.0 % 1.03 [ 0.74, 1.45 ]
Subtotal (95% CI) 107 108 100.0 % 1.03 [ 0.74, 1.45 ]
Total events: 42 (DHA-P), 41 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
0.01 0.1 1 10 100
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Analysis 6.4. Comparison 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-
pyrimethamine, Outcome 4 Total failure (P. falciparum) Day 42 PCR-adjusted.
Review: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 6 Dihydroartemisinin-piperaquine versus Artesunate plus sulfadoxine-pyrimethamine
Outcome: 4 Total failure (P. falciparum) Day 42 PCR-adjusted
Study or subgroup DHA-P AS+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oceania
Karunajeewa 2008 PNG 12/77 17/84 100.0 % 0.77 [ 0.39, 1.51 ]
Subtotal (95% CI) 77 84 100.0 % 0.77 [ 0.39, 1.51 ]
Total events: 12 (DHA-P), 17 (AS+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
0.01 0.1 1 10 100
Favours DHA-P Favours AS+SP
A D D I T I O N A L T A B L E S
Table 1. Detailed search strategy
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 malaria malaria malaria malaria malaria
2 arte* arte* arte* arte* arte*
3 dihydroarte* dihydroarte* dihydroarte* dihydroarte* dihydroarte*
4 amodiaq* amodiaq* amodiaq* amodiaq$ amodiaq$
5 lumefantrine lumefantrine lumefantrine lumefantrine lumefantrine
6 Coartem* Coartem* Coartem* Coartem$ Coartem$
7 mefloquine mefloquine mefloquine mefloquine mefloquine
8 2 or 3 2 or 3 2 or 3 2 or 3 2 or 3
9 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7 4 or 5 or 6 or 7
10 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9 1 and 8 and 9
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Table 1. Detailed search strategy (Continued)
11 - - Limit 10 to humans Limit 10 to human -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2008); upper case: MeSH or EMTREE heading; lower case: free text term.
Table 2. Primary outcome measure (Total failure)
Analysis Participants PCRb-unadjusted PCR-adjusted
Numerator Denominator Numerator Denominator
Primary analysis Exclusions after en-
rolmenta
Excludedc Excluded Excluded Excluded
Missing or indeter-
minate PCR
Included as failures Included Excluded Excluded
New infections Included as failures Included Excluded Excluded
Sensitivity analysis 1
d
As ’Primary analysis’
except: missing or
indeterminate PCR
- - Included as failures Included
Sensitivity analysis 2
e
As ’Sensitivity anal-
ysis 1’ except: new
infections
- - Included as successes Included
Sensitivity analysis 3
f
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as failures Included Included as failures Included
Sensitivity analysis 4
g
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as
successes
Included Included as successes Included
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aNote: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations.
bPCR: polymerase chain reaction.
c’Excluded’ means removed from the calculation.
dTo re-classify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.
eTo re-classify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate
efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may
have proceeded to develop a recrudescence after the new infection.)
fTo re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment failures. For PCR-unadjusted total failure, this represents a true worse-case scenario.
gTo re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment successes.
Table 3. DHA-P versus AS+MQ: Additional secondary outcomes data
Outcome Study ID Measure DHA-P AS+MQ P value Comment
Gametocyte
carriage
Grande 2007
PER
Person game-
tocytemia weeks
per 1000 person
weeks
32.5 24.9 0.31
Mayxay 2006
LAO
Proportion with
gameto-
cytes at any time-
point after treat-
ment (on or after
day 7)
9/110 3/110 0.07
Person game-
tocytemia weeks
per 1000 person
weeks
- - > 0.05 Mean across all groups
was 0.10 (95% CI 0.
03 to 0.20). No dif-
ference between groups
(published data)
Smithuis 2006
MMR
Gametocyte in-
cidence at day 7
18/188 5/218 0.01
Gametocyte in-
cidence at day 14
3/168 1/212 0.12
Person game-
tocytemia weeks
per 1000 person
weeks
- - 0.03 Game-
tocyte carriage in DHA-
P group was higher than
in AS+MQ group (pub-
lished data). Figures not
given
Smithuis 2010
MMR
Person game-
tocytemia weeks
per 1000 person
112.8 29.5 Not stated Data pre-
sented are for fixed-dose
AS+MQ combination.
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Table 3. DHA-P versus AS+MQ: Additional secondary outcomes data (Continued)
weeks
Valecha 2010 AS Person game-
tocytemia weeks
per 1000 person
weeks
20.2
(130/6420)
7.4
(23/3108)
0.01 Published data in paper
presented as “person ga-
metocytemia weeks per
100 person weeks”
Anaemia Ashley 2004b
THA
Median decrease
inHCT by day 7
6.3% 9.4% 0.21 “Mean decrease in HCT
up to day 7 then recovery
in all groups”
Ashley 2005
THA
Absolute
changes in HCT
- - - “Mean decrease in HCT
up to day 7 then recovery
in all groups”
Janssens 2007
KHM
Mean HCT at
day 63
40.0 % (3.7) 40.2% (3.8) Not stated “Patients
in both treatment groups
showed similar haemato-
logical
recovery during the 63-
day follow-up period”.
Mayxay 2006
LAO
Mean HCT days
7 to 42
Not stated Not stated > 0.05 “themean hematocrit af-
ter treatment did not sig-
nificantly differ between
groups”
Smithuis 2006
MMR
Mean haemoglo-
bin at day 28
10.4 g/dL 10.5 g/dL 0.65 Data presented are
for supervised treatment
groups.
Pro-
portion anaemic
(Hb < 10 g/dL)
on day 28
56/152 59/156 0.85 Data presented are
for supervised treatment
groups.
Smithuis 2010
MMR
Mean increase in
haemoglobin
Not stated Not stated > 0.05 “The mean increase of
haemoglobin was simi-
lar among the treatment
groups”
Valecha 2010 AS Mean increase in
Hb fromday 0 to
day 63 in g/dL
1.28 ± 2.22 1.42 ± 2.12 0.30
Hb - Haemoglobin
HCT - Haematocrit
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Table 4. DHA-P versus AS+MQ/AL6: QTc measurements
Study ID No. of partici-
pants
Day Outcome Correction
method
DHA-P
(%)
AS+MQ
(%)
P value
Valecha 2010
AS
1150 At baseline Border-
line QTc (431
to 450ms)
QTcB 16.6 12.1 0.066
QTcF 2.9 1.6 >0.05
Day 2 Border-
line QTc (431
to 450ms)
QTcB 21.4 16.3 0.043
QTcF 13.0 5.3 <0.001
Pro-
longed QTc (>
450ms)
QTcB 8.6 4.2 0.007
QTcF 4.7 5.3 < 0.0011
QTc increase >
60 ms
QTcB 0.9 0.8 > 0.05
QTcF 4.6 2.9 < 0.001
Day 7 No differences
between
groups
N/R N/R > 0.05
DHA-P
(%)
AL6
(%)
P value
Bassat 2009
AF
1553 At baseline Border-
line QTc (431-
450ms)
N/R N/R
Day 2 Border-
line QTc (431-
450ms)
QTcB 29.1 19.8 < 0.001
QTcF 1.0 1.2 0.76
Pro-
longed QTc (>
450ms)
QTcB 9.1 6.9 0.152
QTcF 0.2 0.2 0.992
QTc > 500 ms QTcB 0.19 0.39 > 0.05
QTcF N/R N/R
QTc increase >
60 ms
QTcB 2.7 2.0 > 0.05
QTcF N/R N/R
Day 7 No differences
between
N/R N/R > 0.05
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Table 4. DHA-P versus AS+MQ/AL6: QTc measurements (Continued)
groups
1 In this analysis the direction of effect is reversed. These figures have been confirmed as correct by the study authors.
2 Figures not presented in paper: Taken from Analysis 4.13.
N/R - Not reported
QTcB - QT interval corrected for rate and gender using Bazett’s method.
QTcF - Qt interval corrected for rate and gender using Fridericia’s method.
Table 5. DHA-P versus AS+MQ: Biochemical monitoring and adverse events
Study ID No. of partici-
pants
Tests Days tested Days
reported
Days tested
adequate
to detect ad-
verse events?
For ade-
quate testing,
was reporting
complete?
Re-
sults as pre-
sented in the
paper
Ashley 2004a
THA
134 U&E, LFTs Days 0 and 7 None Adequate1 Incomplete 2 “No biochem-
ical evidence
of toxicity was
observed”.
Grande 2007
PER
522 U&E, LFTs Days 0 and 7 None Adequate1 Incomplete2 “No patient
had abnormal
liver and renal
function
test results of
clinical signifi-
cance, both at
entry and at
day 7”
Tran 2004
VNM
243 LFTs Days 3,7,28 None Adequate1 Incomplete2 “There
were no sig-
nificant differ-
ences between
the three
groups in the
results of liver
function tests
done on all pa-
tients on days
3, 7, and 28”
Valecha 2010
AS
1150 Not clearly
stated
Days 0, 28, 63 None Inadequate3 Incomplete2 “Other
than elevated
liver parame-
ters, as might
be expected in
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Table 5. DHA-P versus AS+MQ: Biochemical monitoring and adverse events (Continued)
this pop-
ulation, there
were no rel-
evant changes
in bio-
chemistry pa-
rameters”.’
1 Judged as adequate given that no clinically important abnormalities were seen at day 7. Longer follow-up is therefore probably
unnecessary.
2 Judged as incomplete as data were not presented. Only a text summary was given.
3 Judged as inadequate as biochemical abnormalities are likely to occur earlier than day 28.
LFT = Liver Function Tests
U&E = Urea and electrolytes
Table 6. DHA-P versus AS+MQ dosing regimens
Study ID Year of study Age limits DHA-P AS+MQ
Ashley 2004a THA 2003 > 14 yrs 6 mg/kg DHA + 48 mg/kg
P in 4 divided doses at 0, 8,
24, and 48 hrs
4 mg/kg AS once daily for
3 days + 8 mg/kg MQ once
daily for 3 days
Ashley 2004b THA 2003 1 to 65 yrs 6 mg/kg DHA + 48 mg/kg
P in 4 divided doses at 0, 8,
24, and 48 hrs
4 mg/kg AS once daily for
3 days + 8 mg/kg MQ once
daily for 3 days
Ashley 2005 THA 2005 1 to 65 yrs 6.4 mg/kg DHA and 51.2
mg/kg P in 4 divided doses
at 0, 8, 24, and 48 hrs or 3
divided doses at 0, 24, and
48 hrs
4 mg/kg AS once daily for
3 days + 8 mg/kg MQ once
daily for 3 days
Grande 2007 PER 2005 5 to 60 yrs Total dose: 6.3 mg/kg DHA
and 50.4 mg/kg PQP in 3
divided doses, given once
daily for 3 days
4 mg/kg AS once daily for
3 days + 8 mg/kg MQ once
daily for 3 days
Janssens 2007 KHM 2003 > 1 yr Adult total dose: 6 mg/kg
DHA and + 48 mg/kg P in
4 divided doses at 0, 8, 24,
and 48 hrs
Children total dose: 6.4
mg/kg DHA + 51.2 mg/kg
P in 4 divided doses at 0, 8,
24, and 48 hrs
Adults: 100 mg AS plus 500
mg MQ twice daily on day
0, 200 mg AS once daily on
days 1 and 2
Children: 4 mg/kg AS once
daily for 3 days + 25 mg/kg
MQ in 2 equal doses on day
0
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Table 6. DHA-P versus AS+MQ dosing regimens (Continued)
Mayxay 2006 LAO 2004 > 1 yr 6.3 mg/kg DHA + 50.4 mg/
kg P in 3 divided doses, once
daily for 3 days
4 mg/kg AS once daily for 3
days + 15 mg MQ base/kg
on day 1 and 10 mg base/kg
on day 2
Smithuis 2006 MMR 2004 > 1 yr 6.3 mg/kg DHA + 50.4 mg/
kg P in 3 divided doses, once
daily for 3 days
4 mg/kg AS once daily for 3
days.
25 mg MQ base/kg as a sin-
gle dose on day 0.
Smithuis 2010 MMR 2009 > 1 yr 2.5 mg/kg DHA + 20 mg/
kg P daily, given once daily
for 3 days
Fixed combination: 4 mg/
kg AS + 8.8 mg/kg MQ
daily, once daily for 3 days.
Loose combination: 4 mg/
kg AS once daily for 3 days
+ 25 mg base/kg MQ as a
single dose on day 0
Tangpukdee 2005 THA Not stated > 14 yrs 6 mg/kg DHA + 45 mg/kg
P in 3 divided doses, given
once daily for 3 days
4 mg/kg AS once daily for
3 days + 8 mg/kg MQ once
daily for 3 days
Tran 2004 VNM 2002 > 2 yrs 40 mg/320 mg tablets
Adults: 2 tablets at 0, 6, 24,
and 48 hrs
Children < 15 yrs: 1 tablet
at 0, 6, 24, and 48 hrs
4 mg/kg AS once daily for 3
days + 25mgbase/kgMQ as
2 divided doses 6 hrs apart
on day 3
Valecha 2010 AS 2007 3m to 65 yrs (≥18 yrs in In-
dia)
DHA: 2.25 mg/kg DHA +
18 mg/kg P daily dose for 3
days
4mg/kg AS once daily for 3
days + MQ none on day 0,
then 15 mg/kg once on day
1 and 10 mg/kg once on day
2
Table 7. DHA-P versus AL6: Additional secondary outcomes data
Outcome Trial ID Measure DHA-P AL6 P value Comment
Gametocyte
carriage
Bassat 2009 AF Person game-
tocytemia weeks
per 1000 person
weeks
43.97 21.43 0.005
Smithuis 2010
MMR
Person game-
tocytemia weeks
per 1000 person
weeks
112.8 58.2 Not stated
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Table 7. DHA-P versus AL6: Additional secondary outcomes data (Continued)
Ratcliff 2007
IDN
Person game-
tocytemia weeks
per 1000 person
weeks
- - Not significant Figures not given.
Karunajeewa
2008 PNG
Post-treatment
gametocytemia
- - No difference Figures not given.
Anaemia Yeka 2008 UGA Mean increase in
Hb (g/dL)
1.75 ± 1.8 1.66 ± 2.0 0.63Mens 2008 KEN Final mean Hb
level (mmol/L)
7.15 ± 1.07 6.79 ± 1.24 Not significant
Arinaitwe 2009
UGA
Mean Hb recov-
ery (g/dL)
0.62 ± 1.68 0.56 ± 1.58 0.41
Agarwal 2013
KEN
Mean Hb in-
crease from base-
line in patients
not re-infected
11.6 g/dL 9.8 g/dL Not stated P value for difference in
mean Hb increase in re-
infected patients and those
not re-infected is given as 0.
9
Mean Hb in-
crease from
baseline in re-in-
fected patients
11.1 g/dL 9.9 g/dL Not stated
Hb - Haemoglobin
Table 8. DHA-P versus AL6: Biochemical monitoring and adverse events
Trial ID No. of partici-
pants
Tests Days tested Days
reported
Days tested
adequate
to detect ad-
verse events?
For ade-
quate testing,
was reporting
complete?
Re-
sults as pre-
sented in the
paper
Bassat 2009
AF
1553 LFTs and re-
nal function
Days 3, 28,
and 42
None Adequate1 Incomplete 2 “...altered liver
en-
zymes (ALT).
.. was similar
between the
two treatment
groups”
The 4ABC
Study 2011
AF
2701 LFT and renal
function
Days 7 and 28 Days 7 and 28 Adequate1 Complete3 “The median
lev-
els of alanine
aminotrans-
ferase and cre-
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Table 8. DHA-P versus AL6: Biochemical monitoring and adverse events (Continued)
atinine before
treatment, as
well as the pro-
portion of pa-
tients with val-
ues above the
normal range
(both clini-
cally and non-
clinically sig-
nif-
icant, the lat-
ter not shown)
, were similar
between
the four study
arms, and this
did not
change during
the follow-ups
at day 7 and
28”
Yavo 2011 AF 384 LFTs Days 0 and 4 Baseline and
day 4
Adequate1 Complete3 “In DP group
from the be-
ginning of the
treat-
ment to day 4,
there was a de-
crease of the
mean of AST
and a small in-
crease of ALT
mean, while in
the AL group,
AST and ALT
means in-
creased. How-
ever, these
variations
were not sig-
nificantly dif-
ferent.
The decrease
of the mean of
creatinin from
the beginning
138Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 8. DHA-P versus AL6: Biochemical monitoring and adverse events (Continued)
of the treat-
ment to day 4
was not signif-
icant in
the DP group
but was signif-
icant in the AL
group. In the
two groups,
the
bilirubin de-
crease was sig-
nificant”
1 Adequate given that no clinically important abnormalities were seen.
2 Incomplete as trial authors did not present data and only gave a text summary.
3 Complete as trial authors presented data for the two days tested.
Table 9. DHA-P versus AS+AQ: Additional secondary outcomes data
Outcome Trial ID Measure DHA-P AS+AQ P value Comment
Gametocyte
carriage
Karema 2006
RWA
Gametocyte
prevalence
- - Not significant Figures not given.
Hasugian 2007
IDN
Post-
treatment game-
tocyte carriage
- - No difference Figures not given.
Anaemia Karema 2006
RWA
Mean PCV at
baseline
31.5 ± 4.9 31.0 ± 5.5 No difference
Mean PCV at
day 14
33.4 ± 3.6 34.0 ± 3.7 0.08
Hasugian 2007
IDN
Proportion
of patients with
anaemia at day 7
- - 0.02 “Although therewas no signif-
icant difference in haemoglo-
bin levels between treatment
groups at the time of admis-
sion, the rates of anemia at
days 7 and 28 were signifi-
cantly higher in AS+AQ re-
cipients”
Propor-
tion of patients
with anaemia at
day 28
- - 0.006
Smithuis 2010
MMR
Mean increase in
haemoglobin
Not stated Not stated > 0.05 “The mean increase of hae-
moglobin was similar among
the treatment groups”
Hb - Haemoglobin
PCV - Packed cell volume
Neutropenia - neutrophil count < 1000/µL
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Table 10. DHA-P versus AS+AQ: Biochemical monitoring and adverse events
Study ID No. of par-
ticipnts
Tests Days tested Days
reported
Days tested
adequate?
For ade-
quate testing,
was reporting
complete?
Re-
sults as pre-
sented in the
paper
Karema 2006
RWA
762 LFTs at one
site only
Days 0 and 14 None Adequate1 Incomplete 2 “No hepa-
totoxicity was
observed,
although anal-
yses were per-
formed at one
site only (data
not shown)”
The 4ABC
Study 2011
AF
2701 LFT and renal
function
Days 7 and 28 Days 7 and 28 Adequate1 Complete3 “The median
lev-
els of alanine
aminotrans-
ferase and cre-
atinine before
treatment, as
well as the pro-
portion of pa-
tients with val-
ues above the
normal range
(both clini-
cally and non-
clinically sig-
nif-
icant, the lat-
ter not shown)
, were similar
between
the four study
arms, and this
did not
change during
the follow-ups
at day 7 and
28”
1 Adequate given that no clinically important abnormalities were seen.
2 Incomplete as trial authors did not present data and only gave a text summary.
3 Complete as trial authors presented data for the two days tested.
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Table 11. Dihydroartemisinin-piperaquine compared to Artemether-lumefantrine for uncomplicated P. falciparum malaria
in Asia and Oceania
Dihydroartemisinin-piperaquine compared to Artemether-lumefantrine for uncomplicated P. falciparum malaria in Asia
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Asia and Oceania
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artemether-lumefantrine (AL6)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
AL6 DHA-P
Treatment failure
Day 28
PCR-unadjusted RR 0.97
(0.64 to 1.47)
1143
(4 trials)
⊕⊕⊕©
moderate1,2,3,4
7 per 100 7 per 100
(4 to 10)
PCR-adjusted RR 2.01
(0.81 to 5.03)
925
(3 trials)
⊕⊕⊕©
moderate1,2,3,4
1 per 100 3 per 100
(1 to 7)
Treatment failure
Day 63
PCR-unadjusted RR 0.94
(0.47 to 1.88)
323
(1 trial)
⊕⊕©©
low4,5,6,7
9 per 100 8 per 100
(4 to 17)
PCR-adjusted RR 1.00
(0.14 to 7.01)
298
(1 trial)
⊕⊕©©
low4,5,6,7
1 per 100 1 per 100
(0 to 7)
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 No serious risk of bias: Trials are generally at low or unclear risk of bias. Exclusion of trials as high risk of selection bias or detection
bias did not change the result.
2 No serious inconsistency: Statistical heterogeneity was low.
3 No serious indirectness: The trials were conducted in adults and children in Indonesia, Thailand, Papua New Guinea, and Myanmar.
4 Downgraded by 1 for serious imprecision: The 95% CI is wide and includes appreciable differences between drugs.
5 No serious risk of bias: This single trial is generally at low risk of bias.
6 Downgraded by 1 for serious indirectness: This single trial is from Myanmar. The results may not be easily generalized to elsewhere.
7 Two trials from Indonesia and Papua New Guinea reported outcomes at Day 42. At this timepoint there was no difference in PCR
unadjusted or PCR adjusted treatment failure (two trials, 572 participants, low quality evidence).
Table 12. Dihydroartemisinin-piperaquine compared to Artesunate plusmefloquine for treating uncomplicatedP. falciparum
malaria in Asia
Dihydroartemisinin-piperaquine compared to Artesunate plus mefloquine for treating uncomplicated P. falciparum malaria
in Asia
Patient or population: Patients with treating uncomplicated P. falciparum malaria
Settings: Endemic settings in Asia
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artesunate plus mefloquine (AS+MQ)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
AS+MQ DHA-P
Treatment failure
Day 28
PCR-unadjusted RR 1.02
(0.28 to 3.72)
3487
(8 trials)
⊕⊕⊕⊕
high1,2,3,4
2 per 100 2 per 100
(1 to 8)
PCR-adjusted RR 0.41
(0.21 to 0.8)
3467
(8 trials)
⊕⊕⊕⊕
high1,2,3,5
1 per 100 0 per 100
(0 to 1)
Treatment failure
Day 63
PCR-unadjusted RR 0.84
(0.69 to 1.03)
2715
(5 trials)
⊕⊕⊕©
moderate1,6,7,8
12 per 100 10 per 100
(8 to 13)
PCR-adjusted RR 0.5
(0.3 to 0.84)
2500
(5 trials)
⊕⊕⊕⊕
high1,7,8,9
3 per 100 2 per 100
(1 to 3)
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Table 12. Dihydroartemisinin-piperaquine compared to Artesunate plusmefloquine for treating uncomplicatedP. falciparum
malaria in Asia (Continued)
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Trials are generally at low risk of selection bias and detection bias. Exclusion of trials as high or unclear risk
of bias did not change the result.
2 No serious inconsistency: Six trials found very few recurrent parasitaemia in both groups. Two trials primarily conducted in Thailand
in areas with multi-drug resistance found an increased risk of recurrent parasitaemia with AS+MQ.
3 No serious indirectness: The trials were conducted in adults and children in Vietnam, Thailand, Cambodia, Myanmar, India, and
Laos.
4 No serious imprecision: The overall result is of no significant difference between treatments. However, where there is P. falciparum
resistance to mefloquine, DHA-P may be superior.
5 No serious imprecision: The overall result is of a statistically significant benefit with DHA-P although this benefit may only be present
where there is resistance to mefloquine.
6 Downgraded by one for serious inconsistency: Of the five trials, one from Thailand in 2005 found a statistically significant benefit
with DHA-P, one from Myanmar in 2009 found a benefit with DHA-P, and three found no difference.
7 No serious indirectness: The trials were conducted in adults and children in Thailand, Cambodia, Myanmar, India, and Laos.
8 No serious imprecision: The overall result is of no significant difference between treatments. Although some trials found statistically
significant differences, these may not be clinically important.
9 No serious inconsistency: There is a small amount of variability between trials, with only one trial showing a statistically significant
benefit with DHA-P.
Table 13. Dihydroartemisinin-piperaquine compared to Artesunate plusmefloquine for uncomplicated P. falciparummalaria
in South America
Dihydroartemisinin-piperaquine compared to Artesunate plus mefloquine for uncomplicated P. falciparum malaria in South
America
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Endemic settings in South America
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artesunate plus mefloquine (AS+MQ)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
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Table 13. Dihydroartemisinin-piperaquine compared to Artesunate plusmefloquine for uncomplicated P. falciparummalaria
in South America (Continued)
AS+MQ DHA-P
Treatment failure
Day 28
PCR-unadjusted - Data unavailable -
- -
PCR-adjusted - Data unavailable -
- -
Treatment failure
Day 63
PCR-unadjusted RR 6.19
(1.4 to 27.35)
445
(1 trial)
⊕⊕©©
low1,2,3
1 per 100 6 per 100
(1 to 24)
PCR-adjusted RR 9.55
(0.52 to 176.35)
435
(1 trial)
⊕⊕©©
low1,2,4
0 per 100 0 per 100
(0 to 0)
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: This trial is at low risk of selection bias and unclear risk of detection bias.
2 Downgraded by 1 for serious indirectness: This findings of this single trial are not easily generalized to other South American countries.
3 Downgraded by 1 for serious imprecision: Although this result reached statistical significance the number of events is very low, and
there is a high possibility that this is a chance finding.
4 Downgraded by 1 for serious imprecision: There were too few events in this single trial to confidently exclude important effects.
Table 14. Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum
malaria in Africa
Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum malaria in
Africa
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Africa
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
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Table 14. Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum
malaria in Africa (Continued)
Comparison: Artesunate plus amodiaquine (AS+AQ)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
AS+AQ DHA-P
Treatment failure
Day 28
PCR-unadjusted RR 0.49
(0.41 to 0.59)
2800
(2 trials)
⊕⊕⊕⊕
high1,2,3,4
20 per 100 10 per 100
(8 to 12)
PCR-adjusted RR 0.67
(0.42 to 1.06)
2486
(2 trials)
⊕⊕⊕©
moderate1,2,3,5
4 per 100 2 per 100
(2 to 4)
Treatment failure
Day 63
PCR-unadjusted RR 0.96
(0.86 to 1.07)
2292
(1 trial)
⊕⊕⊕©
moderate3,6,7,8
37 per 100 35 per 100
(32 to 39)
PCR-adjusted RR 1.8
(0.85 to 3.83)
1506
(1 trial)
⊕⊕⊕©
moderate3,6,7,8
2 per 100 3 per 100
(1 to 6)
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection
bias did not change the result.
2 No serious inconsistency: The trials had similar results and statistical heterogeneity was low.
3 No serious indirectness: The trials were conducted in children in different transmission settings in Burkina Faso, Gabon, Nigeria,
Rwanda, Uganda, Zambia, and Mozambique.
4 No serious imprecision: Both limits of the 95% CI imply appreciable benefit.
5 Downgraded by 1 for serious imprecision: The findings did not reach statistical significance.
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6 No serious risk of bias: This finding is only reported in one trial which was at low risk of bias.
7 Downgraded by 1 for serious imprecision: There 95% CI are wide and include what might be important differences.
8 No data were presented for day 42.
Table 15. Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falci-
parum malaria in Asia
Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falciparum malaria
in Asia
Patient or population: Patients with treating uncomplicated P. falciparum malaria
Settings: Asia
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artesunate plus amodiaquine (AS+AQ)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
AS+AQ DHA-P
Treatment failure
Day 28
PCR-unadjusted RR 0.38
(0.18 to 0.77)
482
(2 trials)
⊕⊕⊕©
moderate1,2,3,4
11 per 100 4 per 100
(2 to 8)
PCR-adjusted RR 0.08
(0.01 to 0.4)
466
(2 trials)
⊕⊕⊕©
moderate1,2,3,4
8 per 100 1 per 100
(0 to 3)
Treatment failure
Day 63
PCR-unadjusted RR 0.49
(0.27 to 0.89)
304
(1 trial)
⊕⊕©©
low4,5,6,7
19 per 100 9 per 100
(5 to 17)
PCR-adjusted RR 0.14
(0.03 to 0.59)
278
(1 trial)
⊕⊕©©
low4,5,6,7
10 per 100 1 per 100
(0 to 6)
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
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Table 15. Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for treating uncomplicated P. falci-
parum malaria in Asia (Continued)
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Trials are generally at low risk of bias. Exclusion of trials as high or unclear risk of selection bias or detection
bias did not change the result.
2 No serious inconsistency: The trials all had similar results and statistical heterogeneity was low.
3 No serious indirectness: The trials were conducted in adults and children in Indonesia and Myanmar.
4 Downgraded by 1 for serious imprecision: Although this result reached statistical significance there are limited data, with few events.
Larger trials are needed to have full confidence in this result.
5 No serious risk of bias: This finding is only reported in one trial which was generally at low risk of bias.
6 Downgraded by 1 for serious indirectness: This trial was from a single setting in Myanmar, and may not be easily generalized to
elsewhere.
7 One trial from Indonesia conducted in 2007 presented day 42 outcomes and at this timepoint there was still an advantage on PCR-
unadjusted treatment failure with DHA-P (RR 0.27, 95% CI 0.10 to 0.72, one trial, 152 participants, moderate quality evidence), and
PCR-adjusted treatment failure (RR 0.10, 95% CI 0.01 to 0.81, one trial, 141 participants, moderate quality evidence).
A P P E N D I C E S
Appendix 1. Adverse event monitoring
DHA-P versus Artesunate plus mefloquine
Trial ID Sample Size Blinding Clinical symp-
toms monitoring
Biochemistry Haematological ECG
Ashley 2004a
THA
134 Open label Inpatient monitor-
ing until day 28
U&E, LFTondays
0 and 7
FBC on days 0 and
7
None
Ashley 2004b
THA
356 Open label Daily review un-
til parasites cleared
then weekly until
day 63
U&E, LFTondays
0 and 7 (DHA-P
group only)
FBC on days 0 and
7
(DHA-P group
only)
Days
0 and 7 (DHA-P
group only)
Ashley 2005
THA
499 Open label Clinical examina-
tion and symptom
enquiry daily un-
til parasites cleared
then weekly until
None Haematocrit
daily until parasites
cleared thenweekly
until day 63
None
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day 63
Grande 2007
PER
522 Open label Clinical assessment
daily until day 3
then weekly until
day 63
U&E, LFTondays
0 and 7,
FBC, PCV days 0
and 7, PCV days
14 and 63
None
Janssens 2007
KHM
464 Open label Clinical examina-
tion and symptom
questionnaire days
0, 1, 2, and 3
None None None
Mayxay 2006
LAO
220 Open label Daily review un-
til parasites cleared
then weekly until
day 42
None None None
Smithuis 2006
MMR
652 Open label Symptom ques-
tionnaire at days 0,
1, 2, 3, and 7
None None None
Smithuis 2010
MMR
491 Open label Review weekly for
9 weeks
None None None
Tangpukdee
2005 THA
180 Open label Inpatient monitor-
ing until day 28.
Assessed us-
ing non-suggestive
questioning
None None None
Tran 2004 VNM 243 Open label Review at days 0, 2,
and 7
LFTs on days 3, 7
and 28
None None
Valecha 2010 AS 1150 Open label Clinical review un-
til parasites cleared
then weekly until
day 63
Blood and urine
samples 0, 28, 63
and on the day of
any recurrent para-
sitaemia
None Days 0, 2, 7, 28, 63
and on the day of
any recurrent para-
sitaemia
DHA-P versus Artemether-lumefantrine
Trial ID Sample Size Blinding Clinical
symptoms mon-
itoring
Biochemistry Haematological ECG
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Adam 2010
SDN
160 Open
label
Review at days 1,
2, 3, 7, 14, 21,
and 28.
None None None
Agarwal 2013
KEN
274 Open label Clinical as-
sessment on days
1, 2, 3, 7, 14, 21,
28, 35, and 42 af-
ter enrolment or
at any day if ill
None None None
Arinaitwe 2009
UGA
671
treated
episodes
Open
label
Review at days 0,
2, 3, 7, 14, 21, 28
after each episode
for 1 year
None None None
Bassat 2009 AF 1548 Open
label
In-patient review
through-
out the dosingpe-
riod then weekly
till day 42
LFT and renal
function at days
3, 28, and 42 and
at clinician’s re-
quest
FBC at days 3, 28
and 42
12-lead ECG at
days 0, 2, and 7
Kamya 2007
UGA
421 Double
blind
Clinical as-
sessment daily till
day 3 thenweekly
until day 42
None None None
Karunajeewa
2008 PNG
250 Open label Clini-
cal assessment on
days 0, 1, 2, 3, 7,
14, 28, and 42.
None None None
Krudsood 2007
THA
191 Open label In-patient review
daily until day 28.
None None None
Mens 2008KEN 146 Open label Review on days 0,
1, 2, 3, 7, 14, and
28.
None None None
Ratcliff 2007
IDN
774 Open label Re-
view and symp-
tom question-
naire daily until
fever and para-
sites cleared then
weekly until day
42
None None None
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Sawa 2013 KEN 298 Single blind Clinical examina-
tion on days 1, 2,
3, 7, 14, 28, and
42.
None None None
The 4ABC
Study 2011 AF
2,701 Single blind Clinical as-
sessment on days
1, 2, 3, 7, 14, 21,
and 28.
LFT and renal
function at days 7
and 28
FBC at days 3, 7,
14, and 28
None
Yavo 2011 AF 384 Open label Clini-
cal assessment on
days 1, 2, 3, 4, 7,
14, 21, and 28.
LFT at baseline
and day 4
None None
Yeka 2008 UGA 414 Single blind Review daily till
day 3 thenweekly
until day 42.
None None None
Zongo 2007
BFA
375 Open label Assessment daily
until day 3 then
weekly until day
42.
None None None
DHA-P versus Artemether plus amodiaquine
Trial ID Sample Size Blinding Clinical symp-
toms monitoring
Biochemistry Haematological ECG
Hasugian 2007
IDN
334 Open label Clinical as-
sessment daily un-
til afebrile then
weekly until day
42
None None None
Karema 2006
RWA
504 Open label Clinical assess-
ment on days 0, 1,
2, 3, 7, 14, 21, and
28.
Differential WBC
count (and LFT at
one site only) at
days 0 and 14
None None
Smithuis 2010
MMR
316 Open label Review weekly for
9 weeks.
None None None
The 4ABC
Study 2011 AF
2477 Single blind Clinical
assessment on days
1, 2, 3, 7, 14, 21,
Liver
and renal function
tests at days 7 and
FBC at days 3, 7,
14, and 28
None
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and 28. 28
DHA-P versus artesunate plus sulfadoxine-pyrimethamine
Trial ID Sample Size Blinding Clinical symp-
toms monitoring
Biochemistry Haematological ECG
Karunajeewa
2008 PNG
245 Open label Clinical assessment
on days 0, 1, 2, 3,
7, 14, 28, and 42
None None None
Appendix 2. Serious adverse event descriptions
DHA-P versus Artesunate plus mefloquine
Trial ID Number of participants Blinding Comment
Ashley 2004a THA 134 Open label No serious adverse events observed.
Ashley 2004b THA 356 Open label No serious adverse events observed.
Ashley 2005 THA 499 Open label 4/166 serious events with AS+MQ (death, severe
anaemia, febrile convulsion, coagulopathy) and 11/333
with DHA-P (2 deaths, bacterial sepsis, febrile convul-
sion, leptospirosis, haematemesis, nephritic syndrome,
severe anaemia, respiratory infection, epigastric pain, and
vomiting)
Grande 2007 PER 522 Open label 3 serious drug related eventswithAS+MQrequiring stop-
ping treatment (encephalopathy, anxiety and arrhythmia,
palpitations, and chest pain)
Janssens 2007 KHM 464 Open label No serious adverse events observed.
Mayxay 2006 LAO 220 Open label One neuropsychiatric reaction in AS+MQ group.
Smithuis 2006 MMR 652 Open label No serious adverse events reported in the first 7 days.
Smithuis 2010 MMR 491 Open label Not reported.
Tangpukdee 2005 THA 180 Open label No serious adverse events observed.
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Tran 2004 VNM 243 Open label 12 events (10 vomiting, 2 dizziness) described as signif-
icant in AS+MQ group and none with DHA-P (P = 0.
002)
Valecha 2010 AS 1150 Open label 12/767 events described as serious in DHA-P group (6
deemed related to drug: 2 cases of anaemia, 1 viral infec-
tion, 1 Wolf-Parkinson-White syndrome, 1 convulsion,
1 encephalitis), 3/381 in AS+MQ group (all deemed re-
lated to drug: 1 anaemia, 1 convulsion, 1 encephalitis)
DHA-P versus Artemether-lumefantrine
Trial ID Number of participants Blinding Comment
Adam 2010 SDN 160 Open
label
All AE described as mild.
Agarwal 2013 KEN 274 Open label 1/137 with DHA-P, 2/137 with AL (all severe malaria
and attributed to new infections)
Arinaitwe 2009 UGA 671 treated episodes Open
label
3/320 with DHA-P, 1/351 with AL6 (all due to devel-
opment of severe anaemia)
Bassat 2009 AF 1548 Open
label
18/1038 with DHA-P and 5/510 with AL6 (P = 0.
2490. One death occurred in each group but the other
SAEs are not described
Kamya 2007 UGA 421 Double
blind
4/211 with DHA-P, 2/210 with AL, all judged to be
unrelated to study meds (3 febrile convulsions, otitis
media, asthma attack, pyomyositis)
Karunajeewa 2008 PNG 250 Open label Overall comment: No treatment withdrawals were at-
tributable to adverse events related to a study drug
Krudsood 2007 THA 191 Open label Overall comment: No significant differences are noted
between the treatments
Mens 2008 KEN 146 Open label One patient treated with DHA-P died on day 14. As-
sessed as unrelated to treatment
Ratcliff 2007 IDN 774 Open label One death 60 days after treatment. Cause not known.
Sawa 2013 KEN 298 Single blind Overall comment: No adverse events reported.
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The 4ABC Study 2011 AF 2701 Single blind 10/1468 with DHA-P compared to 6/1225 with AL6.
The only ones described are one death due todiarrhoeal
disease in the DHA-P group and three deaths in the
AL group (two severe malaria and one unknown cause)
. None were related to treatment
Yavo 2011 AF 384 Open label None reported.
Yeka 2008 UGA 414 Single blind 2/215 with AL, 5/199 with DHA-P, all judged un-
related to study meds (2 convulsions, 2 pyomyositis,
vomiting, severe anaemia, dehydration)
Zongo 2007 BFA 375 Open label None observed.
Bassat 2009 AF 1548 Open
label
No difference in QT prolongation.
DHA-P versus Artesunate plus amodiaquine
Trial ID Number of participants Blinding Comment
Hasugian 2007 IDN 334 Open label 3 with AS+AQ (2 vomiting, 1 ataxia), none with DHA-
P.
Karema 2006 RWA 504 Open label Not reported (one seizure with AS+AQ).
Smithuis 2010 MMR 316 Open label Not reported.
The 4ABC Study 2011 AF 2477 Single Blind Occurencemore frequent in AS+AQ group (15/1003 in
the AS+AQgroup versus 10/1468 in theDHA-P group)
. The only ones described are one severe malaria case in
AS+AQ group and one death due to diarrhoeal disease
in DHA-P group
DHA-P versus artesunate plus sulfadoxine-pyrimethamine
Trial ID Number of participants Blinding Comment
Karunajeewa 2008 PNG 245 Open label Overall comment: No treatment withdrawals were at-
tributable to adverse events related to a study drug
Footnotes
153Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
AE = adverse event; AL6 = artemether-lumefantrine; AQ = amodiaquine; AS = artesunate; DHA-P = dihydroartemisinin-piperaquine;
ECG: electrocardiogram; MQ = mefloquine; QT = interval between the Q and T waves of an ECG; SAE = serious adverse event; SP
= sulfadoxine-pyrimethamine.
Appendix 3. Adverse events GRADE tables
Dihydroartemisinin-piperaquine compared to Artesunate plus mefloquine for treating uncomplicated P. falciparum malaria
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Malaria endemic areas
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artesunate plus mefloquine (AS+MQ)
Outcomes Number of participants having adverse
events (95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
AS+MQ DHA-P
Serious adverse events (includingdeaths) 8 per 1000 9 per 1000
(4 to 18)
3522
(8 trials)
moderate1,2,3,4
Gastroenterologi-
cal
Early vomiting 7 per 100 6 per 100
(5 to 8)
4114
(9 trials)
moderate2,3,5,6
Nausea 20 per 100 14 per 100
(12 to 16)
4531
(9 trials)
moderate3,5,7,8
Vomiting 13 per 100 8 per 100
(6 to 10)
2744
(5 trials)
moderate3,5,7,8
Anorexia 15 per 100 13 per 100
(11 to 15)
3497
(6 trials)
low3,5,7,9
Diarrhoea 6 per 100 8 per 100
(6 to 11)
2217
(5 trials)
moderate3,5,7,8
Abdominal pain 11 per 100 11 per 100
(9 to 13)
3887
(7 trials)
moderate3,5,7,10
Neuro-psychiatric Headache 12 per 100 10 per 100
(8 to 12)
2039
(4 trials)
low3,5,8,11
Dizziness 36 per 100 26 per 100
(24 to 28)
4531
(9 trials)
moderate3,5,7,8
Sleeplessness 21 per 100 10 per 100
(8 to 13)
2551
(6 trials)
moderate3,5,7,8
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Fatigue 8 per 100 3 per 100
(2 to 6)
872
(2 trials)
low5,7,12
Nightmares 10 per 100 1 per 100
(0 to 7)
220
(1 trial)
low5,12
Anxiety 11 per 100 1 per 100
(0 to 4)
522
(1 trial)
low5,12
Blurred vision 9 per 100 4 per 100
(2 to 9)
464
(1 trial)
low5,12
Tinnitus 9 per 100 4 per 100
(1 to 11)
220
(1 trial)
low5,12
Cardio-respiratory Palpitations 18 per 100 11 per 100
(8 to 15)
1175
(3 trials)
moderate3,5,7,8
Cough 10 per 100 8 per 100
(5 12)
1148
(1 trial)
low5,9
Dyspnoea 9 per 100 3 per 100
(1 to 10)
220
(1 trial)
low5,13
Prolonged QT in-
terval
(adverse event)
4 per 100 5 per 100
(3 to 9)
1148
(1 trial)
low9,14,15
Prolonged QT in-
terval
(Bazett’s
correction)
4 per 100 9 per 100
(5 to 15)
1148
(1 trial)
low5,9,15
Prolonged QT in-
terval
(Fridericia’s
correction)
5 per 100 4 per 100
(3 to 8)
1148
(1 trial)
low5,9,15
Musculoskeletal/
dermatological
Arthralgia 6 per 100 5 per 100
(3 to 9)
1148
(1 trial)
moderate5,10,14
Myalgia 6 per 100 6 per 100
(4 to 10)
1148
(1 trial)
moderate5,10,14
Urticaria 2 per 100 1 per 100
(0 to 4)
719
(2 trials)
low5,13
Pruritis 3 per 100 2 per 100
(1 to 4)
872
(2 trials)
low5,13
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Rash 1 per 100 0 per 100
(0 to 7)
220
(1 trial)
low5,13
The assumed risk of adverse events in the AS+MQ group is an average risk across trials. The corresponding risk with DHA-P (and
its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Only eight of the 11 trials made any comment on serious adverse events. None of these eight trials were
blinded.
2 No serious inconsistency: None of the eight trials found statistically significant differences.
3 No serious indirectness: These trials recruited both adults and children, and were conducted in Asia and South America.
4 Downgraded by 1 for imprecision: These trials do not exclude the possibility of rare but clinically important adverse effects.
5 Downgraded by 1 for serious risk of bias: All trials were open label.
6 No serious imprecision: The 95% CI around the absolute effect is narrow and excludes clinically important differences.
7 No serious inconsistency: This finding was consistent across trials with no significant statistical heterogeneity.
8 No serious imprecision: The result is statistically significant and the meta-analysis is adequately powered to detect this effect.
9 Downgraded by 1 for serious imprecision: This result does not reach statistical significance.
10 No serious imprecision: The finding is of no difference between treatments and the sample size is adequately powered to detect
differences if they existed.
11 Downgraded by 1 for serious inconsistency: There is moderate heterogeneity between trials.
12 Downgraded by 1 for serious indirectness: Only two trials have assessed this outcome.
13 Downgraded by 1 for imprecision: Limited data available and the result is not statistically significant.
14 Downgraded by 1 for serious risk of bias: This trial is unblinded. Only a few of the recorded prolonged QT intervals were registered
as adverse events which removed the statistical significance. The reasons for this are unclear.
15 No serious indirectness: This single large trial was conducted in adults and children in Thailand, Laos, and India
Dihydroartemisinin-piperaquine compared to Artemether-lumefantrine for uncomplicated P. falciparum malaria
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Malaria endemic areas
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artemether-lumefantrine (AL6)
Outcomes Number of participants having adverse
events (95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
AL6 DHA-P
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Serious adverse events (includingdeaths) 6 per 1000 10 per 1000
(6 to 17)
7022
(8 trials)
moderate1,2,3,4
Gastroenterologi-
cal
Early vomiting 2 per 100 3 per 100
(2 to 5)
2695
(3 trials)
moderate2,3,5,6
Vomiting 9 per 100 9 per 100
(8 to 11)
6761
(9 trials)
moderate2,3,5,6
Nausea 2 per 100 2 per 100
(1 to 7)
547
(2 trials)
low2,3,5,7
Diarrhoea 12 per 100 12 per 100
(10 to 14)
4889
(7 trials)
moderate2,3,5,6
Abdominal pain 19 per 100 16 per 100
(12 to 20)
911
(5 trials)
low2,3,5,8
Anorexia 15 per 100 14 per 100
(12 to 17)
3834
(5 trials)
moderate2,3,5,6
Neuro-psychiatric Headache 27 per 100 33 per 100
(25 to 44)
309
(2 trials)
low2,3,5,8
Sleeplessness 1 per 100 3 per 100
(1 to 9)
547
(2 trials)
low2,3,5,7
Dizziness 3 per 100 4 per 100
(2 to 11)
547
(2 trials)
low3,5,7
Sleepiness 0 per 100 0 per 100
(0 to 0)
384
(1 trial)
low2,3,5,7
Weakness 17 per 100 18 per 100
(15 to 21)
1812
(5 trials)
moderate2,3,5,6
Cardio-respiratory Cough 42 per 100 42 per 100
(40 to 45)
4342
(5 trials)
moderate2,3,5,6
Coryza 68 per 100 66 per 100
(60 to 72)
832
(2 trials)
low1,2,3,8
Prolonged QT in-
terval
(adverse event)
3 per 100 2 per 100
(1 to 5)
1548
(1 trial)
low8,10,11
Prolonged QT in-
terval
(Bazett’s
correction)
7 per 100 9 per 100
(6 to 11)
1548
(1 trial)
low5,8,11
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Prolonged QT in-
terval
(Fridericia’s
correction)
0 per 100 0 per 100
(0 to 2)
1548
(1 trial)
low5,8,11
Musculoskeletal/
dermatological
Pruritis 2 per 100 4 per 100
(2 to 6)
2033
(5 trials)
moderate2,3,5,6
Facial oedema 0 per 100 0 per 100
(0 to 0)
384
(1 trial)
low2,3,5,7
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: All but one of the trials are open label. However, we did not down grade for this outcome.
2 No serious inconsistency: The finding is consistent across all trials. Statistical heterogeneity is low.
3 No serious indirectness: Trials were mainly conducted in children in Africa, with few trials in Asia or in adults.
4 Downgraded by 1 for serious imprecision: No statistically significant difference was detected between treatments. However the
current sample size does not exclude the possibility of rare but clinically important differences.
5 Downgraded by 1 for risk of bias: The majority of trials are open label.
6 No serious imprecision: The finding is of no effect and the CIs around the absolute effect excludes clinically important differences.
7 Downgraded by 1 for serious imprecision: There are limited data
8 Downgraded by 1 for serious imprecision: The result does not reach statistical significance.
9 No serious imprecision: The total number of participants is high and findings are precise.
10 Downgraded by 1 for serious risk of bias: This trial is unblinded. Only a few of the recorded prolonged QT intervals were registered
as adverse events which removed the statistical significance. The reasons for this are unclear.
11 No serious indirectness: This single trial was conducted in children in Uganda, Kenya, Mozambique, Zambia, and Burkina Faso
Dihydroartemisinin-piperaquine compared to Artesunate plus amodiaquine for uncomplicated P. falciparum malaria
Patient or population: Patients with uncomplicated P. falciparum malaria
Settings: Malaria endemic areas
Intervention: Dihydroartemisinin-piperaquine (DHA-P)
Comparison: Artesunate plus amodiaquine (AS+AQ)
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Outcomes Number of participants having adverse
events (95% CI)
No of participants
(trials)
Quality of the evi-
dence
(GRADE)
AS+AQ DHA-P
Serious adverse events (including
deaths)
2 per 100 1 per 100
(0 to 1)
2805
(2 trials)
moderate1,2,3,4
Gastrointestinal Early vomiting 6 per 100 5 per 100
(3 to 10)
650
(2 trials)
low3,5,6,7
Vomiting 11 per 100 8 per 100
(7 to 11)
2471
(1 trial)
moderate7,8,9,10
Nausea 17 per 100 17 per 100
(11 to 28)
316
(1 trial)
moderate5,9,11,12
Diarrhoea 11 per 100 11 per 100
(9 to 14)
2787
(2 trials)
moderate2,3,12,13
Abdominal pain 13 per 100 12 per 100
(7 to 21)
316
(1 trial)
low5,7,9,11
Anorexia 11 per 100 10 per 100
(8 to 12)
2787
(2 trials)
low2,3,7,13
Neuro-psychiatric Headache 1 per 100 1 per 100
(0 to 9)
316
(1 trial)
low5,9,11,14
Sleeplessness 14 per 100 11 per 100
(6 to 20)
316
(1 trial)
low5,7,9,11
Cardio-respiratory Cough 31 per 100 32 per 100
(28 to 36)
2471
(1 trial)
moderate7,8,9,10
Palpitations 23 per 100 20 per 100
(13 to 30)
316
(1 trial)
low5,7,9,11
*The basis for the assumed risk (for example, themedian control group risk across trials) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Only one of the two trials was blinded. However, we did not downgrade for this outcome.
2 No serious inconsistency: The finding is consistent across all trials. Statistical heterogeneity is low.
3 No serious indirectness: Trials were mainly conducted in children in Africa and Asia, with few Asian adults.
4 Downgraded by 1 for serious imprecision: The number of events is low despite the findings reaching statistical significance and the
total number of participants being high.
5 Downgraded by 1 for risk of bias: The trial that reported this finding was open-label
6 No serious inconsistency: The finding is consistent across all trials. Statistical heterogeneity can be explained by difference in
definition of early vomiting.
7 Downgraded by 1 for serious imprecision: The result does not reach statistical significance.
8 No serious risk of bias: The trial that reported this outcome had low risk of bias for blinding of adverse events.
9 No serious inconsistency: This outcome was only reported in one trial.
10 No serious indirectness: This trial was mainly conducted in children in Africa.
11 No serious indirectness: The trial was mainly conducted in children and adults in Asia.
12 No serious imprecision: The finding is of no effect but the CIs around the absolute effect excludes clinically important differences.
13 Downgraded by 1 for risk of bias: Only one trial was blinded for adverse events.
14 Downgraded by 1 for serious imprecision: There are limited data and the 95% CI is wide
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